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Summary 
Transthyretin (TTR) is the plasma homotetrameric carrier of thyroxine (T4) and retinol, in 
the latter case through binding to retinol binding protein (RBP). TTR is synthesized in the 
liver and choroid plexus of the brain, which are the sources of TTR in the plasma and 
cerebrospinal fluid, respectively. Several mutations in TTR lead to the occurrence of 
familial amyloid polyneuropathy (FAP), a neurodegenerative disorder characterized by 
TTR amyloid deposition particularly in the peripheral nervous system (PNS). In the 
plasma, a small TTR fraction is carried in high-density lipoproteins (HDL), through binding 
to apolipoprotein A-I (apoA-I). We further investigated the nature of the TTR-apoA-I 
interaction and found that TTR was able to process proteolytically apoA-I, suggesting that 
TTR is a novel cryptic protease. The cryptic nature of TTR proteolytic activity comes not 
only from the fact that it lacks canonical structural protease determinants, but also 
because its physiological function is apparently unrelated to proteolysis. Several 
indications, as an optimum pH of activity of approximately 7, cleavage after a Phe residue 
in apoA-I, and inhibition by serine protease inhibitors, allowed the assumption of TTR 
being a “Serine-like” protease. We investigated which serine residues could constitute the 
nucleophile of the catalytic machinery of TTR, by using site-directed mutagenesis and 
active site labeling. However, the approaches used to identify the catalytic residues of 
TTR did not provide conclusive results, as were directly affected by post-translational 
modifications occurring during purification of the recombinant protein leading to a low 
percentage of enzymatic activity in the final TTR preparations. Among the TTR post-
translational modifications described, we found that glutathionylation is crucial for TTR 
proteolysis, as it completely inactivates the catalytic function of the protein. In this work we 
also addressed the relevance of apoA-I cleavage by TTR in lipoprotein metabolism. We 
showed that, by cleaving apoA-I, TTR impacts on HDL biology and in the development of 
atherosclerosis as it reduces the ability of apoA-I to promote cholesterol efflux and 
increases apoA-I amyloidogenicity. Not excluding apoA-I as the prime substrate for TTR 
proteolysis, we investigated the putative existence of other TTR natural proteolytic 
substrates. We observed that apoA-I is the unique TTR proteolytic substrate in the 
plasma. Nonetheless, in vitro, TTR is able to cleave neuropeptide Y (NPY) and myelin 
basic protein (MBP), suggesting a role for TTR proteolytic activity in nerve biology. In this 
respect, we further demonstrated that TTR proteolytic activity is necessary for the ability of 
this protein to enhance neurite outgrowth, which reinforces the existence and relevance of 
TTR substrates in the nervous system. In summary, our work contributed to assign a 
novel function for TTR which might impact in the biology of the nervous system as well as 
in amyloidosis. 
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Sumário 
A Transtirretina (TTR) é uma proteína homotetramerica que funciona como o 
transportador plasmático de tiroxina e retinol, neste caso através da formação de um 
complexo com a proteína de ligação ao retinol. A TTR é sintetizada no fígado e no plexus 
coróide do cérebro, os quais constituem as fontes de TTR no plasma e no líquido 
encefalorraquidiano, respectivamente. Várias mutações pontuais na TTR estão 
associadas com a polineuropatia amiloidótica familiar (PAF), uma doença 
neurodegenerativa caracterizada pela deposição de TTR na forma de amilóide 
particularmente no sistema nervoso periférico (SNP). No plasma, uma percentagem de 
TTR circula nas lipoproteínas de alta densidade através de ligação à apolipoproteína A-I 
(apoA-I). A investigação da interacção TTR-apoA-I demonstrou que a TTR tem a 
capacidade de clivar a apoA-I, o que revelou que a TTR é uma nova protease críptica. A 
natureza críptica da TTR advém não só do facto da função fisiológica da TTR não estar 
relacionada com proteólise, mas também da proteína não possuir os determinantes 
estruturais característicos de uma protease. Diversas indicações, como um pH óptimo de 
actividade de aproximadamente 7, clivagem após um resíduo Phe, e inibição por 
inibidores de serinas proteases, sugeriram que a TTR é uma serina protease. A 
investigação dos resíduos que poderiam constituir o local activo da TTR foi efectuada 
através de mutagénese dirigida e modificação química do local activo. Contudo, os 
métodos usados não providenciaram resultados conclusivos, uma vez que foram 
afectados por modificações pós-traducionais da enzima efectuadas no processo de 
purificação da proteína recombinante, e também pela reduzida percentagem de enzima 
activa presente nas preparações de TTR. Entre as várias modificações pós-traducionais 
descritas para a TTR, determinámos que a glutationilação é crucial na actividade 
proteolítica da TTR, uma vez que inibe completamente a actividade da enzima. Neste 
projecto foi também analisada a relevância da clivagem da apoA-I pela TTR no 
metabolismo das lipoproteínas. Observámos, que ao clivar a apoA-I, a TTR tem um efeito 
na biologia das lipoproteínas de alta densidade e no desenvolvimento da arteriosclerose, 
uma vez que reduz a capacidade da apoA-I induzir o efluxo de cholesterol e também 
aumenta a amiloidogenicidade da apoA-I. A possível existência de outros substratos da 
TTR, para além da apoA-I, foi também analisada neste trabalho. Verificámos que a apoA-
I é o único substrato plasmático da TTR. Contudo, observámos que in vitro a TTR cliva o 
neuropeptido Y (NPY) e a proteína constituinte da mielina, myelin basic protein (MBP), o 
que sugere uma relação entre a actividade proteolítica da TTR e a biologia do nervo. 
Também verificámos que a actividade proteolítica da TTR é necessária para a sua função 
de aumentar o crescimento das neurites, o que evidencia a possível existência de 
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substratos da TTR no sistema nervoso. Em resumo, este trabalho contribuiu para revelar 
uma novo função para a TTR que poderá ter um papel importante na biologia do sistema 
nervoso e em amiloidose. 
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Sommaire 
La transthyrétine (TTR) est le transporteur plasmatique de la thyroxine (T4) et du rétinol, 
dans le dernier cas en liant au rétinol-binding protein (RBP). La TTR est synthétisée dans 
le foie et le plexus choroïde du cerveau, qui sont les sources de TTR dans le plasma et le 
fluide cérébro-spinal, respectivement. Plusieurs mutations dans la TTR mènent à 
l'occurrence de la polyneuropathie amyloïde familiale (FAP), un désordre 
neurodégénérative caractérisé par le dépôt amyloïde de TTR en particulier dans le 
système nerveux périphérique (PNS). Dans le plasma, une petite fraction de TTR est 
transportée par les lipoprotéines à haute densité (HDL), à travers de l'apolipoprotéine AI 
(apoA-I). Nous avons étudié la nature de l'interaction TTR-apoA-I et avons constaté que la 
TTR pouvait cliver l'apoA-I, suggérant que la TTR est une protéase cryptique. La nature 
cryptique de l'activité protéolytique de la TTR vient non seulement du fait qu'elle manque 
des déterminants structurales canoniques de protéase, mais également parce que sa 
fonction physiologique est apparemment indépendante de la protéolyse. Plusieurs 
indications, comme un pH optimum d'activité d’approximativement 7, le clivage après un 
résidu de Phe dans l'apoA-I, et l’inhibition par des inhibiteurs de sérine protéase, ont 
permis l'hypothèse que la TTR soit une protéase "Sérine-like". Nous avons étudié quels 
résidus de sérine pourraient constituer le nucléophile de la machinerie catalytique de la 
TTR, par mutagénèse-dirigée et par marcation du local actif. Cependant, les 
méthodologies employées pour identifier les résidus catalytiques de la TTR n'ont pas 
fourni des résultats conclusifs, car ils étaient directement affectés par des modifications de 
l'enzyme se produisant pendant la purification de la protéine récombinante, ainsi que par 
le bas pourcentage d'enzyme active dans les préparations finales de TTR. Parmi les 
modifications de TTR décrites, nous avons déterminé que la glutathionilation est cruciale 
pour la protéolyse de TTR, car elle inactive complètement la fonction catalytique de la 
protéine. Dans ce travail nous avons également adressé la pertinence du clivage de 
l'apoA-I par la TTR dans le métabolisme des lipoprotéines. Nous avons prouvé que clivant 
l’apoA-I, la TTR affecte la biologie des HDL et le développement de l'athérosclérose car 
elle réduit la capacité de l'apoA-I de favoriser le flux de cholestérol et elle augmente 
l'amyloidogénicité de l’apoA-I. Sans exclure que l’apoA-I n’est pas le substrat principal de 
la TTR, nous avons étudié l'existence putative d'autres substrats de TTR. Nous avons 
observé que l'apoA-I est le substrat unique de la TTR dans le plasma. Néanmoins, la TTR 
in vitro peut cliver le neuropeptide Y (NPY) et la myelin basic protein (MBP), suggérant un 
rôle pour l'activité protéolytique de la TTR dans la biologie du nerf. À cet égard, nous 
avons démontré que l'activité protéolitique de la TTR est nécessaire pour la capacité de 
cette protéine augmenter la croissance de neurites, ce qui renforce l'existence et la 
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pertinence des substrats de TTR dans le système nerveux. En résumé, notre travail a 
contribué pour assigner une nouvelle fonction de la TTR dans la biologie du système 
nerveux aussi bien que dans des amyloïdoses. 
 
 
  
 
 
 
 
 
 
 
 
PART I 
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1 TRANSTHYRETIN 
Transthyretin, formerly named pre-albumin due to its electrophoretic migration pattern 
ahead of albumin, is a plasma protein originally discovered by Kabat et al. in 1942 in the 
human cerebrospinal fluid (CSF) and later in the plasma (Seibert and Nelson, 1942). This 
protein is mainly synthesized in the liver and the choroid plexus of the brain, but is also 
expressed in the retinal pigment of the eye (Soprano et al., 1985; Dickson et al., 1985a; 
Cavallaro et al., 1990). 
The name TransThyRetin (TTR) reflects its physiological roles of this protein, which are 
the plasma transport for the thyroid hormone thyroxine (T4) (Woeber and Ingbar, 1968) 
and for retinol, in the latter case through binding to retinol binding protein (RBP) 
(Goodman, 1987). 
1.1 TTR gene structure and regulation 
The ttr gene is a single copy-gene located inchromosome 18 (Whitehead et al., 1984); it 
spans approximately 7 Kb and has four exons, three introns, a TATA box-like sequence at 
position –30 to –24 bp followed by a GC rich region of approximately 20 bp, a CAAT box 
at position –101 to –96 bp and overlapping sequences homologous to glucocorticoid 
responsive elements at positions –224 and –212 bp (Figure 1). Exon 1 codes for a signal 
peptide of 20 amino acids and the first three residues of the mature protein; exon 2, codes 
for amino acid residues 4-47; exon 3 codes for amino acid residues 48-92; and exon 4 
codes for the 35 last amino acid residues 93-127 (Sasaki et al., 1985; Tsuzuki et al., 
1985). The introns, termed I1, I2 and I3, span 934 bp, 2090 bp and 3308 bp, respectively. 
Introns I1 and I3 contain two independent open reading frames (ORFs) but their function 
is not clear (Tsuzuki et al., 1985; Soares et al., 2003).  
 
Figure 1 – Human TTR gene structure. Exons 1 to 4 (E1 to E4) and introns 1 to 3 (I1 to I3); E1: 
sequence homologous to mouse enhancer; E2: human specific enhancer; GCR: glucocorticoid 
responsive element; CAT: CAAT box; AATAAA: polyadenylation signal. Adapted from Monteiro FA, 
PhD thesis. 
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The TTR genomic structure has been extensively described in human (Sasaki et al., 
1985), rat (Fung et al., 1988), and mouse (Costa et al., 1986). The mouse and rat genes 
are also composed by four exons and show a gene organization similar to that of the 
human ttr gene. Two major regulatory regions are present in the 5’ flanking region of the 
ttr gene, a proximal promoter and a distal enhancer. These TTR regulatory domains are 
bound by members of four different liver-enriched transcription factor families (HNF-1, 
HNF-3, HNF-4, HNF-6), CCAAT/enhancer binding proteins (C/EBP), and the growth 
factor-inducible AP-1 protein. The TTR enhancer is also recognized by an uncharacterized 
ubiquitous factor (UF) and contains a HNF-3 binding site specific for the HNF-3β isoform 
(Figure 2). These regions are sufficient for directing TTR expression in the liver (Samadani 
and Costa, 1996). TTR gene expression also occurs in the choroids plexus, but little is 
know about the regulatory mechanisms. 
 
Figure 2 - Schematic representation of TTR regulatory regions. Adapted from (Samadani and 
Costa, 1996) 
 
The transcription of the TTR gene results in an approximately 0.7 kb single mRNA. The 
TTR mRNA encodes a pro-TTR monomer, which contains a 20- amino acid signal peptide 
located in the N-terminal region. Pro-TTR is processed during its migration through the 
endoplasmatic reticulum membrane to yield the native TTR monomer (Soprano et al., 
1985).  
1.2 TTR expression and evolution 
The two major sites of TTR expression are the liver and the epithelial cells of the choroid 
plexus of the brain; this pattern of gene expression was described in several species, 
namely in the rat (Dickson et al., 1985b; Fung et al., 1988), human (Dickson and 
Schreiber, 1986), sheep (Schreiber et al., 1990), chicken (Southwell et al., 1991), and pig 
(Duan et al., 1995). TTR expression has also been described in the eye of cattle, sheep 
and eye (Cavallaro et al., 1990; Mizuno et al., 1992), in the rat and human pancreas 
(Jacobsson et al., 1990), in the visceral yolk sac during fetal rat development (Soprano et 
al., 1986), in the developing chicken heart (Barron et al., 1998), and in minor amounts in 
the stomach, heart, skeletal muscle and spleen (Soprano et al., 1985). More recently, TTR 
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synthesis has also been demonstrated in the human placenta (McKinnon et al., 2005). 
During vertebrate evolution, the sites of TTR expression changed significantly. In the case 
of fish, although some authors state that, as in the case of amphibians, TTR in 
synthesized by the liver only during development, (Richardson et al., 2005), at least in the 
Sparus aurata case TTR is synthesized by the liver throughout life (Santos and Power, 
1999). In reptiles and Australian polyprotodont marsupials, TTR is synthesized by the liver 
only during development and by the choroid plexus throughout life; while in birds, 
diprodont marsupials, and eutherians, TTR is synthesized by both the liver and the 
choroid plexus throughout life (Richardson et al., 2005). The conservation of TTR in the 
choroid plexus from reptiles to mammals throughout life led to the hypothesis that the 
expression of the TTR gene first arose in the brain of reptiles what coincided with an 
increase in size of the brain, as the reptiles were the first species possessing traces of a 
cortex (Schreiber and Richardson, 1997). On the other hand, the existence of TTR in fish 
suggested that TTR evolved in a common fish ancestor of the tetrapod evolutionary line 
(Santos and Power, 1999). During human embryonic development, TTR is first expressed 
in the tela choroidea, the precursor of the choroid plexus, followed by expression in the 
liver (Harms et al., 1991; Richardson et al., 1994). This pattern of TTR expression in the 
choroid plexus, conserved throughout evolution and starting early in embryonic 
development, points to a pivotal role for TTR in the brain. 
1.3 TTR structure 
TTR is a 55-kDa homotetrameric protein, with each monomer constituted by 127 amino 
acid residues (Kanda et al., 1974). The X-ray crystal structure of human TTR was 
determined at 1.8 Å by Blake et al. in 1978, indicating a β-sheet-dominant secondary 
structure. The polypeptide chain is arranged in 8 antiparallel β-strands, designated A 
through H, forming the monomer that contains two β-sheets composed by strands DAGH 
and CBEF (Figure 3). The β-strands are 6-9 residues long, excepting strand D that has 
only 3 residues. The β-sheets are linked by seven loops and a small helical region, 
involving amino acids 75 to 83, located at the end of strand E. The N- and C-terminal 
regions of each monomer are composed by 10 and 5 unorganized residues, respectively. 
To form the dimer two monomers associate through hydrogen bonds between strands H 
and F of each monomer, leading to the extension of the two 4-stranded-sheets in each 
monomer to two 8-stranded sheets in the dimer. The resulting strand arrangement in the 
dimer is DAGHH’G’A’D’and CBEFF’E’B'C’ (the prime symbol refers to a strand from a 
different monomer) (Figure 3).  
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Figure 3 - Structure of the TTR dimer. PDB entry 1ETB. Each monomer contains two β-sheets 
composed of strands DAGH and CBEF, which extend to two 8-stranded β-sheets in the dimer. 
Adapted from (Hamilton et al., 1993). 
 
The interactions between the two dimers to form the tetramer, are established by 
hydrogen bonds between main chain atoms belonging to loop AB of one monomer and 
strand H’ from the other monomer as well as hydrophobic contacts; these interactions are 
much weaker than those between the two monomers in a dimer. The assembly of the 
tetramer with their inner eight-stranded sheets DAGHH’G’A’D’ face-to-face leads to the 
formation of a narrow cylindrical channel running through the centre of the molecule 
(Figure 4). 
 
Figure 4 - Structure of the TTR tetramer. PDB entry 1TTA. Kindly provided by Dr Luís Gales, 
Molecular Structure Group, IBMC. 
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The three-dimensional TTR structure has been highly conserved among vertebrates, as 
revealed by the similar crystal structures of human (Blake et al., 1978b), chicken (Sunde 
et al., 1996), rat (Wojtczak, 1997), and fish (Folli et al., 2003) TTR. The most important 
regions such as the hydrophobic core and the areas involved in quaternary structure 
interactions or ligand binding sites are maintained. The main difference between them is 
the lack of the helical region in the structure of chicken TTR, which is replaced by a loop 
(Sunde et al., 1996). In terms of primary structure, the region of the TTR sequence that 
changed the most during vertebrate evolution was the N-terminal region. In lower 
vertebrates this region is longer and more hydrophobic, while in eutherians the N-terminal 
region is shorter and more hydrophilic. 
1.4 TTR metabolism 
The liver is the main source of the plasma-circulating TTR. TTR concentration in the 
plasma ranges from 170 to 420 µg/mL (Vatassery et al., 1991). The protein synthesized in 
the epithelial cells of the choroid plexus is secreted into the cerebrospinal fluid (CSF) 
(Dickson et al., 1987), where TTR concentration varies from 5 to 20 µg/mL (Vatassery et 
al., 1991) and represents 20% of the total CSF proteins (Weisner and Roethig, 1983).  
The biological half-life of TTR is about 2-3 days in humans (Socolow et al., 1965; 
Vahlquist et al., 1973), and 29 hours in rats (Dickson et al., 1982). A report of a catabolic 
study performed in rats has shown that the major sites for TTR degradation are the liver 
(36-38% of total body TTR degradation), muscle (12-15%), and skin (8-10%). Tissues that 
were sites of 1-8% of body TTR degradation, included kidneys, adipose tissue, testes, and 
the gastrointestinal tract. The same degradation sites were determined for both TTR 
synthesized in the liver and in the choroid plexus; no TTR degradation was observed in 
the nervous system (Makover et al., 1988). 
Although the mechanism of cellular uptake of TTR is not fully understood, several studies 
suggested a receptor-mediated mechanism. In 1990, a report from Divino and Schussler 
described a saturable high affinity binding of TTR to human hepatomas, which 
corroborates the existence of a TTR-receptor. Ten years later, a mechanism involving 
megalin, a multiligand receptor, member of the low density lipoprotein receptor (LDLr) 
family, was described for renal uptake of TTR (Sousa et al., 2000b). This mechanism was 
inhibited by the receptor-associated protein (RAP), a ligand for all members of the LDLr 
family.  TTR ability to bind megalin was shown to be similar in the presence or absence of 
its ligands, T4 and RBP. As RBP is also a megalin ligand, it was proposed that this renal 
receptor had a role in TTR-mediated renal uptake of T4 (Sousa et al., 2000b). Further 
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investigation on receptor-mediated TTR internalization was explored in the liver, as this 
organ is responsible for the major rate of TTR degradation. Experiments performed with 
hepatomas and primary hepatocytes showed TTR internalization mediated by an 
unidentified specific receptor (Sousa and Saraiva, 2001). TTR uptake by the hepatic 
receptor was affected by its ligands, with a 70% decrease for TTR complexed with RBP 
and a 20% increase for TTR bound to T4. As observed with megalin, TTR hepatic uptake 
was inhibited by RAP. The hypothesis that this unidentified hepatic receptor could belong 
to the LDLr family was investigated; however, none of the known members of the LDLr 
family was implicated in TTR uptake in the liver; as such, another unidentified RAP-
sensitive receptor seems to be involved in TTR internalization in the liver. 
1.5 TTR physiological functions 
The main and better-studied physiological functions of TTR are the plasma transport of 
thyroxine (T4) (Woeber and Ingbar, 1968) and retinol, in this case through binding to 
retinol binding protein (RBP) (Kanai et al., 1968). More recently, apolipoprotein A-I was 
described as another ligand of TTR (Sousa et al., 2000a). Novel TTR functions, 
particularly related with the nervous system, have also been reported. 
1.5.1 Transport of thyroxine (T4) 
Thyroid hormones (THs) are synthesized by the thyroid gland, and are essential for 
normal mammalian development, growth and metabolism. T4 is the main thyroid-secreted 
product and T3 derives mainly from tissue T4 deiodination. T4 and T3 are generally 
transported bound to plasma proteins. In humans, more than 99% of T4 circulates bound 
mainly to the TH-distributor proteins (THDPs): thyroxine-binding globulin (TBG), TTR and 
albumin (Bartalena, 1990). Peculiarly, the percentage of T4 transported in each THDP is 
inversely proportional to the plasma concentration of each THDP; the concentration of 
each THDP in human plasma is 0.015 g/L for TBG, 0.25 g/L for TTR and 42 g/L for 
albumin, and the corresponding percentages of T4 transported in each THDP are of 75%, 
15% and 10%, respectively (Richardson, 2007). In rodents, TTR is the major carrier of T4 
(Davis et al., 1970); TBG, the principal carrier of thyroxine in humans, is present in 
neonatal but almost absent in adult rodent serum (Vranckx et al., 1990) 
TTR is responsible for the transport of the thyroid hormone thyroxine (T4) in the plasma 
and in the brain. Two identical binding sites for T4 are located in the central channel of the 
TTR tetramer (Blake et al., 1978b) (Figure 5). The chemistry of the channel is 
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characterized by three elements arranged linearly along it: i) a hydrophilic patch formed by 
the hydroxyl groups of Ser 117 and Thr 119; ii) a hydrophobic patch formed by the methyl 
groups of the Leu 17, Thr 106, Ala 108, Leu 110, Thr 119, and Val 121; and iii) a group of 
charged residues including the paired side chains of Lys 15, Glu 54, and His 56 (Blake et 
al., 1978a). The proximity of the side chains of Leu 110, Ser 115 and Ser 117 causes a 
marked local constriction that separates the two T4 binding sites. These binding sites 
present negative cooperativity (Ferguson et al., 1975); therefore, each TTR tetramer 
carries no more than one T4 molecule. TTR also binds thiiodothyronine (T3), the biological 
active form of THs, although with much lower affinity.  
 
 
Figure 5 - A. Structure of the TTR-thyroxine complex. PDB entry 2ROX. T4 molecules are 
represented by sticks. Kindly provided by Dr Luís Gales, Molecular Structure Group, IBMC. B. 
Table of TTR residues situated at thyroxine-binding channel. 
 
The role of plasma proteins in the transport of hormones to target tissues has been a 
subject of some controversy. In the case of TTR, based on its pattern of expression 
conserved throughout evolution and starting early during embryonic development, it has 
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for a long time been suggested that the protein is involved in thyroid hormone 
homeostasis and hormone delivery to the brain (Dickson et al., 1987; Dratman et al., 
1991). However, studies performed with TTR knockout (KO) mice revealed that TTR is not 
required for normal T4 tissue uptake or distribution, and its absence does not impair 
hormone tissue contents, despite the low circulating levels of total T4 (Palha et al., 1994; 
Palha et al., 1997). Even in the brain, with TTR being the major protein synthesized in 
choroid plexus, the distribution of T4 is not influenced by the absence of the transporter 
protein. Furthermore, no other protein was found to replace TTR in the transport of T4 
(Palha et al., 2000). More recent experiments were performed to investigate whether TTR 
has a storage/buffer role in thyroid hormone homeostasis, and it was demonstrated that 
even under conditions of increased hormone demand, wild-type (WT) and TTR KO mice 
show similar behaviours in terms of thyroid hormone metabolism (Sousa et al., 2005). 
These observations reinforced the idea that TTR is not necessary for the metabolism of T4 
and are in agreement with the free hormone hypothesis for T4 uptake (Mendel, 1989). The 
free hormone theory states that the hormone biological activity depends on its free rather 
than protein bound plasma concentration.  
1.5.2 Transport of retinol 
In mammals, a well-regulated transport and storage system provides tissues with the 
correct amounts of retinoids in spite of normal fluctuations in daily vitamin A intake. Retinyl 
esters obtained from the diet are delivered to the liver and this retinoid is either stored or 
secreted as retinol. Retinol, or vitamin A, circulates in the plasma bound to the retinol 
binding protein (RBP). RBP is synthesized and secreted primarily by hepatocytes and is 
the sole specific transport protein for retinol in the circulation. In the plasma, RBP-retinol is 
found in a complex with TTR; this association is proposed to facilitate RBP release from 
its site of synthesis in the endoplasmic reticulum and to prevent renal filtration of RBP 
(Goodman, 1984; Wolf, 1984). The presence of retinol bound to RBP is essential for the 
formation of a stable complex with TTR (Noy et al., 1992). The location of the TTR binding 
sites for RBP was initially revealed by the crystal structure of human TTR complexed with 
chicken RBP (Monaco et al., 1995). Later, the structure of the human complex was also 
described (Naylor and Newcomer, 1999). The main residues of contact between the two 
molecules are Arg 21, Val 20, Leu 82 and Ile 84, contributed by two TTR monomers, and 
Trp 67, Phe 96, Leu 63 and Leu97 from RBP. Another interaction, involving the C-
terminus of RBP, occurs in the protein-protein recognition interface; this interaction 
correlates with the observation that naturally occurring truncated forms of the protein are 
more readily cleared from plasma than full-length RBP (Naylor and Newcomer, 1999). In 
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vitro one tetramer of TTR can bind two molecules of RBP. However, the concentration of 
RBP in the plasma is limiting, and the complex isolated from serum is composed of TTR 
and RBP in a 1:1 molar complex (Monaco et al., 1995) (Figure 6). 
 
 
Figure 6 - A. Structure of the TTR-RBP complex. PDB entry 1QAB. RBP is shown in blue. Kindly 
provided by Dr Luís Gales, Molecular Structure Group, IBMC. B. Table of TTR residues involved in 
RBP binding. 
 
The delivery of retinol to cells through the circulating TTR-RBP complex is the major 
pathway through which cells and tissues acquire retinol. Studies performed with TTR KO 
mice, revealed that the levels of plasma retinol and RBP in these animals are very low, 
approximately 5% of those observed in WT mice (Episkopou et al., 1993). However, 
despite the low plasmatic levels of RBP-retinol, no differences were observed in the tissue 
levels of total retinol between WT and TTR KO mice, with mutant mice lacking symptoms 
of vitamin A deficiency (Episkopou et al., 1993; van Bennekum et al., 2001). The low 
levels of circulating RBP-retinol in TTR KO mice were explained by an increased renal 
filtration of the complex in these animals (van Bennekum et al., 2001), supporting the 
hypothesis that TTR prevents the loss of RBP-retinol from circulation through glomerular 
filtration. The hypothesis that TTR could inhibit RBP secretion was also investigated, as 
RBP hepatic levels of TTR KO mice were shown to be 60% higher than those of WT mice 
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(Wei et al., 1995). However, experiments performed with primary hepatocytes from WT 
and TTR KO mice have shown that both strains secrete RBP at equivalent rates (van 
Bennekum et al., 2001).  
The mechanism by which tissues of TTR KO mice maintain normal total retinol 
concentrations in the face of low circulating retinol-RBP concentrations is not clearly 
understood. Several hypotheses are under investigation; the existence of an alternative 
mechanism for retinol tissue delivery in TTR KO mice constitutes one possibility. As 
lipoproteins transport retinyl esters in the circulation, it is possible that either postprandial 
lipoproteins (chylomicrons and their remnants) or lipoproteins of hepatic origin (VLDL and 
LDL) play a more important role in retinol delivery to tissues than RBP (van Bennekum et 
al., 2001). Another proposed mechanism was that a decrease in retinol catabolism might 
compensate the reduced delivery of retinol to the tissues of TTR KO mice; the levels of 
retinoic acid (the active form of retinol) in the plasma from TTR KO mice were shown to be 
approximately 2.3-fold higher than in WT mice, suggesting that plasma retinoic acid is the 
source of tissue retinol in TTR KO mice (Wei et al., 1995).  
The observations described suggest that TTR has not a crucial role in retinol delivery to 
tissues, constituting simply a carrier of the RBP-retinol complex that might act as a 
reservoir of retinol. In fact, recently, STRA6, a multitransmembrane domain protein, was 
identified as a specific membrane receptor for RBP. STRA6 binds to RBP with high affinity 
and has robust retinol uptake activity from the vitamin A–RBP complex. The RBP receptor 
is widely expressed in embryonic development and in adult organ systems, representing a 
major physiological mediator of cellular vitamin A uptake (Kawaguchi et al., 2007). 
1.5.3 TTR interaction with apolipoprotein A-I (apoA-I) 
Besides transporting T4 and retinol, TTR has been shown to be associated with 
lipoproteins. TTR presence in lipoproteins was reported in isolated low density lipoproteins 
(LDL) and in high density lipoproteins (HDL) from normal subjects and in Japanese familial 
amyloidotic polyneuropathy (FAP) patients, carrying a TTR Met30 mutation (Tanaka et al., 
1996). TTR was shown to associate with the HDL fraction to the same extent both in normal 
individuals and FAP patients, whereas the LDL fraction from the FAP patients showed higher 
amounts of TTR than normal individuals (Tanaka et al., 1996). At that time, nothing was 
known about the nature and significance of this association. In 2000, a report by Sousa et 
al demonstrated that 1-2% of the total TTR plasma concentration circulates associated 
with HDL, and that association occurs through TTR binding to apolipoprotein A-I (apoA-I, 
the major apolipoprotein constituent of HDL particles). However, the physiological role of 
the TTR-ApoA-I /HDL interaction was not assessed at the time. In the same year, a report 
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by the same authors (de Sousa et al., 2000) described an amyloidogenic variant of apoA-
I, Leu178His, where apoA-I and WT TTR composed the amyloid fibrils. These two reports 
suggested that the TTR-apoA-I interaction might be relevant not only in physiological 
conditions but also in amyloidosis. 
The interaction of TTR with apoA-I was subject of further investigation in this thesis; as 
such, the second and third sections of this introduction will describe the biology of apoA-I 
and the role of this apolipoprotein in amyloidosis, respectively. Moreover, new insights on 
this interaction will be presented in the description of the research project. 
1.5.4 Novel TTR functions  
Mutations in TTR are associated with familial amyloid polyneuropathy (FAP) (Saraiva, 
2001), a neurodegenerative disorder characterized by deposition of TTR amyloid fibrils, 
particularly in the peripheral nervous system (PNS) (this condition will de developed 
thoroughly in the third section of this introduction) The origin of TTR deposited in the PNS 
of FAP patients is unknown. Under physiological conditions, TTR has access to the nerve 
through the blood and the CSF. A function for TTR in nerve biology could explain its 
preferential deposition in the PNS. New functions for TTR specifically related with the 
nervous system were characterized with studies performed with TTR KO mice: i) TTR is 
involved in sensorimotor performance (Fleming et al., 2007): TTR KO mice present a 
sensorimotor impairment when assessed functionally; ii) the absence of TTR is associated 
with increased exploratory activity and reduced signs of depressive-like behavior, as was 
demonstrated in standardized tasks used to assess depression, exploratory activity and 
anxiety performed with TTR KO mice (Sousa et al., 2004); iii) TTR is involved in the 
homeostasis of the nervous system, namely by regulating neuropeptide maturation: TTR 
KO mice present increased levels of neuropeptide Y (NPY) as a consequence of 
peptidylglycine α-amidating monooxygenase (PAM) overexpression, and present a NPY 
overexpressor phenotype (Nunes et al., 2006); iv) TTR plays a role in nerve regeneration: 
TTR KO mice present a decreased regenerative capacity after sciatic nerve crush; 
furthermore, this phenotype is rescued when TTR is expressed locally in the nerve of TTR 
KO mice (Fleming et al., 2007); and v) TTR influences spatial reference memory: young 
TTR KO mice display spatial reference memory impairment that is not further observed 
with increasing aging, suggesting that TTR accelerates the poorer cognitive performance 
normally associated with aging (Sousa et al., 2007). Together, these studies performed in 
TTR KO mice suggest that TTR is important in both peripheral and central nervous system 
biology. 
In addition to the functions determined from the TTR KO mice phenotypes, TTR has been 
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suggested to protect against amyloid beta (Aβ) peptide deposition, the key pathological 
feature in Alzheimer’s disease (AD). In vitro studies have shown that TTR, as well as two 
other CSF proteins, apolipoproteins E and J, are able to bind soluble Aβ and to prevent Aβ 
amyloid fiber formation (Golabek et al., 1995). Subsequent reports have provided data 
suggesting that TTR regulates Aβ deposition in vivo: i) TTR is reduced in the brain of 
human AD patients comparing with control individuals (Serot et al., 1997) ii) TTR levels in 
the human brain are negatively correlated with the abundance of amyloid plaques 
(Merched et al., 1998); iii) DNA microarrays studies with transgenic mice overexpressing 
mutant amyloid precursor protein (APP) revealed that TTR expression is increased well 
before the onset of amyloid deposition, meaning that TTR is upregulated in response to 
elevated Aβ levels (Stein and Johnson, 2002); and iv) a recent report has shown that the 
genetic reduction of TTR accelerates Aβ deposition in a transgenic mouse model for AD 
backcrossed with TTR KO mice (Choi et al., 2007). Besides these observations, the 
mechanism by which TTR reduces Aβ aggregation is poorly understood. Regarding the 
TTR domains that interact with Aβ, it was shown that the region near Trp 41 in TTR is 
involved in binding to Aβ aggregates (Liu and Murphy, 2006). Further investigation should 
address the nature of the interaction between TTR and Aβ. 
In summary, either TTR itself, or indirectly through its ligands, is apparently involved in 
different aspects of nervous system biology in physiological and pathological conditions. 
1.6 TTR variants 
More than 100 variants of TTR have been described and the majority of them are related 
with amyloidosis (www.hotthyroidology.com; Saraiva, 2004). All TTR variants result from 
single amino acid substitutions in the polypeptide chain, with the exception of one amino 
acid deletion at position 122 (Uemichi et al., 1997). Among the amyloidogenic variants of 
TTR, in most cases they are related with neuropathies (Saraiva, 2001), although they may 
also be related with cardiomyopathy (Saraiva et al., 1990; Saito et al., 2001), carpal tunnel 
syndrome (Izumoto et al., 1992; Murakami et al., 1994), vitreous TTR deposition (Salvi et 
al., 1993; Zolyomi et al., 1998) and leptomeningeal involvement (Petersen et al., 1997; 
Brett et al., 1999; Yazak et al., 2000).  
The most common amyloidogenic variant is TTR Val30Met (Saraiva et al., 1984), which is 
related with FAP. In the third section of this introduction, amyloid related disorders will be 
discussed and TTR amyloidosis will be further detailed. 
TTR mutations without pathogenic consequences have also been reported; these are 
termed non-amyloidogenic TTR variants. Two relevant examples of non-amyloidogenic 
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mutations are TTR Gly6Ser, present in 12% of the Caucasian population and considered 
a polymorphism (Jacobson et al., 1995), and TTR Thr119Met, present in 0.8% of the 
Portuguese population (Alves et al., 1997). 
Several studies addressing the biochemistry of TTR variants, regarding ligand binding 
affinity, tetrameric stability and three-dimensional structure, in comparison with the WT 
protein were performed. The crystal structure of TTR Leu55Pro revealed significant 
alterations in the regions of dimer–dimer contacts (Sebastiao et al., 1998), which is in 
accordance with the decreased stability of the tetramer (McCutchen et al., 1993; Lashuel 
et al., 1998). These observations correlate with the high amyloidogenicity of this variant. In 
addition, TTR Leu55Pro/TTR WT heterotetramers obtained from the plasma of an 
heterozygotic carrier revealed a very low binding affinity for T4, while recombinant TTR 
Leu55Pro did not bind T4 (Almeida and Saraiva, 1996). TTR Thr119Met shows, in vitro, an 
increased T4 binding affinity (Almeida et al., 1997) and a marked resistance against 
amyloid formation (McCutchen et al., 1995). X-ray analysis of the TTR Thr119Met–T4 
complex demonstrated that this variant presents alterations in the T4 binding channel, 
including dimer–dimer contacts (Sebastiao et al., 2001). 
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2 APOLIPOPROTEIN A-I 
Apolipoprotein A-I (apoA-I) was one of the first apolipoproteins to be identified and 
characterized (Brewer et al., 1978). ApoA-I is the main protein component of human high-
density lipoproteins (HDL) and plays a pivotal role in the mechanism of reverse cholesterol 
transport (Fielding and Fielding, 1995). The two major sites of apoA-I synthesis are the 
liver and intestine, being the liver the major contributor to plasmatic apoA-I and HDL levels 
(Ikewaki et al., 1993). 
2.1 ApoA-I gene structure, expression and regulation 
The gene for apoA-I is 1.8 kb in length and resides in an apolipoprotein gene cluster 
located on the long arm of chromosome 11. With reference to the orientation of the apoA-I 
gene, from 5' to 3' the genes in the cluster are apoA-I, apoC-111, and apoA-IV. ApoA-I 
contains four exons and three introns (Figure 7). Only three of the exons are located in the 
translated region: exon 2 codifies the prepropeptide of 24 amino acids (composed by an 
18-amino acid signal peptide and a 6-amino acid propeptide); exon 3 and 4 hold the 
coding sequences of the mature protein residues 1-43 and 44-243, respectively (Law and 
Brewer, 1984). Intron 1 interrupts the 5' untranslated region of the gene; intron 2 interrupts 
a coding region of the gene very close to the signal peptidase cleavage site; and intron 3 
interrupts the part of the gene encoding the mature peptide (Li et al., 1988). 
 
 
Figure 7 - Structural organization of the human apoA-I gene. The wide bars represent the 
exons, and the thin line the introns. Adapted from www.ncbi.nlm.nih.gov. 
 
The transcriptional regulation of the apoA-I gene is complex and being influenced by 
several factors: i) polymorphisms in its promoter sequence (Pagani et al., 1990; Barre et 
al., 1994); ii) hormonal and nutritional signals, such as estrogens, which activate apoA-I 
expression (Brinton, 1996; Harnish et al., 1998; Zhang et al., 2001); iii) thyroid hormones 
and 9-cis-retinoic acid may increase apoA-I expression through specific response 
elements in the gene promoter when bound to the thyroid hormone receptor and to the 
retinoid X receptor (Hargrove et al., 1999); iv) 25-dihydroxycholecalciferol inhibits apoA-I 
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gene expression via the vitamin D receptor and a vitamin D response element of the 
apoA-I promoter (Wehmeier et al., 2005); and v) anti-oxidant molecules such as α-
tocopherol and ascorbate are also able to inhibit apoA-I expression (Mooradian et al., 
2006). 
In mammals, the apoA-I gene is expressed only in the liver and the intestine. ApoA-I is 
synthesized with a prepropeptide of 24 amino acids. After cleavage of the 18-amino acid 
signal peptide, the pro-protein is secreted to the plasma, where the hexapeptide pro-
segment is cleaved by an unidentified metalloprotease (Scanu et al., 1984).  
2.2 ApoA-I structure 
ApoA-I is a 28-kDa, 243-amino acid protein. Comparison of sequences amongst 
mammals indicates that the N-terminal domain of apoA-I is highly conserved while the 
central and C-terminal domains show conservative substitutions. In terms of secondary 
structure, the apoA-I sequence, apart from the first N-terminal 44 residues, appears to be 
organized into eight α-helical segments of 22 amino acids and 11-mer repeats frequently 
separated by proline residues (Brouillette et al., 2001). 
Approximately 5% of human plasma apoA-I exists in a lipid-free state. Currently there is 
no strong consensus as to whether this fraction is truly lipid-free or if it contains trace 
amounts of lipids (lipid-poor). Structural studies have been performed with apoA-I 
completely delipidated as in this form it can be studied in aqueous solution. The crystal 
structure of lipid-free apoA-I was recently resolved at 2.4 Å. In this structure apoA-I folds 
as a monomer and consists of two helical domains, a four-helix antiparallel bundle formed 
by the N-terminal three-quarters of apoA-I and a two-helix bundle adopted by the C-
terminal quarter of the molecule (Ajees et al., 2006) (Figure 8). 
 
 
Figure 8 - Structure of lipid-free human apoA-I. PDB entry 2A01. 
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During the transition from lipid-free to lipid-bound apoA-I, several conformational changes 
occur in the apoA-I molecule, suggesting that its structure is different between discoidal 
and spherical HDL. The discoidal HDL particles, due to their short-life, are not easily 
isolated from human plasma. In order to study the structure and biology of those particles, 
methods were developed to reconstitute discs in vitro (Matz and Jonas, 1982). The data 
obtained with reconstituted HDL particles (rHDL) suggested the “5/5 double-belt” model  
(Figure 9) in which two ring-shaped apoA-I molecules wrap around a patch of 
phospholipids bilayer, each on its own leaflet, in an antiparallel orientation. In this model 
helix 5 of each apoA-I molecule is the point of overlap between the two molecules 
(Segrest et al., 1999). Although the majority of HDL found in plasma exists as spherical 
particles, much less is known about the conformation of apoA-I in those particles 
(Davidson and Thompson, 2007). 
 
 
Figure 9 – Representation of the “5/5 double-belt” model. The model shows two molecules of 
apoA-I, one on top and one on the bottom, that surround a patch of phospholipid bilayer (not 
shown). This model was built using the  Δ1–43 deletion mutant of apoA-I. The N-terminal amino 
acid 44 is shown in red space-fill form, and the C-terminal 50 amino acids are in yellow with the 
terminus in yellow space-fill. Helix 5, the point of overlap of the two molecules, is indicated in blue. 
Adapted from (Davidson and Thompson, 2007). 
 
Limited proteolysis has been used as an in vitro tool for the elucidation of structural 
features of apoA-I. All limited proteolysis studies have clearly shown that lipid-poor apoA-I 
is more susceptible to proteolysis than the lipid-bound protein and that the C-terminal part 
is preferentially cleaved (Ji and Jonas, 1995; Roberts et al., 1997; Rogers et al., 1998). 
Studies with rHDL particles have shown that the proteolytic fragments of apoA-I dissociate 
from lipids upon cleavage, reinforcing the concept that the C-terminal part of apoA-I is 
more effective in determining intimate contact between lipids and the protein (Obici et al., 
2006). 
Regarding the relation between apoA-I structure and function, it was demonstrated that 
the C-terminal part of apoA-I plays an essential role in the process of ABCA-1 mediated 
lipid efflux (Burgess et al., 1999), leading to formation of the nascent HDL particles, 
whereas its central region has been implicated in the activation of lecithin cholesterol 
acyltransferase (LCAT) (Uboldi et al., 1996). Regarding binding to SR-BI, which is 
important for the selective cholesterol uptake (Trigatti et al., 2003), it was proposed that 
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the N-terminus and the C-terminus of apoA-I directly or indirectly contribute independently 
to binding to the receptor (Liadaki et al., 2000). 
In summary, it seems that the α-helical segment in the N-terminus of apoA-I modulates its 
lipid-free structure while the C-terminus mediates the interaction with lipids (Tanaka et al., 
2006). 
2.3 ApoA-I function and metabolism 
The mechanisms regulating apoA-I-HDL plasmatic levels are related with the apoA-I 
central role in the mechanism of reverse cholesterol transport (RCT), in which peripheral 
cell cholesterol is returned to the liver for subsequent metabolism. The process of reverse 
cholesterol transport is specially critical for macrophages, which lack the ability to regulate 
the influx of cholesterol from modified low-density lipoproteins (LDL), and are therefore 
easily transformed into cholesterol-loaded foam cells, typical of early atherosclerotic 
lesions. Low plasma apoA-I-HDL levels are a major risk factor to coronary artery disease 
(Gordon and Rifkind, 1989). ApoA-I is involved in each of the three steps of RCT: i) 
transfer of free cholesterol (FC) to acceptors mediated by the ATP-binding cassette 
transporter A1 (ABCA-1); ii) esterification of cholesterol to cholesteryl esters (CE) by the 
enzyme lecitin cholesterol acyl transferase (LCAT); and iii) delivery of CE to the liver 
mediated by the scavenger receptor class B type 1 (SR-BI) (Figure 10).   
 
The role of apoA-I in RCT modulates HDL metabolism and function. Lipid-free apoA-I and 
poorly-lipidated apoA-I are secreted by the hepatocytes and acquire free cholesterol in the 
peripheral cells, upon interaction with ABCA-1, forming the nascent discoidal HDL (preβ-
HDL) particles (Tsujita et al., 2005). ApoA-I synthesized in the intestine is secreted as a 
component of the chylomicrons, and is transferred to HDL particles in the circulation 
 
 
Figure 10 - Schematic representation of the reverse cholesterol transport process and HDL 
metabolism. Adapted from (Rader and Pure, 2000). 
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through action of the lipoprotein lipase (Schaefer et al., 1978). Mature spherical HDL (α-
HDL) are generated from the nascent HDL by the conversion of cholesterol into 
cholesteryl esters mediated by the HDL-associated enzyme LCAT (Jonas, 2000). This 
reaction ensures that nascent HDL are normally absent in human plasma. In the last step 
of RCT, CE transported in spherical HDL are delivered to the liver and steirodogenic 
tissues, through apoA-I-mediated interaction between HDL and SR-BI, for subsequent 
excretion in the bile. SR-BI mediates the efflux of CE from HDL to cells without HDL 
particle degradation; this process is termed selective cholesterol uptake (de Beer et al., 
2001; Trigatti et al., 2003). Only 5% of plasma apoA-I circulates in lipid-free or lipid-poor 
form. The protein cycles between that form and the HDL-bound form through the action of 
several factors. CE can be transferred to apoB containing lipoproteins, in an exchange for 
triglycerides, through the action of CE transfer protein (CETP) and returned to the liver via 
the LDLr. The TG-enriched HDL become the substrate for hepatic lipase (HL) and other 
endothelial lipases (EL), which degrade TG and phospholipids (transferred to HDL by the 
phospholipid transfer protein, PLTP). This results in shrinkage of the HDL particle, with 
release of surface material, including lipid-free apoA-I (Rye and Barter, 2004).  
Lipid-free apoA-I can be catabolised via the kidney or recycle into HDL either by 
incorporation in pre-existing HDL particles or through interaction with ABCA-1 (Rader, 
2003). The kidney seems to be the major site for apoA-I degradation. As lipid-free and 
lipid-poor apoA-I have a smaller size than the cut-off value of the glomerular barrier, these 
particles may be readily removed from the circulation by glomerular filtration. Filtered 
apoA-I is totally reabsorbed in the proximal convoluted tubule being almost undetectable 
in the urine (Glass et al., 1983). Cubilin, a multiligand receptor expressed in the kidney 
binds apoA-I mediating apoA-I endocytosis (Moestrup and Kozyraki, 2000).  
2.4 ApoA-I mutations 
More than 50 natural mutants of apoA-I have been reported and about one-half are 
associated with reduced HDL levels (Sorci-Thomas and Thomas, 2002). Mutations 
associated with low HDL concentrations fall into two main categories: those that poorly 
activate LCAT and those associated with amyloidosis. Mutations associated with 
abnormal LCAT activation are located in the apoA-I region encompassing amino acids 
121-186, while mutation in the N-terminus of the protein are found in human amyloid 
proteins (Sorci-Thomas and Thomas, 2002) A list of natural occurring apoA-I mutations 
together with their functional and clinical consequences is represented in Figure 11. 
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Figure 11 - Natural occurring human apoA-I mutations. Panel A, apoA-I mutations associated 
with hereditary amyloidosis. Panel B, apoA-I mutations associated with low plasma HDL 
concentrations. (*) indicate apoA-I mutations that display a dominant negative phenotype in 
heterozygous carriers. Panel C, apoA-I mutations not associated with low plasma HDL 
concentrations. The shaded areas in panels A through C illustrate a rolling average of mutation 
frequency. Each apoA-I mutation is shown at its approximate primary sequence location. Columns 
A, B, C list references for each numbered apoA-I mutation. Adapted from (Sorci-Thomas and 
Thomas, 2002). 
 
ApoA-I amyloidosis will be described in detail in the following section. 
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3 AMYLOIDOSIS 
Amyloidosis includes a group of disorders that results from the abnormal deposition of a 
particular protein, in the form of amyloid fibrils, in one or more organs. Classification of 
amyloidosis is based on the type of amyloid fibril protein, and about 27 different unrelated 
proteins are known to form amyloid fibrils in vivo (Westermark, 2005). 
3.1 Amyloid 
The definition of amyloid is mainly based on its  β-sheet fibrillar structure. The unifying 
structure is an assembled protein fibril in which the sheets are parallel to the fibril direction 
and where the strands run perpendicular to the fibril (Eanes and Glenner, 1968; Glenner, 
1980a, b). This organization is believed to be common to all amyloid fibrils, irrespective of 
the biochemical nature. Electron microscopy studies indicate that the basic assembled 
unit is a thin filament of approximately 4 nm, and that the mature fibrils consist of a few 
such protofilaments aligned in parallel, often with a twist (Shirahama and Cohen, 1967). 
Another characteristic feature of amyloid fibrils is the affinity for Congo Red; amyloid fibrils 
present a green birefringence under polarized light, after Congo Red staining. This feature 
is the most commonly used to define amyloid. According to the Nomenclature Committee 
of the International Society of Amyloidosis the designation of amyloid is restricted to in 
vivo material, deposited extracellularly or intracellularly, with typical staining reactions. 
This designation was first restricted to extracellular deposits, but with the increasing 
evidence that certain types of amyloid start inside the cell, the designation was changed 
(Westermark, 2005). 
The amyloid-precursor proteins usually exist in a soluble circulating form that, by some 
undefined mechanism, precipitate and form insoluble fibrillar deposits. The main fibrillar 
protein and a set of additional components, common to all amyloid deposits, generally 
compose the amyloid deposits. Serum amyloid-P (SAP) and heparan sulfate proteoglycan 
(HSPG) are two examples of these additional components, and they seem to have an 
effect on the stabilization of the fibrils. However, the mechanism through which these 
components associate or participate in the mechanism of fibril formation is still not known 
(Westermark, 2005). 
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3.2 Amyloidoses 
Amyloid disorders can be divided in two major types: localized amyloidoses, where 
deposits occur in a single tissue or organ; and systemic amyloidoses, where deposits are 
found in many or most tissues and organs. Some amyloid precursor proteins are involved 
both in localized and systemic amyloidosis forms, as the cases of immunoglobulin light 
chain (AL), immunoglobulin heavy chain (AH), and apoA-I (Westermark et al., 2007). 
Other designations are commonly used to name amyloidosis: i) primary amyloidosis, 
which commonly refers to AL amyloidosis, occurs independently of another disease, i.e. 
no specific cause or disease is related to the abnormal protein deposits; ii) secondary 
amyloidosis, which commonly refers to AA amyloidosis, occurs "secondarily" as a result of 
another illness: and iii) familial amyloidosis, which designation indicates that the disorders 
are genetically determined. 
3.2.1 Localized amyloidoses 
In localized amyloidoses, generally the fibril precursor protein is synthesized at the site of 
deposition, without being previously transported by the plasma. However, there are some 
exceptions. For example, apoA-I may give rise to systemic amyloidosis from the 
circulating precursor, while the origin of the precursor in the localized AApoAI-amyloid 
forms is not known with certainty. In the case of AL amyloidosis, it occurs sometimes as a 
localized form in tumors. In these cases, the precursor protein is produced by a clone of 
plasma cells present at the site of deposition.  
Specific amyloid deposits are commonly found in association with aging; these conditions 
are named senile localized amyloidoses. Two examples are the Aβ-amyloid in the brain, 
associated with Alzheimer’s disease, and islet amyloid polypeptide (IAPP)-amyloid in the 
islets of Langerhans, associated with Type 2 Diabetes. A list of the described localized 
amyloidoses in humans is presented in Table 1. 
Table 1 - Amyloid Fibril Proteins and Precursors of Localized Amyloidoses. Adapted from 
(Westermark et al., 2007). 
Amyloid Protein Precursor Syndrome or involved tissues 
AL Immunoglobulin light chain Primary 
Myeloma-associated 
AH Immunoglobulin heavy chain Primary 
Myeloma-associated 
AApoAI Apolipoprotein A-I Aorta, meniscus 
ADan ADan protein precursor Familial dementia, Danish 
Aβ Amyloid β protein precursor Alzheimer’s disease, aging 
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APrP Prion protein Spongioform encephalopathies  
ACal (Pro)calcitonin C-cell thyroid tumors 
AIAPP Islet amyloid polypeptide Islets of Langerhans 
Insulinomas 
AANF Atrial natriuretic factor Cardiac atria 
APro Prolactin Aging pituitary 
Prolactinomas 
AIns Insulin Iatrogenic 
AMed Lactadherin Senile aortic, media 
AKer Kerato-epithelin Cornea, familial 
AOaap Odontogenic ameloblast 
associated protein 
Odontogenic tumors 
ALac Lactoferrin Cornea 
ASemI Semenogelin I Seminal vesicles 
ATau Tau Alzheimer´s disease,  
fronto-temporal dementia, 
aging, other cerebral conditions 
 
3.2.2 Systemic amyloidoses 
In systemic amyloidoses, the protein precursor is synthesized at one or several locations 
and secreted to the plasma, where it is transported to the deposition sites. Systemic 
amyloidoses are characterized by the deposition of amyloid in many tissues and organs. 
With the exception of ABri amyloidosis, the brain is generally not affected. These 
disorders usually involve the heart or kidneys. However, there is sometimes a deposition 
pattern variation within one specific type of amyloidosis as, for example, the case of ATTR 
amyloidosis that will be discussed later. Two important questions regarding systemic 
amyloidoses are still not answered. One, is why the proteins deposit in certain locations; 
and the second, is related with the local where the precursor protein obtains its 
amyloidogenic fold, at the deposition site or earlier. A list of the human proteins described 
as major components in systemic amyloidoses is presented in Table 2. Although most of 
these proteins are unrelated, two families are over-represented, the immunoglobulin-
related proteins and the apolipoproteins. 
Table 2 - Amyloid Fibril Proteins and Precursors of Systemic Amyloidoses. Adapted from 
(Westermark et al., 2007). 
Amyloid Protein Precursor Syndrome or involved 
tissues 
AL Immunoglobulin light chain Primary  
Myeloma-associated 
AH 
 
Immunoglobulin heavy chain Primary 
Myeloma-associated 
Aβ2M β2-microglobulin Hemodialysis-associated 
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ATTR 
 
Transthyretin Familial  
Senile systemic 
AA Serum amyloid A Secondary, reactive 
AApoAI Apolipoprotein AI Familial 
AApoAII Apolipoprotein AII Familial 
AGel Gelsolin Familial 
ALys Lysozyme Familial 
AFib Fibrinogen α-chain Familial 
ACys Cystatin C Familial 
ABri ABri protein precursor Familial dementia, British 
 
 
In the following two sections, two types of amyloidoses, ATTR amyloidosis and AApoA-I 
amyloidosis, will be discussed in detail, as they were the subject of ourstudy in the 
research project of this thesis. 
3.2.3 ATTR-amyloidosis 
Transthyretin is the major fibril protein and is the precursor of three types of amyloidoses: 
familial amyloidotic polyneuropathy (FAP; Andrade, 1952), familial amyloidotic 
cardyomyopathy (FAC; Nordlie et al., 1988) and systemic senile amyloidosis (SSA; 
Cornwell et al., 1988). 
ATTR-amyloidosis is an autossomal dominant disease, with most of the affected 
individuals being heterozygous for a pathogenic mutation and expressing both normal and 
variant TTR. More than 90 amyloidogenic mutations in TTR have been described 
(Saraiva, 2001), presenting some clinical heterogeneity including cardiomyopathy (Saraiva 
et al., 1990; Saito et al., 2001), carpal tunnel syndrome (Izumoto et al., 1992; Murakami et 
al., 1994), vitreous TTR deposition (Salvi et al., 1993; Zolyomi et al., 1998) and 
leptomeningeal involvement (Petersen et al., 1997; Brett et al., 1999; Yazak et al., 2000) 
but, in most cases, associated with neuropathy. 
Familial amyloidotic polyneuropathy (FAP) was first described by Corino de Andrade in 
1952 in the Portuguese population. In 1978, Costa et al. demonstrated that TTR was the 
most abundant protein in the amyloid fibrils, and in 1984 biochemical studies by Saraiva et 
al. revealed that a mutation, TTR Val30Met, was present in the FAP patients. FAP is a 
neurodegenerative disorder characterized by the systemic extracellular deposition of 
mutated TTR, particularly in the peripheral nervous system (PNS), leading to organ 
dysfunction and ultimately, death. The manifestation of this disease does not start until 
adult life, and leads to a progressive and severe sensory, motor and autonomic 
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polyneuropathy fatal in about 10 to 20 years (Coutinho et al., 1980).  
The most aggressive amyloidogenic variants are Leu12Pro and Leu55Pro producing an 
early-onset progressive form of liver amyloidosis and a form of neuropathy associated 
cardiomyopathy, respectively (Jacobson et al., 1992; Brett et al., 1999). With exception of 
the cases of homozygous individuals for TTR Val30Met (Skare et al., 1990), TTR 
Leu58His (Jacobson et al., 1994), and TTR Val122Ile (Jacobson et al., 1991), 
amyloidogenic TTR variants are normally found in the heterozygous state. Some 
individual are carriers of two different mutated alleles, as the cases of heterozygous for 
His90Asn/Thr119Met and Val30Met/ThrMet119 (Saraiva et al., 1991; Curtis et al., 1991; 
Almeida et al., 1997; Alves et al., 1997). Thr119Met is commonly referred as a protective 
mutation since when expressed with Val30Met, in the Val30Met/ThrMet119 heterozygous, 
a more benign form of the disease is found. 
Although cardiac amyloidosis is a frequent secondary manifestation in FAP, some TTR 
variants lead to a specific form of cardiomyopathy without neuropathy. Familial cardiac 
amyloidosis (FAC) is related mainly to two TTR variants: TTR Val122Ile and TTR 
Leu111Met. The Val122Ile variant is associated with one of the latest-onset and slowest 
progressive forms of amyloidosis, and is present in approximately 3-4% of African-
Americans (Gorevic et al., 1989; Jacobson et al., 1996). 
Senile systemic amyloidosis (SSA), also called senile cardiac amyloidosis, is the most 
prevalent form of TTR amyloidosis affecting approximately 25% of individuals older than 
80. In SSA, normal (non-mutated) TTR forms amyloid deposits in the heart (Gustavsson et 
al., 1995). 
3.2.3.1 Hypotheses for TTR amyloidogenesis 
The mechanism of TTR fibril formation is still not completely characterized. It is believed 
that other factors besides TTR inherent tendency to self-aggregate (given it’s high β-sheet 
content) are important for its amyloidogenic process. 
The two main mechanistic hypotheses that were proposed to induce TTR 
amyloidogenesis are described below. 
The conformational hypothesis 
The conformational hypothesis was based on the alterations of the TTR structure 
mediated by mutations or other factors, which would favor the formation/exposure of new 
structural motifs that would lead to tetramer dissociation and formation of partially 
unfolded intermediates. In accordance with this hypothesis, data on in vitro fibril formation 
suggests that the TTR monomer is the intermediate in the pathway of TTR fibrillogenesis, 
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and that the stability of the tetramer is the most important factor in amyloid fibril formation 
(Quintas et al., 2001) (Figure 12).  
 
 
Figure 12 - Hypothetical pathway of TTR amyloid fibril assembly. Native TTR tetramer 
molecule dissociates into modified monomers that self-aggregate producing non-fibrillar TTR 
aggregates, protofibrils and amyloid fibrils; adapted from (Sousa and Saraiva, 2003). 
 
Several crystal structures of TTR mutants were determined in order to analyse the effect 
of amyloidogenic amino acid substitutions in the overall structure of the molecule. 
Crystallographic works on amyloidogenic variants such as TTR Val30Met (Hamilton et al., 
1993), TTR Val122Ile (Damas et al., 1996), and TTR Ile84Ser (Hamilton et al., 1996), 
revealed an overall structural homology with the WT protein. However, the crystal of TTR 
Leu55Pro, a mutation associated with one of the most aggressive forms of TTR-
amyloidosis, showed several structure alterations in comparison to the WT molecule and 
revealed that changes in the D strand together with the contacts of the AB loop and the α-
helix are pivotal in amyloid formation (Sebastiao et al., 1998). Subsequently, in vitro 
studies were performed with another TTR amyloidogenic variant, Tyr78Phe (Anesi et al., 
2001), which, by analogy with the X-ray structure of TTR Leu55Pro, should present 
destabilization in the AB loop and consequently in the tetrameric fold. This variant was 
very prone to amyloid formation. Moreover, the protein was recognized by a monoclonal 
antibody known to react only with highly amyloidogenic mutant proteins (Redondo et al., 
2000). These observations are in agreement with the conformational hypothesis; the 
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destabilization of the tetrameric fold introduced by mutations is in the basis of TTR 
fibrillogenesis. However, normal (non-mutated) TTR can also form amyloid, meaning that 
besides the mutation in the TTR molecule other factors may intervene in the 
amyloidogenicity of the protein. 
The Proteolytic hypothesis 
Proteolysis has been thought to play an important role in most types of amyloidosis. In 
several cases, an amyloid peptide is generated by proteolytic cleavage of the 
corresponding protein precursor. 
In the cases of SSA and in some FAP patients, apart from full-length protein, TTR 
fragments are found in the amyloid deposits. These observations raised the hypothesis 
that proteolysis could trigger TTR fibril formation (Saraiva and Costa, 2001). The 
incorporated TTR fragments in the amyloid deposits are the C-terminal regions of the 
protein, meaning that proteolysis occurs in the N-terminal region of the protein with the 
consequent loss of the N-terminus. The described cleavage sites occur in the same region 
of the molecule, independently from the variant involved: in SSA fibrils, the fragments 
observed result from cleavage at positions 46, 49 and 52 (Cornwell et al., 1988); in TTR 
Val30Met (Wahlquist et al., 1991), TTR Val122Ile (Gorevic et al., 1989) and TTR Phe33Ile 
(Pras et al., 1983; Nakazato et al., 1984) fragments result from cleavage at position 49; in 
the case of TTR Leu111Met carriers contain TTR molecules cleaved at positions 46, 49 
and 59 are found in the amyloid deposits (Hermansen et al., 1995). 
In a report from Bergstrom et al. in 2005, studies performed with 14 SSA patients and 11 
Swedish FAP patients have shown two distinct patterns of amyloid deposition. In all SSA 
patients and 5 of the FAP patients, amyloid deposits presented an homogeneous but 
patchy distribution within specific regions of the cardiac tissue, were weakly congophilic 
and composed mainly by ~79-residue C-terminal fragments of TTR (meaning that 
cleavage occurs in the same region as described above); while in the remaining 6 FAP 
patients amyloid was distributed throughout the cardiac tissue, was strongly congophilic, 
and was composed by intact TTR molecules. These authors proposed the existence of 
two mechanisms for fibril formation in TTR amyloidosis. One, involving the incorporation of 
full-length monomers in the fibrils, and a second where cleavage of the TTR molecule 
results in fibrils composed mainly by C-terminal fragments. This report clearly shows that 
there are several pathways in the fibrillogenesis of TTR, but at least one, probably non-
essential, includes proteolysis. The role of proteolysis in TTR amyloidosis should 
constitute a subject of further investigation. 
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3.2.4 Apolipoprotein A-I-amyloidosis 
Apolipoprotein A-I (apoA-I)-amyloidosis occurs as a hereditary and a nonhereditary form. 
Hereditary ApoA-I amyloidosis is a systemic disorder caused by several variants of the 
protein. The non-hereditary form is more frequent and is a localized type of amyloidosis 
with deposition of non-mutated apoA-I within the atherosclerotic plaques. 
3.2.4.1 Systemic ApoA-I amyloidosis 
The first amyloidogenic variant of apoA-I was described by Nichols et al. in 1988, and 
resulted from a substitution of a glycine by arginine at position 26, Gly26Arg. Currently, 
twelve mutations in the apoA-I gene have been associated with systemic amyloidosis 
(Benson, 2003). Apart from the Gly26Arg case, the only variant associated with peripheral 
neuropathy, the main clinical features of apoA-I amyloidosis are hepatopathy and 
nephropathy (Benson and Kincaid, 2007). In some patients, a progressive cardiomyopathy 
is observed (Benson and Kincaid, 2007). The skin and larynx are also frequently involved 
(Gregorini et al., 2005). ApoA-I amyloidosis is an autossomal dominant disorder and all 
affected individual are heterozygous for one of the twelve described mutations. The 
majority of apoA-I amyloidogenic mutations resulted in the introduction of an additional 
positive charge in the amino acid sequence, suggesting that this electrostatic alteration 
might play a pathogenic role (Pepys et al., 1996). However, three distinct described apoA-
I variants, including Leu90Pro, Leu75Pro and Leu64Pro, do not imply an additional 
positive charge, but rather confirm the loss of a hydrophobic residue (Obici et al., 1999; 
Coriu et al., 2003; Murphy et al., 2004; Obici et al., 2004). 
ApoA-I amyloid fibrils are mainly composed by fragments of the mutated protein 
corresponding to its 70-100 N-terminal residues. Almost all amyloidogenic mutations of 
apoA-I occur in the N-terminus of the protein, which is the portion of the protein found in 
the amyloid fibrils; four additional mutations were found in the C-terminal region 
encompassing residues 173-178, namely Arg173Pro, Leu174Pro, Ala175Pro and 
Leu178His. In these cases, the mutation is in a position that is more C-terminal than the 
fragments identified in the fibril (Hamidi Asl et al., 1999; Obici et al., 1999; Lachmann et 
al., 2002). 
3.2.4.2 Localized apoA-I amyloidosis 
A localized form of apoA-I amyloidosis in found within the atherosclerotic plaques. In most 
cases of atherosclerotic-associated apoA-I amyloidosis, amyloid fibrils are derived from N- 
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terminal fragments of WT apoA-I (Mucchiano et al., 2001a), although there are described 
cases caused by deposition of apoA-I variants (Amarzguioui et al., 1998).  
In an attempt to explain the appearance of apoA-I amyloid deposits within atherosclerotic 
plaques, it was suggested that during atherosclerosis, which involves inflammation, 
elevated levels of the acute phase reactant serum amyloid A (SAA) might displace apoA-I 
from HDL, leading to an increased concentration of lipid-free apoA-I in the intima and 
conformational changes of apoA-I which would make it more fibrillogenic (Mucchiano et 
al., 2001b). 
3.2.4.3 Hypotheses for ApoA-I amyloidogenesis 
Unlike other amyloid precursor proteins, such as TTR, apoA-I has no β-structure. 
Moreover, the presence of wild-type apoA-I amyloid deposits in atherosclerotic plaques, 
rules out the hypothesis that the alterations resulting from mutations are the only 
explanation for apoA-I amyloidogenicity. 
In both systemic and localized forms of apoA-I amyloidosis, N-terminal fragments of 
mutated and WT protein, respectively, are present in the amyloid fibrils. Based on these 
facts, proteolysis seems to represent a major pathway in apoA-I fibrillogenesis. 
Biochemical data suggested that the cleavage of the full-length apoA-I and the release of 
the N-terminal fragments could represent the regulatory step in the fibrillogenic pathway of 
apoA-I (Andreola et al., 2003). Proteolysis seems to be crucial for any further metabolic 
processing of apoA-I; enhanced proteolytic susceptibility is described for apoA-I variants 
associated with metabolic abnormalities. The apoA-I mutation Leu159Arg affects the 
protein secretion, reduces the half-life of circulating apoA-I, and has a dominant negative 
effect on WT apoA-I (McManus et al., 2001). In this mutation a N-terminal polypeptide is 
released in plasma and appears to prime a degradative, rather than a fibrillogenic, 
pathway (McManus et al., 2001). N-terminal peptides of apoA-I amyloidogenic variants are 
undetectable in the plasma, what can be due to a faster catabolism of these fragments, 
but also to a very fast absorption on the amyloid fibrils. Furthermore, the different fate of 
the fragments, degradation or deposition, can be due to differences in the compartment in 
which the proteolytic event takes place (Obici et al., 2006). 
In 1995 Wisniewski et al. reported the in vitro conditions for full-length apoA-I 
fibrillogenesis. Some reports described trace amounts (Soutar et al., 1992; Obici et al., 
1999) of full-length apoA-I present in amyloid deposits composed of N-terminal fragments 
of the protein. In a case involving the variant Leu178His, the deposits appear to contain 
both an N-terminal-derived fragment and substantial amounts of full-length apoA-I (de 
Sousa et al., 2000). Although, these observations suggest that proteolysis may not be 
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essential for apoA-I fibrillogenesis, it surely enhances apoA-I amyloidogenicity. 
3.2.4.4 ApoA-I as a minor component in other amyloidosis 
WT apoA-I is related with amyloidosis, not only as a major constituent of amyloid fibrils, 
but also as a minor component of in various kinds of amyloidosis in which apoA-I is not 
the prime amyloid precursor protein. ApoA-I has been shown to colocalize with senile 
plaques in Alzheimer´s disease patients (Wisniewski et al., 1995). More recently, apoA-I 
colocalization was described in various kinds of systemic amyloidoses not-related with 
apoA-I mutations, as AA, AL, ATTR, and Aβ2M amyloidosis (Sakata et al., 2005). First it 
was hypothesized that apoA-I might only be trapped in amyloid deposits, as serum 
proteins trapped in amyloid deposits were previously reported (Rocken et al., 1996; Strege 
et al., 1998); but the presence of apoA-I present in crude-extracted AL amyloid, suggested 
that apoA-I was an insoluble component of amyloid deposits. Furthermore, in the 
immunohistochemical analysis of the systemic amyloidosis cases, the anti-apoA-I 
immunoreactive area of amyloid deposits was variable within each case, suggesting that 
in those cases apoA-I might not be essential for amyloidogenesis (Sakata et al., 2005). 
The role of apoA-I in other amyloidoses not related with apoA-I mutations is unclear. In the 
case of AD, apoA-I has been shown to bind Aβ and promote Aβ fibrillogenesis in vitro 
(Wisniewski et al., 1995). Further studies concerning the relation between apoA-I and 
each of the amyloid precursor proteins of the cases described are needed.  
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4 PROTEASES 
Proteases are pivotal in several physiological and pathological mechanisms. Protease is 
the commonly used synonym for the term peptidase, the designation recommended by the 
International Union of Biochemistry and Molecular Biology (IUBMB) for the subclass of 
hydrolases that act on peptide bonds. Peptidases can be divided in: 
• Exopeptidases – cleavage near the N- or C-terminus of polypeptide chains 
o Aminopeptidases – release a single N-terminal amino acid residue 
o Dipeptidyl-peptidases and Tripeptidyl-peptidases – release dipeptides or a 
tripeptides from the N-terminus 
o Peptidyl-dipeptidases – release dipeptides from the C-terminus 
o Carboxypeptidases – release a single C-terminal aminoacid residue 
o Dipeptidases – cleavage of dipeptides  
o Omegapeptidases – remove terminal residues that are substituted, cyclized 
or linked by isopeptide bonds  
• Endopeptidases or proteinases – cleavage of internal peptide bonds within the 
polypeptide chain 
 
Regarding the catalytic mechanism, proteases are divided into six major types (Rawlings 
et al., 2006): serine, cysteine, aspartic, metallo, threonine, and glutamic proteases. 
According to the Merops database, a system created by Rawlings and Barret in 1993, 
proteases within a catalytic type are further classified in families and clans. The term 
family is used for proteases with statistically significant similarities in amino acid 
sequence; groups of families for which there are indications of evolutionary relationships 
(as a common three-dimensional structure or active site arrangement) are assigned into a 
clan. Each family and clan has an identifier that shows the catalytic type of the protease 
contained in the group. The identifiers are: A (aspartic), C (cysteine), M (metallo), S 
(serine), P (mixed catalytic type), T (threonine) and G (glutamic) (Rawlings et al., 2006). 
 
The interaction of a substrate with a protease also follows a specific nomenclature that 
has been introduced in 1967 by Schechter and Berger (Figure 13). This system considers 
that the amino acid residues of the polypeptide substrate bind in enzyme subsites of the 
active site. The substrate amino acid residues are called P, being the ones on the N-
terminal side of the scissile bond numbered P3, P2, P1 and those on the C-terminal side 
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numbered P1', P2', P3'... The P1 and P1' residues are those residues surrounding the 
scissile bond. The subsites on the protease that interact with the substrate are called S 
and are numbered S3, S2, S1, S1', S2', S3'... corresponding to each P site. 
 
 
Figure 13 - Schematic representation of a protease-substrate interaction according to the 
Schechter and Berger nomenclature (1967). Adapted from http://delphi.phys.univ-
tours.fr/Prolysis/ 
 
For most of the proteases, the proteolytic mechanism and substrates are well defined. 
However several proteases, named cryptic proteases, pursue an “obscure” nature which 
is related to either of the following aspects: i) lack of structural protease features and/or 
undisclosed proteolytic mechanism; ii) unclear physiological function and/or unknown 
physiological substrate; iii) substrate well-defined but protease still unidentified, and finally 
iv) proteases that raise evolutionary questions as to the origin of certain biological events 
(Liz and Sousa, 2005). 
 
In this section the various mechanistic classes of proteases will be described, including in 
each of the classes some examples of cryptic proteases.  
4.1 Serine Proteases 
Over one third of all known proteolytic enzymes are serine proteases. This large family of 
enzymes hydrolyzes the peptide bond of a substrate via a nucleophilic serine residue in 
the active site. The serine proteases comprise two major families:  the chymotrypsin family 
and the subtilisin family. The chymotrypsin family is the largest of all of the protease 
families and includes enzymes involved in several physiological processes such as 
digestion (chymotrypsin, trypsin, and elastase), immune response (tryptase), blood 
coagulation (thrombin), fibrinolisys (plasmin, kallikrein) and reproduction (acrosein). The 
chymotrypsin family is included in Clan PA; this clan encloses proteases with distinct 
catalytic types but that share homology in the active site. The subtilisin (Clan SB) is the 
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second largest family of serine proteases and includes bacterial enzymes such as 
subtilisin. In the chymotrypsin family there are three main activity types: trypsin-like where 
there is cleavage of amide substrates following Arg or Lys at P1, chymotrypsin-like where 
cleavage occurs following one of the aromatic amino acids at P1, and elastase-like with 
cleavage following an Ala at P1. Most members of the subtilisin family are nonspecific 
peptidases with a preference to cleave after hydrophobic residues (Rawlings et al., 2006). 
The general three dimensional structure is different in the chymotrypsin and subtilisin 
families but they share the active site geometry and catalytic mechanism. The standard 
mechanism for canonical serine proteases requires four major structural features 
(Hedstrom, 2002) (Figure 14): 
• Catalytic triad, constituted by a histidine, the general base, an aspartate, the acid 
and a serine, the nucleophile. These residues are close to each other in the active 
site but far apart in the amino acid sequence. In chymotrypsin, His 57, Asp 102 
and Ser 195 form the catalytic triad, and in subtilisin the active site is constituted 
by Asp 32, His 64 and Ser 221. 
• Oxyanion hole, constituted by enzyme atoms that form hydrogen bonds with the 
negatively charged oxygen atom of the carbonyl of the scissile peptide bond. In 
chymotrypsin the backbone NHs of Gly 193 and Ser 195 form the oxyanion hole. 
Subtilisin also contains an oxyanion hole formed by the side chains of Asn 155, 
Thr 220, and the backbone NH of Ser 221. 
• Specificity pocket, formed by enzyme residues that accommodate the side chain 
of the residue located before the scissile peptide bond (P1). 
• Main chain substrate binding, corresponds to the main chain of enzyme 
residues that form an antiparallel beta sheet with the backbone of the P1-P3 
residues of a peptide substrate. 
 
 
Figure 14 - Structure of chymotrypsin. PDB entry 8GCH. Residues in red: catalytic triad; 
residues in white: oxyanion hole; residues in green: specificity pocket; residues in yellow: main 
chain substrate binding.  
Adapted from http://www.med.unibs.it/~marchesi/pps97/course/section12/serprot4.html 
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This mechanism involves two phases: acylation and deacylation. The acylation step starts 
with the attack of the Ser (nucleophile) to the carbonyl group of the substrate peptidic 
bond, assisted by the His that acts as a general base, leading to the formation of a 
tetrahedral transition state intermediate. The resulting protonated His is stabilized by a 
hydrogen bond formed with the Asp. The negatively charged oxygen of the tetrahedral 
intermediate is stabilized by hydrogen bonds with the oxyanion hole residues. Assisted by 
the protonated His, the C-terminal part of the peptide substrate is released leading to the 
formation of the acyl-enzyme intermediate. In the deacylation step, the acyl-enzyme 
intermediate is hydrolyzed by a water molecule to release the N-terminal part of the 
peptide and to restore the Ser-hydroxyl of the enzyme. The deacylation occurs through a 
reverse reaction of the acylation. A water molecule works as the nucleophile attacking the 
carbon atom of the substrate and leading also to the formation of a tetrahedral 
intermediate, and the His residue accepts the proton (Polgar, 2005)(Figure 15). The 
previously described catalytic mechanism, involving a catalytic triad, is valid for several 
serine proteases. However, between different families, the order in sequence of the amino 
acids that constitute the triad is variable (Table 4). In more recently identified families of 
serine proteases, the members of the catalytic triad and the mechanism of action changed 
to some extent (Hedstrom, 2002; Polgar, 2005) Several proteases with novel catalytic 
triads and dyads have been found (non-canonical serine proteases) (Table 3). 
 
Table 3 – Catalytic triads and their variations. Adapted from (Hedstrom, 2002). 
Family Active site 
 
Chymotrypsin 
 
His-Asp-Ser 
Subtilisin Asp-His-Ser 
Prolyl oligopeptidase Ser-Asp-His 
Clp Ser-His-Asp 
 
Cytomegalovirus assemblin His-His-Ser 
Sedolisin Glu-Asp-Ser 
Dipeptidase E Ser-His-Glu 
D-Ala-D-Ala peptidase C Ser-Lys 
Lex A Ser-Lys 
Lon Protease Ser-Lys 
Signal Peptidase I Ser-Lys 
Rhomboid Ser-His 
Penicillin acylase N-terminal Ser 
Canonical catalytic Triad 
Non-Canonical catalytic site 
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Figure 15 - Schematic representation of the catalytic mechanism of serine proteases. The 
enzyme is represented in black and the substrate in pink. Adapted from http://delphi.phys.univ-
tours.fr/Prolysis/.  
 
In the human cytomegalovirus peptidases (Clan SH) the active site is constituted by a His-
His-Ser triad. This is a combination not seen in peptidases of any other family. The 
residues His63, His157 and Ser132 that constitute the catalytic triad superimpose on the 
His57 Asp102 Ser195 triad of trypsin, suggesting a similar catalytic mechanism. The 
residues Arg165 and Arg166 of the virus protease form the oxyanion hole, with Arg165 
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corresponding to Gly193 in trypsin and forming one hydrogen bond, and with a second 
hydrogen bond formed by a water molecule localized in the side chain of Arg166. The 
herpevirus proteases are active only as homodimers (Qiu et al., 1996; Hoog et al., 1997). 
In the sedolisin family (Clan SB), a family of carboxyl serine peptidases, the residues of 
the catalytic triad are Glu-Asp-Ser, with an additional acidic Asp residue in the oxyanion 
hole. The folding of sedolisin is similar to the one of subtilisin.  The nucleophilic Ser 
residue is the equivalent to Ser in the Asp, His, Ser triad of subtilisin, and the Glu is a 
substitution for the His general base in subtilisin. The Asp residue is not structurally 
related with Asp32 from the subtilisin triad but in this new catalytic triad the mechanism is 
similar to that of the canonical serine proteases. One difference is that sedolisin contains 
only one oxyanion binding site, an Asp, which is equivalent to Asn155 in subtilisin 
(Wlodawer et al., 2003). 
The dipeptidase E family (Clan PC) constituted by exopeptidases that hydrolyse alpha-
aspartyl bonds, the catalytic triad is constituted by the residues Ser-His-Glu. In this case 
the Glu residue replaces the Asp residue of the canonical triads (Rawlings et al., 2004) 
Besides variations in the constituents of the canonical catalytic triad, several Ser-Lys/His 
dyads have been described. In the D-Ala-D-Ala peptidase C family (Clan SE), catalysis is 
performed by a Ser-Lys dyad in which the serine carries the nucleophile and the lysine 
acts as the general base (Silvaggi et al., 2003). In the LexA (Clan SF), Lon protease (Clan 
SJ), and signal peptidase I (Clan SF) families the active site is also a Ser-Lys dyad (Luo et 
al., 2001). These enzymes, follow the canonical acyl-enzyme pathway of serine 
proteases. In the Rhomboid family (Clan ST), a family of membrane-bound serine 
proteases from Drosophila, a catalytic dyad also exists but formed by Ser-His (Pascall 
and Brown, 2004). 
The N-terminal nucleophile peptidases belong to the mechanistic class of serine 
proteases, but pursue a unique fold and a novel catalytic mechanism. One member of this 
group of enzymes is penicillin acylase, a self-cleaving precursor protein. This enzyme is 
not a protease but hydrolyses amide bonds. The catalytic residue is a N-terminal Ser in 
which the hydroxyl is the nucleophile in catalysis, and its amino group serves as a general 
base (Brannigan et al., 1995). 
4.1.1 Cryptic serine proteases: Mesotrypsin, the inibitor resistant serine protease 
Three isoforms of trypsinogen are secreted by the human pancreas and, on the basis of 
their electrophoretic mobility are commonly referred to as cationic and anionic trypsinogen, 
and mesotrypsinogen. Cationic and anionic trypsinogen, constitute the bulk of secreted 
trypsinogen, whereas mesotrypsinogen represents only less than 10% of the total 
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trypsinogen (Rinderknecht et al., 1984). An alternatively spliced form of mesotrypsinogen 
in which the signal peptide is replaced with a novel sequence is expressed in the human 
brain (Wiegand et al., 1993) and is referred to as "brain trypsinogen” (Trypsinogen IV); 
there is however no evidence for the activation of this protease, that might in fact have a 
function unrelated to proteolytic activity (Chen and Ferec, 2003). Recent studies performed 
with recombinant Trypsinogen IV from E. coli, activated with enteropeptidase to liberate 
the active trypsin IV, suggested that the enzyme can cleave and activate the protease-
activated receptors PAR1 and PAR2 being involved in inflammation and hyperalgesia 
(Knecht et al., 2007) 
The cryptic nature of mesotrypsin consists in its resistance to polypeptide trypsin 
inhibitors, such as the soybean trypsin inhibitor or the pancreatic secretory trypsin inhibitor 
(Rinderknecht et al., 1984; Nyaruhucha et al., 1997; Katona et al., 2002). Analysis of the 
crystal structure of mesotrypsin provided evidence that the presence of an Arg residue in 
place of the highly conserved Gly198 (Gly193 in the chymotrypsin numbering system) is 
responsible for the peculiar inhibitor resistance (Szmola et al., 2003); Arg198 occupies the 
S2' subsite and its long side-chain sterically clashes with protein inhibitors and possibly 
substrates (Szmola et al., 2003). Despite the high resolution of the crystal structure, the 
biological function of mesotrypsin has remained mysterious until very recently, and it was 
even suggested that mesotrypsin might have been abandoned by evolution, as no 
important role in physiology could be assigned (Rinderknecht et al., 1984). Conflicting 
theories proposed however that pancreatic activation of mesotrypsin might either cause or 
protect against pancreatitis, as the inhibitor-resistant trypsin activity could freely activate or 
degrade other pancreatic zymogens (Rinderknecht et al., 1984; Nyaruhucha et al., 1997). 
A recent study finally identified a unique and specific role for mesotrypsin in the 
degradation of trypsin inhibitors and explained this cryptic enzymatic activity by 
evolutionary selection of Arg198 (Szmola et al., 2003); such a function is advantageous in 
the digestion of naturally occurring trypsin inhibitors, providing a rationale for the evolution 
of this trypsin isoform. Szmola et al. also demonstrated that cathepsin B activates 
mesotrypsinogen at a higher rate than cationic and anionic trypsinogens. Their 
observations not only indicated a physiological role for mesotrypsin, but also suggested 
that its premature activation could contribute to the pathogenesis of human pancreatitis. 
The specialized mesotrypsin function could explain the relatively low levels of mesotrypsin 
secretion, as opposed to the largely expressed nonspecific digestive enzymes (Szmola et 
al., 2003).  
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4.2 Cysteine Proteases 
Cysteine proteases have a catalytic mechanism that involves a cysteine residue. The 
cysteine protease family includes plant proteases such as papain (the archetype and the 
better-studied member of the family, Figure 16), actinidin and bromelain, several 
mammalian lysosomal cathepsins, the cytosolic calpains (calcium-activated) and the 
caspases. 
 
 
Figure 16 – Structure of papain. PDB entry 9PAP. Adapted from http://delphi.phys.univ-
tours.fr/Prolysis/. 
 
The active site of cysteine proteases is constituted by a Cys-His dyad with a catalytic 
mechanism similar to the one of serine proteases using as nucleophile a thiol group 
instead of a hydroxyl group. The first step is the deprotonation of the thiol group of the 
active cysteine by the histidine residue. The next step is the nucleophilic attack by the 
deprotonated sulfur of the cysteine on the substrate carbonyl carbon leading to the 
formation of a covalent tetrahedral intermediate. In a third step, the C-terminal part of the 
substrate is released, the histidine residue in the protease is restored to its deprotonated 
form, and a thioester intermediate linking the substrate to the cysteine thiol is formed. The 
thioester bond is subsequently hydrolyzed by a water molecule releasing the N-terminal 
part of the substrate and restoring the thiol group of the nucleophilic cysteine (Figure 17). 
Cysteine proteases are distributed in 3 major structurally distinct clans (Rawlings et al., 
2006): 
- Clan CA is the largest clan of cysteine proteases, with about half of the total number of 
families of cysteine proteases including the papain and the calpain families. Enzymes in 
Clan CA have the catalytic residues in the sequence order Cys-His and in addition to this 
dyad a third residue is important to the catalytic mechanism; this is either a Arg or a Asp 
residue which is thought to orientate the imidazole group of the catalytic His. Regarding 
substrate specificity, papain prefers a Phe residue in P2 and calpains also prefer 
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hydrophobic residues in P2, so this P2 preference seems to be a general characteristic of 
the clan CA. In contrast, the majority of proteases from this clan do not shown pronounced 
P1 specificity. 
- Clan CD includes 5 families of cysteine proteases, being the most relevant ones the 
mammalian legumain and the caspases. Proteases from this clan have an active site 
catalytic dyad with a His-Gly-spacer-Ala-Cys motif (the dyad is in the reverse order to clan 
CA). In contrast to clan CA, proteases from clan CD have a strict specificity for P1 with 
caspases cleaving after Asp residues and legumain after Asn. Proteases from the other 
families of this clan prefer Lys or Arg in P1.  
- Clan PA is composed by families from mixed type and in the case of cysteine proteases 
includes the picornain family. The protease type of the picornain family is the picornain 3C 
protease from hepatitis A virus which crystal structure (Matthews et al., 1994) revealed an 
unmistakably similarity to the chymotrypsin structure with a cysteine replacing the serine. 
The substrate specificity of picornains has the P1 and P1’ sites as the major determinants, 
being Gln-Gly the typical cleaved bond. 
 
 
 
Figure 17 - Proposed catalytic mechanism for cysteine proteases. Adapted from Chibale, 
2003. 
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4.2.1 Cryptic cysteine proteases: Peroxisomal Processing Proteases 
An example of a cryptic cysteine protease discussed in this section will be the peroxisomal 
signal peptidases. Intracellular proteases play an important role in virtually all cellular 
compartments; a specific group of proteases, the processing proteases, are responsible 
for removal of signal sequences from newly synthesized proteins during or after import to 
a given organelle. A well-studied organelle in this perspective is the mitochondrion, where 
several mitochondrial processing proteases have been identified and characterized. This 
is however not the case of the peroxisome where peroxisomal processing enzyme(s) are 
still under investigation. Peroxisomal proteins are commonly produced at their final size 
and are targeted to the peroxisome via a peroxisomal targeting signal. Two distinct 
peroxisomal signal targeting sequences (PTSs) have been defined:  the C-terminal PTS1, 
consisting of a tripeptide with the consensus sequence (S/A/C)(K/R/H)L (Gould et al., 
1989), present in almost all peroxisomal proteins; and the N-terminal PTS2 (Swinkels et 
al., 1991; Jansen et al., 1997), which consists of a nonapeptide with the consensus 
(R/K)(L/I)(X)2(V/I/L)(X)2(H/Q)L (Rachubinski and Subramani, 1995). Till recently, little 
information was available on peroxisomal proteases, although protease activity has been 
demonstrated (Gray et al., 1970; Komov et al., 1988; Authier et al., 1995). One of these 
studies addressed the enzyme that catalyzes the second step in the biosynthesis of ether 
phospholipids, the peroxisomal alkyl-dihydroxyacetonephosphate synthase (alkyl-DHAP 
synthase), which is synthesized as a precursor with a cleavable N-terminal presequence 
of 58 amino acids containing the PTS2 sequence. This presequence shares sequence 
homology with peroxisomal thiolases (Authier et al., 1995), suggesting that both enzymes 
are processed by the same protease(s). In 1995 Authier et al described a protease that 
degrades a synthetic peptide corresponding to the PTS2 containing leader peptide of rat B 
peroxisomal thiolase and shown to be a metalloendopeptidase. Although the free 
presequence of the enzyme was a substrate for the protease, the full-length prethiolase 
was not bound nor cleaved by the protease (Authier et al., 1995); it was therefore 
concluded that another yet undefined peroxisomal protease cleaves the presequence, 
which is then further degraded by the metalloendopeptidase (Biermann and van den 
Bosch, 1999). Characterization of this processing protease showed that the enzyme has 
an optimum pH of 6.5 and is inhibited by N-ethylmaleimide, iodoacetamide, chymostatin, 
and Zn, clearly suggesting that it belongs to the class of cysteine proteases (Biermann 
and van den Bosch, 1999). Recently, a novel peroxisomal protease Tysnd1, or trypsin 
domain containing 1, was shown to be responsible for both removal of PTS2-containing 
leader peptide from prethiolase and for specific processing of all PTS1 proteins involved in 
β-oxidation of fatty acids (Kurochkin et al., 2007). Tysnd1 has two protease-like domains, 
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a trypsin-like serine and a cysteine peptidase domain. The enzyme undergoes 
autoproteolysis, presumably for auto-activation, generating two protease forms; the first 
contains both protease-related domains, whereas the second one contains only the 
cysteine-like domain. These observations demonstrate the generation of two separate 
protease domains from a single translation product.  Studies with protease inhibitors 
showed no significant blocking of Tysnd1 activity by metallo-, serine and aspartic 
inhibitors. Tysnd1 was completely inhibited N-ethylmaleimide (NEM), which is a general 
sulfhydryl modifier agent. However, the failure of E64 and leupeptine, two specific cysteine 
protease inhibitors, to block Tysnd1 activity suggested that this enzyme is not a 
conventional cysteine protease, but may represent a new family of proteolytic enzymes 
(Kurochkin et al., 2007). All together, these observations show a cryptic nature for Tysnd1. 
Further studies are necessary in order to elucidate the nature and mechanism of 
peroxisomal processing proteins. 
4.3 Aspartic proteases 
Aspartic proteases constitute a mechanistic class of enzymes that use an Asp dyad to 
hydrolyze peptidic bonds. Most of aspartic proteinases belong to the Clan AA, being the 
major families included in this clan the pepsin and the retropepsin ones. The pepsin family 
includes digestive enzymes (such as pepsin and chymosin), lysosomal cathepsins, 
processing enzymes (such as rennin) and fungal proteases. The retropepsin family 
comprises the viral proteinases, including the human immunodeficiency virus (HIV) 
protease (Figure 18A) (Rawlings et al., 2006). Cellular aspartic proteases are generally 
monomeric and bilobed with one Asp in each homologous lobe contributing to the 
catalytically active dyad of Asp residues. In contrast, viral aspartic proteases are dimeric in 
their active form, constituted by two identical subunits, each one carrying one catalytic 
Asp. Each monomer of the viral proteases is roughly equivalent to one domain of a 
eukaryotic aspartic proteinase. It has been proposed that the eukaryotic aspartic 
proteases may have evolved divergently from a primitive dimeric enzyme, resembling the 
retroviral protease.  
In contrast to serine and cysteine proteases, the aspartic proteases don’t use a functional 
group as a nucleophile; in their catalytic mechanism a water molecule, activated by one of 
the Asp residues, performs the nucleophilic attack to the carbonyl of the scissile bond. 
Simultaneously, a second proton transfer takes place from the other Asp residue to the 
carbonyl oxygen of the substrate peptidic bond leading to the formation of a non covalent 
tetrahedral intermediate. The rupture of the peptidic bond is mediated by two further 
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proton transfers to the substrate intermediate in a general acid-base mechanism (Figure 
18B). 
 
 
A B 
 
Figure 18 – A. Structure of HIV-1 protease. PDB entry 5HVP. The two catalytic aspartyl residues, 
each contributed by one monomer, are shown as ball and sticks. Adapted from 
http://delphi.phys.univ-tours.fr/Prolysis/. B. Schematic representation of the catalytic 
mechanism of aspartic proteases. The enzyme is represented in black and the substrate in pink. 
Adapted from http://delphi.phys.univ-tours.fr/Prolysis/ 
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4.3.1 Cryptic aspartic proteases: Secretases in Alzheimer’s disease 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder, affecting 
millions of people worldwide. The amyloid hypothesis of AD, describes the pathogenesis 
of this disorder as a cascade of proteolytic events, having as initial substrate the amyloid 
precursor protein (APP), a type-1 transmembrane protein with unclear function that has 
been related to cell adhesion, neurite outgrowth and long-term potentiation, among others. 
APP undergoes proteolysis in two different pathways (Lichtenthaler and Haass, 2004): the 
amyloidogenic pathway that generates amyloid β-protein (Aβ), and the non-amyloidogenic 
pathway that prevents Aβ generation (Selkoe and Schenk, 2003). The secretases involved 
in both pathways have their cryptic nature mainly related to the fact that although they 
were mostly investigated in relation to their involvement with AD, their physiological 
function is not fully characterized. 
In the non-amyloidogenic pathway, APP is cleaved by α-secretase, which cuts APP within 
the Aβ domain, preventing Aβ peptide generation. α-secretase is a member of the a 
disintegrin and metalloprotease (ADAM) family of proteases (Allinson et al., 2003) and it is 
presently unclear whether one or more members of the ADAM family are the relevant α-
secretase. In the amyloidogenic pathway, APP is first cleaved in the N-terminus by the β-
site APP-cleaving enzyme (BACE-1), β-secretase (Haass, 2004), which generates a 
membrane-bound APP C-terminal fragment. β-Secretase was identified as a type 1 
transmembrane protein containing aspartyl protease activity (Vassar, 2001) and belonging 
to the pepsin family of aspartyl proteases, but defining a novel subgroup of membrane-
associated proteases. Although additional candidate BACE-1 substrates have been 
recently identified (Kitazume et al., 2001; Lichtenthaler et al., 2003), the biological function 
of this protein is still unclear. What seems clear from the available reports is that APP is 
not its main substrate as it does not provide the optimal cleavage site for BACE-1 (Liu et 
al., 2002); the Swedish mutation in APP, which is related to familial AD cases, strongly 
enhances APP cleavage by BACE-1 by generating an ‘optimized’ cleavage site (Citron et 
al., 1992). In addition, BACE-1 has only limited access to APP in polarized cells, which 
would not be expected if it would be its main substrate. 
After BACE-1 cleavage of APP, γ-secretase is required for a proteolytic process that was 
long thought to be impossible, intramembrane cleavage (Haass, 2004). A number of 
evidence suggested that two homologous presenilins (PS), presenilin 1 (PS1) and 
presenilin 2 (PS2) are needed for γ-secretase cleavage. PS mutations are linked to 
aggressive early-onset familial AD (Sherrington et al., 1995); in these mutations, γ-
secretase cleavage is shifted two amino acids to the C-terminus (Hardy and Selkoe, 2002) 
increasing the Aβ42 (highly amyloidogenic) to Aβ40 ratio. Direct evidence implicating PS 
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in the catalytic core of γ-secretase came from the finding that PS contain two highly 
conserved aspartate residues within transmembrane domains 6 and 7 that once mutated 
resulted in lack of Aβ production (Wolfe et al., 1999). Moreover, holoPS is thought to be a 
zymogen, which is activated by autoproteolysis within the large cytoplasmic loop (Haass 
and Steiner, 2002). In contrast with other conventional aspartyl proteases, PS lack the 
D(T/S)G(T/S) aspartyl protease active site and contain instead a GXGD motif (Haass and 
Steiner, 2002). Recent evidence suggest convergent evolution of a novel active site for 
intramembrane proteolysis, as this motif is fully conserved in proteinases including signal 
peptide peptidases (Weihofen and Martoglio, 2003), that we will address in more detail 
later in this review. It is also noteworthy that PS are however not sufficient for γ-secretase 
activity; a set of four proteins is required to build up a γ-secretase complex (De Strooper, 
2003), namely nicastrin (Nct) (Yu et al., 2000), the anterior pharynx-defective phenotype 
protein (APH-1) and the PS-enhancer (PEN-2) (Francis et al., 2002). Similarly to BACE-1, 
PS probably did not evolve to produce pathogenic Aβ peptide. PS1 knockout mice have 
been generated and present a phenotype close to the one described for the Notch 
knockout (Selkoe and Kopan, 2003). So far, several additional PS substrates have been 
identified besides APP and Notch (De Strooper, 2003), including the APP-like molecules 1 
and 2 (APLP-1 and -2), the ErbB-4 receptor tyrosine kinase, E-cadherin, N-cadherin, the 
LDL receptor-related protein (LRP), Nectin-1-α, the Notch ligands Delta and Jagged, and 
CD44. Taken together, these new findings suggest that PS have important biological 
functions, unrelated to Aβ generation. 
4.4 Metalloproteases 
Metalloproteinases probably represent one of the oldest proteinase classes and are found 
from bacteria to higher organisms. They differ widely in their sequences and their 
structures but the great majority contain a zinc atom, or another heavy metal, that is 
catalytically active. Metalloproteases are distributed by several clans, being clan MA the 
major one, and including the well-studied thermolysin (Figure 19A) and matrix 
metalloprotease families. All peptidases in the thermolysin family bind a single, catalytic 
zinc ion; they possess an HEXXH motif, in which the His are zinc ligands and the Glu is an 
active site residue (Jongeneel et al., 1989). A Glu residue located C-terminally to HEXXH 
motif also binds the zinc ion. Metallopeptidases in which the zinc is bound by HEXXH plus 
Glu are known as 'Gluzincins'. The catalytic domain from the matrix metalloproteases 
contains three conserved His in the motif HEXXHXXGXXH, which ligate the catalytic zinc 
ion. The proteases of this family are termed "metzincins", due to a conserved Met located 
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C-terminally to the zinc ligands (Bode et al., 1993). In both thermolysin and matrix 
metalloprotease families the Glu residue within the catalytic motif activates a zinc-bound 
water molecule providing the nucleophile that performs the attack to the peptide bonds. 
This catalytic mechanism leads to the formation of a non covalent tetrahedral 
intermediate, which is coordinated to the zinc by the nucleophilic water and the carbonyl 
oxygen from the substrate. This intermediate is further decomposed by transfer of the 
glutamic acid proton to the leaving group. The C-terminal part of the substrate is released 
and the N-terminal peptide is replaced by a water molecule (Figure 19B). 
 
 
A 
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Figure 19 - A. Structure of the active site of thermolysin. PDB entry 1LNF. B. Schematic 
representation of the catalytic mechanism of metalloproteases. The enzyme is represented in 
black and the substrate in pink. Adapted from http://delphi.phys.univ-tours.fr/Prolysis/ 
General Introduction________________________________________________________________________________ 
 
 48 
4.4.1 A cryptic metallopeptidase that couples deubiquitination and degradation by 
the proteasome 
In eukaryotes the protease responsible for most regulatory intracellular proteolysis is the 
26S proteasome (Voges et al., 1999; Glickman, 2000; Zwickl et al., 2000; Glickman and 
Maytal, 2002), which can be divided into two subcomplexes, the 670 kDa 20S proteolytic 
core particle (where proteolysis occurs), and the 900 kDa 19S regulatory particle (RP) 
(Glickman et al., 1998). Substrates destined for degradation are labelled with polyubiquitin 
chains, which requires covalent attachment of the carboxyl terminus of polyubiquitin to an 
amino group of the substrate (Pickart, 2001; Weissman, 2001; Glickman and 
Ciechanover, 2002), as described by the work of the Nobel Laureates, Ciechanover, 
Hershko and Rose. Ubiquitinated proteins are then degraded rapidly in the cellular "waste 
disposers", the proteasomes. Examples of processes governed by ubiquitin-mediated 
protein degradation are cell division, DNA repair, quality control of newly produced 
proteins, and certain aspects of immune defense. When degradation does not work 
correctly, pathological conditions develop and therefore knowledge of ubiquitin-mediated 
protein degradation offers an opportunity to develop drugs against these disorders. 
In an ubiquitinated protein, the attached polyubiquitin chain must be released to facilitate 
the translocation of the unfolded substrate across the central proteolytic chamber of the 
20S core. This process is performed by deubiquitinating enzymes (DUBs). Different DUBs 
that can hydrolyze ubiquitin from substrates bound to the proteasome have been reported 
(Baek, 2003; Kim et al., 2003; Wing, 2003; Guterman and Glickman, 2004). Almost all 
known DUBs are cysteine proteases that specifically hydrolyze an amide bond between 
the carboxyl terminus of the ubiquitin moiety (Gly76) and an amino group on the substrate 
(either a Lys residue or the N terminus) (Wilkinson, 2000; Baek, 2003). It has however 
been reported that the human pad1 homologue/regulatory particle 11 in yeast 
(POH1/Rpn11) subunit of the 19S complex is responsible for substrate deubiquitination 
during proteasomal degradation that unlike all other known DUBs appears to be a Zn2+-
dependent protease (Yao and Cohen, 2002). Several observations pointed to the 
existence of an unusual DUB: i) POH1 activity was insensitive to ubiquitin-aldehyde, a 
potent DUB inhibitor, and to ubiquitin vinylsulphone, an irreversible DUB inhibitor (Yao and 
Cohen, 2002); ii) this DUB activity required ATP and was completely blocked by o-
phenantroline (Verma et al., 2002). The identities of the critical residues suggested that 
POH1/Rpn11 is a Zn2+ -dependent metalloprotease: assays performed with different 
Rpn11 mutants suggested that His109, His111 and Asp122 are the DUB active-site 
residues, as these mutants were lethal in yeast. On the other hand, the viability of the 
Cys116Ser mutant excluded a cysteine protease mechanism (Yao and Cohen, 2002). 
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When the 19S complex was incubated with the Zn2+ chelator N,N,N´,N´-tetrakis(2-
pyridylmethyl)-ethylenediamine (TPEN), deubiquitination was inhibited and this effect was 
prevented when TPEN was pre-incubated with excess Zn2+ (Yao and Cohen, 2002). 
Sequence alignment of Rpn11 revealed a conserved metalloprotease motif 
JAB1/MPN/Mov34 metalloenzyme (JAMM) (Verma et al., 2002). The JAMM family is 
defined by the consensus motif E(X)nHXH(X)7S(X)2D that resembles the active site of 
metallo-(specifically Zinc-) proteases. The cryptic nature of this new DUB family comes 
from the fact that not only its mechanism is not fully understood but also to the fact that it 
constitutes the only example of deubiquitinating enzymes without a cysteine nucleophile. 
Among the consensus sequence residues, the Asp, Glu and two His residues are likely to 
be the metal ligands. The fifth residue in the consensus sequence, the conserved Ser, 
could be a candidate for stabilizing the oxyanion hole (Guterman and Glickman, 2004). 
The identification of unrelated families of proteases for removal of ubiquitin and their 
diverse mechanisms of action point to the possibility that additional novel deubiquitinating 
enzymes can be discovered and possibly related to proteasome function. 
4.5 Threonine Proteases 
The class of threonine proteases was described by Lowe et al. in 1995, when the crystal 
structure of the archaebacterium proteasome from Thermoplasma acidophilum was 
determined, which revealed a N-terminal threonine in the active site. As refered above, the 
proteasome system constitutes the major pathway for selective degradation of proteins in 
eukaryotes. Substrates destined for degradation are labelled with polyubiquitin chains and 
are degraded by the eukaryotic 26 S proteasome complex, which can be divided into two 
subcomplexes, the 20 S proteolytic core particle and the 19 S regulatory particle. The 20 
S catalytic unit is also present in archaea and some eubacteria, being the one from 
Thermoplasma acidophilum a useful tool for structural and mechanistic studies as it 
pursues the same basic architecture as the eukaryotic proteasome. This complex is a 
cylindrical unit constituted by four superimposable 7-membered rings. The two outer rings 
contain alpha-type subunits whereas the two inner rings are composed of beta-type 
subunits in which are located the active sites (Figure 20A)(Lowe et al., 1995). In all forms 
of the proteasome, the peptidase beta-type subunits are N-terminal nucleophile 
hydrolases in which the threonine residue located in the N-terminus constitutes the active 
site. The catalytic beta-type subunits are synthesized as inactive protein precursors, which 
are activated by N-terminal cleavage, making threonine the N-terminal residue. The 
catalytic structure of the proteasome is related to the one of other N-terminal hydrolases 
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such as penicillin acylase (previously described in this thesis in the serine proteases 
section), which utilizes the N-terminal serine as the catalytic residue (Lowe et al., 1995). 
The catalytic mechanism of threonine proteases was proposed to be similar to the one of 
serine proteases (previously described in this thesis in the serine proteases section) 
involving the formation of an acyl-enzyme intermediate. In the case of the proteasome, the 
threonine residue functions both as the nucleophile (the hydroxyl group) and as the 
general base (the amino group) (Figure 20B) (Kisselev et al., 2000). 
 
 
 
Figure 20 – A. Structure of the 20S proteasome from the archaeon T. acidophilum. PDB 
entry 1PMA. B. Proposed catalytic mechanism of threonine proteases. Adapted from 
(Kisselev et al., 2000). 
4.6 Glutamic proteases 
The glutamic proteases constitute the most recently created class of proteases (Rawlings 
et al., 2006). This group of enzymes constituted by several fungal carboxyl peptidases 
was previously included in the family of aspartic proteases. The fungal scytalidoglutamic 
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protease (SGP) is the representative member of this class and was discovered by Murao 
et al. in 1972, being at the time characterized as a pepstatin-insensitive carboxyl protease 
because of its acidic optimum pH and insensitivity to pepstatin. More recently the three-
dimensional structure of SGP was solved and revealed a unique fold with a novel catalytic 
mechanism (Figure 21A). The SGP active site is constituted by a catalytic dyad of Glu and 
Gln residues and the proposed hydrolytic mechanism involves the nucleophilic attack of a 
water molecule, activated by the Glu residue that functions as a general base, on the 
carbonyl of the substrate scissile bond with the formation of a tetrahedral intermediate. 
The Gln residue provides electrophilic assistance and oxyanion stabilization (Figure 21B) 
(Fujinaga et al., 2004). The substrate specificity of SGP is also unique particularly in the 
preference at P3 (basic amino acid), P1’ (small amino acid) and P3’ (basic amino acid) 
(Kataoka et al., 2005). Glutamic proteases are also termed Eqolisins derived from the 
active site residues Glu (E) and Gln (Q). 
 
Figure 21 – A. The proposed catalytic mechanism of scytalidoglutamic peptidase (SGP). 
Adapted from (Fujinaga et al., 2004). B. Structure of SGP. PDB entry 1S2B. Catalytic residues are 
shown in ball-and-stick representation: Gln107 in pink and Glu190 in dark blue. 
 
The six mechanistic classes described in this section show how nature mixed different 
active site structures and substrate binding properties with common features of 
proteolysis; the chemical mechanism of hydrolysis of the peptide bond is common to all 
proteolytic enzymes. 
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4.7 Fibronetin: four proteinases within a single protein 
Fibronectin (FN) is a plasma multifunctional glycoprotein (pFN, plasma fibronectin) that 
can also be found on cell surfaces (cFN, cell surface fibronectin). FN has been involved in 
a variety of biological processes namely in cell adhesion, migration, wound healing, 
metastasis, embryonic development, thrombosis and bacterial infection (Akiyama and 
Yamada, 1987; Humphries, 1993). It consists of two almost identical subunits divided into 
different domains (Figure 22). Several studies have demonstrated that fibronectin 
fragments perform different functions from the ones performed by the intact protein such 
as inhibition of endothelial growth or promotion of tissue reconstruction. Other fragments 
stimulate the expression of matrix metalloproteinases, tumor necrosis factor-α, tissue 
inhibitor of metalloproteinase 1 and urokinase type plasminogen activator (Beezhold and 
Personius, 1992) (De Petro et al., 1983; Tremble et al., 1992). Finally, several studies 
reported the existence of four different cryptic proteinases (as their physiological 
relevance is unknown as well as their proteolytic mechanism) in human pFN designated 
as fibronectinase (a serine protease), FN-gelatinase and FN-lamininase (aspartic 
proteases) and FN-type IV- collagenase (a metalloprotease) (Emod et al., 1990; 
Planchenault et al., 1990; Lambert Vidmar et al., 1991b; Lambert Vidmar et al., 1991a). It 
is however noteworthy that the four enzymes in fibronectin, that we will next address in 
detail, need further characterization in order to unequivocally demonstrate their existence. 
 
Figure 22 - Schematic domain structure of fibronectin. Fibronectin is constituted by three types 
of internal repeating modules designated type I, II and III. At the top of the figure are indicated the 
binding domains of fibronectin. ED-A and ED-B: extra domains A and B. Adapted from (Liz and 
Sousa, 2005) 
4.7.1 Fibronectinase  
Fibronectinase (Fnase) is a cryptic proteinase still uncharacterised at the structural level 
and with unclear physiological function, associated with the N-terminal heparin/fibrin 
binding domain of FN (Lambert Vidmar et al., 1991a). The enzyme could be generated 
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from the purified 70 kDa pFN fragment produced by cathepsin D digestion and was 
activated in the presence of Ca2+ and inhibited by diisopropyl fluorophosphate (DFP), 
phenylmethanesulfonyl fluoride (PMSF) and ethylenediaminetetraacetic acid (EDTA) 
(Lambert Vidmar et al., 1991a). 
The mechanism of Fnase activation occurs by autodigestion of the N-terminal 70 kDa FN 
fragment in the presence of Ca2+, and comprises three steps. The first step includes the 
cleavage of the bond Arg259-Ala260 between the heparin-binding and collagen-binding 
domains concomitant with the cleavage of a 2-3 kDa polypeptide in the C-terminal 
extremity of the fibronectin N-terminal heparin-binding fragment. In the second step, a 4 
kDa fragment is cleaved off from the C-terminal extremity resulting in the formation of a 23 
kDa form containing the N-terminus. The third step involves a cleavage of the bond Lys85-
Asp86 in finger 2, concomitant with the loss of 1 kDa and with the appearance of a new N-
terminal sequence DSMIW (residues 86-90). This cleavage product (22 kDa) is composed 
of two chains: a light chain of 8 kDa, which begins with the blocked N-terminal residue 1, 
and a heavy chain of 14 kDa, which begins with the sequence DSMIW (residues 86-90). 
The opening of the loop (finger) structure allows an enhanced flexibility of the tertiary 
structure of the two linked polypeptides, which in turn may be favourable for the formation 
of a catalytically active form (Lambert Vidmar et al., 1991a). It was hypothesised that the 
catalytic active site was probably formed by the amino acid residues Asp24, His128 and 
Ser164; however site-directed mutagenesis of these residues and subsequent loss of 
activity assays have not been reported in the literature. Similarly, the three-dimensional 
structure of the active site is lacking and sequence homology between FN and other 
proteases is limited. Therefore, the proteolytic activity of Fnase is only supported by 
circumstantial evidence; although the Fnase enzymatic properties do not correspond to 
any known plasma proteinase, the presence of a non-identified proteinase contaminant, 
which would be co-purified with FN fragments, cannot be excluded a priori. Direct 
structural evidence such as covalent labelling with DFP (an inhibitor of Fnase activity) and 
sequential identification of the active site in Fnase is needed (Lambert Vidmar et al., 
1991a). [An Escherichia coli expression system was developed in order to make Fnase 
available for characterization (Schnepel et al., 2001). Both plasmatic and recombinant 
Fnase were able to cleave plasma FN having preference for bonds with an arginine 
residue in P1 position, a cleavage specificity similar to trypsin-like proteinases. Sequence 
homology revealed however that Fnase shares homology regions with prohormone 
convertases, which belong to the family of subtilisin-like proteinases. Besides FN, both 
human actin and myosin were identified as substrates of Fnase (Schnepel et al., 2001), 
revealing a possible role for this enzyme in the pathological process of muscular 
dystrophy where an increased production of cathepsin D was observed in patient tissue 
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samples (Gopalan et al., 1987). As the in vitro generation of Fnase is initiated by cleavage 
of FN by cathepsin D, it was suggested that increased Fnase activity in these patients 
might contribute to the proteolytic processes in this disorder (Schnepel et al., 2001).  
4.7.2 Fibronectin-gelatinase and fibronectin- lamininase  
In addition to Fnase, human plasma fibronectin has been described as containing two 
additional latent aspartic proteinases: FN-gelatinase and FN-lamininase (Emod et al., 
1990; Planchenault et al., 1990) that similarly to Fnase have still uncharacterized structure 
and unclear physiological function. Both enzymes can be generated and activated in the 
presence of Ca2+ from the 190 kDa FN fragment generated by digestion with cathepsin D 
(Emod et al., 1990; Planchenault et al., 1990). FN-gelatinase (35 kDa) is located in the 
central domain of FN and has denaturated collagen type IV (Planchenault et al., 1990) 
and fibronectin as preferential substrates. FN-lamininase (25 kDa) is located in the 
carboxy-terminal heparin-binding domain and preferentially cleaves laminin and 
denaturated collagen (Emod et al., 1990). Both FN-derived enzymes are inhibited by 
PMSF and also by pepstatin A (Emod et al., 1990; Planchenault et al., 1990), similarly to 
retroviral aspartic proteinases. Comparison of their sequences with retroviral proteinases 
reveals a high resemblance to these enzymes. The cleavage specificity of FN-lamininase 
and FN-gelatinase was identified using the B chain of oxidized bovine insulin; both 
enzymes have a preference for peptide bonds flanked at P1´ by hydrophobic and by 
aromatic amino acids (Unger and Tschesche, 1999), which is characteristic of several 
aspartic proteinases, including retroviral ones. Also, as in retroviral proteinases, in FN-
gelatinase and FN-lamininase, the formation of dimers seemed to be essential to combine 
two catalytically important aspartic acid residues in the active site (Unger and Tschesche, 
1999). Again, critical experiments demonstrating that the observed enzymatic activities 
are related to FN, such as experiments aiming at the identification of the catalytic Asp 
residues, need to be performed in order to structurally characterize FN-gelatinase and FN-
lamininase. Regarding the biological relevance of the cryptic FN-gelatinase and FN-
lamininase, no reports exist in the literature and clearly more studies are needed to 
determine their physiological relevance. 
4.7.3 Fibronectin type IV collagenase 
Finally, fibronectin has been described as containing a metalloprotease located in the 
collagen-binding domain of human FN, but again no structural data exists characterizing 
the catalytic mechanism of this enzyme. Fnase activates the collagen-binding domain of 
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FN into two metalloproteinases, FN-type-IV collagenases A and B (FnColA and FnColB), 
both inhibited by metalloproteinase inhibitors (Lambert Vidmar et al., 1991b). The 
generated 40 kDa FnColA degrades native collagen type IV, heat-denaturated collagen 
type I, and laminin, a different substrate specificity from type IV collagenase (gelatinase), 
FN-lamininase and FN-gelatinase. The 27 kDa form of the enzyme, FN-type IV 
collagenase B (FnColB), has a narrow specificity and degrades preferentially native 
collagen type IV. Both enzymes begin with the same N-terminal sequence VYQPQPH 
(residues 262-268 of fibronectin) but, contrary to FnColA, FnColB has lost the C-terminal 
region of type I repeats, where the major gelatin-binding determinants of fibronectin are 
located. FnColA and B are similar to domain II of collagenase type IV (Lambert Vidmar et 
al., 1991b). An E.coli expression system for further characterization of the proteolytic 
activity of cryptic human FnColA and B, was developed by Schnepel and Tschesche in 
2000. Catalytic activity of recombinant FnColA and FnColB was detected against gelatin, 
type II and type IV collagen and α- and β- casein. Inhibition studies showed that TIMP-2, 
EDTA, and batimastat are efficient inhibitors of recombinant FnCol (Schnepel and 
Tschesche, 2000). As for the case of the other two FN protease activities (serine 
protease-like and aspartic protease-like) structural data is not available and further 
experiments are needed in order to characterize FnCol. 
Given the ubiquitous occurrence of fibronectin, the significance of FN type IV collagenase 
in physiological or pathological processes is not well understood. Most studies on the 
pathophysiological role of FN fragments have been devoted to the cleavage of articular 
cartilage in osteoarthritis and rheumatoid arthritis patients (Xie et al., 1992), as levels of 
FN fragments are highly elevated in their synovial fluids. It has been hypothesized that 
FnColA and B could not only induce other proteases, but may also contribute to the 
proteolytic potential of synovial fluid. It was also suggested that FN type IV collagenase 
could be involved in malignant processes, given the fact that cleavage of type IV collagen 
was shown to be a prerequisite for degradation of basement membrane and is thus 
involved in tumor invasion and metastasis (Schnepel and Tschesche, 2000). However, 
similarly to several of the cryptic enzymes here reviewed, further investigation is needed in 
order to establish their physiological function. 
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5 CONCLUDING REMARKS 
TTR is a plasma homotetrameric protein that acts physiologically as the carrier of T4 and 
retinol, in the latter case through binding to RBP. Point mutations in TTR are related to 
familial amyloid polyneuropathy, a neurodegenerative disorder characterized by 
deposition of TTR amyloid fibrils particularly in the nerve. In normal conditions, a fraction 
of TTR is carried in HDL through binding to apoA-I. ApoA-I, a 243-amino acid protein, is 
synthesized by the liver and plays a key role in the formation, metabolism and catabolism 
HDL cholesterol esters. Amyloidogenic variants of ApoA-I have been also reported. In 
ApoA-I amyloidosis, amyloid fibrils are mainly characterized by deposition of N-terminal 
fragments of variable length of the mutated protein. Interestingly, in a case of ApoA-I 
amyloidosis, analysis of fibrils revealed co-deposition of mutated apoAI and wild type TTR, 
suggesting that TTR could trigger apoA-I fibril formation. 
The analysis of the interaction between TTR and apoA-I was the basis for the 
development of the research project of this thesis. 
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Objectives 
The interaction of TTR with apoA-I constituted the basis for further investigation in this 
thesis, as we determined that TTR was able to cleave apoA-I. 
The goal of this research project was to gain insights into the newly identified cryptic 
protease activity of TTR and to elucidate its physiological relevance and importance in 
pathological conditions. To achieve this aim, we proposed to: 
 
• Chapter 1: Characterize TTR as a novel cryptic protease. 
 
• Chapter 2: Identify the catalytic active site of TTR. 
 
• Chapter 3: Study the relevance of apoA-I cleavage by TTR in health and disease. 
 
• Chapter 4: Search for new putative natural TTR substrates. 
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Abstract 
Transthyretin (TTR) is a plasma homotetrameric protein that acts physiologically as a 
transporter of thyroxin (T4) and retinol, in the latter case through binding to retinol binding 
protein (RBP). A fraction of plasma TTR is carried in high-density lipoproteins by binding 
to apolipoprotein AI (apoA-I). We further investigated the nature of the TTR-apoA-I 
interaction, and found that TTR from different sources (recombinant and plasmatic) is able 
to process proteolytically apoA-I, cleaving its C-terminus after Phe225. TTR-mediated 
proteolysis was inhibited by serine protease inhibitors (PMSF, Pefabloc, DFP, chymostatin 
and TPCK), suggesting a serine-like activity. A fluorogenic substrate corresponding to a 
apoA-I fragment encompassing aminoacid residues 223 to 228 (Abz-ESFKVS-EDDnp) 
was used to characterize the catalytic activity of TTR including optimum reaction 
conditions (37ºC and pH 7) and catalytic constant (Km= 29 µM); when complexed with 
RBP, TTR activity was lost whereas when complexed with T4 only a slight decrease was 
observed. Cell lines expressing TTR were able to degrade Abz-ESFKVS-EDDnp two fold 
more efficiently than control cells lacking TTR expression; this effect was reversed by the 
presence of RBP in cell culture media, therefore proving a TTR-specific proteolytic 
activity. TTR can act as a novel plasma cryptic protease, and might have a new potentially 
important role under physiological and/or pathological conditions. 
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Introduction 
Transthyretin (TTR) is a plasma protein of four identical subunits of approximately 14 kDa 
(Blake et al., 1978b) that is mainly synthesized by the liver and the choroid plexus of the 
brain (Dickson et al., 1985a). Under physiological conditions TTR functions as a carrier for 
both thyroxine (T4) and retinol (vitamin A), in the latter case through binding to the retinol-
binding protein (RBP) (Monaco, 2000). We have previously determined that apolipoprotein 
AI (apoA-I) is also a TTR ligand; physiologically, a fraction of plasma TTR circulates in 
high-density lipoproteins (HDL) through binding to apoA-I (Sousa et al., 2000a), its major 
protein component. The physiological meaning of this interaction remains to be explained, 
but it first suggested that it might be relevant in physiological conditions namely in lipid 
and/or TTR metabolism. Previous evidence suggested that TTR and lipoprotein biology 
might be related. In the kidney, megalin, a member of the lipoprotein receptor family is 
responsible for TTR tubular reabsorption (Sousa et al., 2000b). Furthermore, TTR uptake 
by the liver (its major site of degradation) is sensitive to the receptor-associated protein, 
an inhibitor of uptake of all the ligands of the lipoprotein receptor family (Sousa and 
Saraiva, 2001). 
Several point mutations in TTR have been linked to the occurrence of TTR related 
amyloidosis (ATTR), a disorder that is characterized by the extracellular systemic 
deposition of mutated or wild-type (wt) TTR as amyloid fibrils (Saraiva et al., 1984; 
Cornwell et al., 1988), leading to organ dysfunction and death. The mechanisms by which 
soluble proteins self-assemble into a fibrillary structure are unknown. Proteolysis has been 
thought to play an important role in most types of amyloidoses; in several cases, an 
amyloid peptide is generated by proteolysis of the corresponding protein precursor 
(Schormann et al., 1998; Kisilevsky, 2000). C-terminal TTR peptides with proteolysis 
occurring between aminoacid residues 42 and 59, in addition to intact protein, have been 
found in amyloid fibrils of some ATTR patients (Gustavsson et al., 1995). This raised the 
hypothesis that proteolysis could trigger fibril formation.  
Amyloidogenic variants of apoA-I have also been reported (Walsh, 1999). ApoA-I, a 243-
aminoacid protein, is synthesized by the liver and plays a key role in the formation, 
metabolism and catabolism of HDL cholesterol esters. Numerous attempts have been 
made to determine the arrangement of the amphipathic helices of apoA-I in nascent HDL 
discs, as they appear to be a critical intermediate in reverse cholesterol transport; 
however, the tertiary arrangement of apoA-I molecules on HDL particles is not defined yet. 
In apoA-I amyloidosis (AApoAI), amyloid fibrils are characterized by deposition of N-
terminal fragments of variable length of the mutated protein (Walsh, 1999). Interestingly 
we identified an amyloidogenic variant of apoA-I, Leu 178 His, where fibrils presented 
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both mutated apoA-I and wt TTR that co-localized in amyloid deposits as seen by 
immunohistochemistry and analysis of extracted fibrils (de Sousa et al., 2000). This data 
further suggested that the interaction between apoA-I and TTR might be relevant not only 
physiologically but also in pathological conditions.  
In this report we further investigated the apoAI-TTR interaction and verified that TTR is 
able to process proteolytically apoA-I.  
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Methods 
Proteins and protease inhibitors 
Recombinant TTR was produced in Escherichia coli D1210 transformed with pINTR 
plasmid carrying TTR cDNA (Furuya et al., 1989). The protein was isolated and purified as 
previously described (Almeida et al., 1997). Briefly, after osmotic shock of bacteria, 
protein extracts were run on a diethylaminoethyl (DEAE)-cellulose (Whatman) ion 
exchange chromatography, dialyzed, lyophilised and isolated in native preparative 
Prosieve agarose (FMC) gel electrophoresis following the supplier’s instructions. After 
electrophoresis, the TTR band was excised and electroeluted in an Elutrap system 
(Schleider and Schuell) in 38 mM glycine, 5 mM Tris pH 8.3, overnight at 50 V (4ºC). A 
final purification by high pressure liquid chromatography (HPLC) was performed on a 
Protein Pak 125 column (Waters), coupled to a high-precision pump (P-302) and a 
halocrome-280 UV detector (Gilson), using as eluent 200 mM sodium phosphate buffer 
pH 7 at a flow rate of 0.4 mL/min, and 400 µL fractions were collected. Protein standards 
used for calibration were: bovine serum albumin (67 kDa), ovalbumin (43 kDa), 
chymotrypsinogen A (25 kDa) and lysozyme (14 kDa). Serum TTR was purified as 
previously described (Almeida et al., 1997). Briefly, plasma was dialyzed against 77 mM 
NaCl, 50 mM phosphate buffer, pH 7.6 and run on a DEAE-cellulose ion exchange 
column after which protein fractions were dialyzed, lyophilised and chromatographed on a 
Blue-Sepharose column (Amersham Pharmacia Biotech). Plasma TTR was isolated by 
preparative electrophoresis followed by electroelution and HPLC as described above for 
recombinant TTR. Serum RBP was isolated by affinity in a TTR column and saturated with 
3.3 mg/mL all-trans retinol (Sigma) in ethanol as follows: 25 µL all-trans retinol were 
incubated with 800 µL RBP 1 mg/mL at 37ºC in the dark for 1 h; excess retinol was 
separated from RBP by gel filtration in 10 mL columns Biogel P-6 DG (Bio-Rad). 
Recombinant ApoA-I, α2-macroglobulin and diisopropyl fluorophosphate (DFP) were from 
Calbiochem. Phenylmethanesulfonyl fluoride (PMSF) and thyroxine (T4) were from Sigma. 
Pefabloc, pefabloc SC plus, chymostatin, Nα-p-tosyl-L-phenylalanine-chloromethyl ketone 
(TPCK), Nα-p-tosyl-L-Lysine-chloromethyl ketone (TLCK), antipain, aprotinin, 
phosphoramidon, E64, EDTA, bestatin, pepstatin and leupeptin were from Roche. 
 
TTR proteolysis assay using ApoA-I as substrate 
TTR and apoA-I at an equimolar ratio were incubated in 50 mM Tris pH 7 at 37ºC for 3h, 
unless otherwise stated. After incubation, reactions were run on 15% SDS-PAGE gels and 
visualized by coomassie blue staining (0.125% coomassie blue reagent, 50% methanol 
and 10% acetic acid). For inhibition assays TTR was pre-incubated with each of the 
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protease inhibitors (either 4 mM pefabloc, 4 mM pefabloc Plus, 10 mM EDTA, 10 µM E-
64, 10 µM phosphoramidon, 10 µM bestatin, 0.3 µM aprotinin, 100 µM TPCK, 100 µM 
TLCK, 100 µM chymostatin, 100 µM leupeptin, 100 µM antipain, 1 mM PMSF, 100 µM 
DFP, 1 µM pepstatin, and α2-macroglobulin equimolar with TTR) for 30 min at 37ºC before 
apoA-I addition.  
 
Analysis of apoA-I cleavage products 
For N-terminal sequencing of cleavage products, the apoAI-TTR reaction was run on a 
15% SDS-PAGE gel, transferred to a polyvinylidene fluoride (PVDF) membrane 
(Amersham Pharmacia Biotech) and stained with coomassie blue for 5 min. Pieces of 
membrane containing apoA-I fragments were excised and N-terminal sequencing was 
performed on an Applied Biosystems model 494 protein sequencer. For matrix assisted 
laser desorption ionization mass spectrometry (MALDI-MS), apoA-I cleavage products 
were cut from a 15% SDS-PAGE gel stained with coomassie blue. Gel bands were 
reduced by incubation with 0.01 M dithiothreitol, 0.1 M Tris pH 8.5, alkylated with 0.015 M 
iodoacetamide, 0.1 M Tris pH 8.5 and prepared for trypsin digestion by washing once with 
0.05 M Tris pH 8.5, 25% acetonitrile and twice with 0.05 M Tris pH 8.5, 50% acetonitrile. 
After destaining, gel bands were digested with trypsin and analyzed on a Perspective 
Voyager DE-RP mass spectrometer in a linear mode (Henzel et al., 1993). For C-terminal 
sequencing of the apoA-I fragments, 200 µg TTR and 100 µg of apoA-I were incubated in 
50 mM Tris pH 7 overnight at 37ºC and the reaction was run on a 15% SDS-PAGE gel, 
transferred to a PVDF membrane and stained with coomassie blue. Pieces of membrane 
containing apoA-I fragments were excised and C-terminal sequencing was performed on 
an Applied Biosystems model 494 protein sequencer (Boyd et al., 1992). 
 
SDS-PAGE zymography 
12% SDS polyacrylamide gels containing casein (Bio Rad) were used to identify 
caseinolytic activity of TTR. 25 µg of recombinant TTR were run per lane. After 
electrophoresis, gels were incubated in 2.5% Triton X-100 (renaturation buffer, Bio Rad) 
for 30 min, and subsequently overnight at 37ºC in 50 mM Tris, 200 mM NaCl, 5 mM CaCl2 
and 0.02% Brij 35 (development buffer, Bio Rad). Gels were then stained with 0.5% 
coomassie in 40% methanol, 10% acetic acid for 2 h, and destained in 40% methanol, 
10% acetic acid for 1 h. For Western blot analysis, proteins were transferred to a 
nitrocellulose membrane (Amersham Life Science), blocked with 5% blocking buffer (5% 
non-fat dried milk in phosphate buffer saline, PBS), incubated for 1h at room temperature 
with rabbit polyclonal anti-TTR (DAKO, 1:2000 in blocking buffer) and 1h at room 
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temperature with anti-rabbit IgG conjugated with horseradish peroxidase (The Binding 
Site, 1:5000 in blocking buffer). The immunoblot was developed using 3,3´-
diaminobenzidine (DAB, Sigma) as substrate. 
 
Fluorometric assessment of proteolysis  
TTR proteolytic activity was tested with a fluorogenic peptide (Abz-ESFKVS-EDDnp, 
Global Peptide) encompassing the sequence of apoA-I cleaved by TTR. Abz-ESFKVS-
EDDnp is an internally quenched fluorescent peptide, where Abz (ortho-aminobenzoic 
acid) is the fluorescent donor and EDDnp [N-(ethylenediamine)-2,4-dinitrophenyl amide] is 
the fluorescent quencher. A stock solution of peptide substrate was prepared by 
dissolving the peptide in 50% dimethyl sulfoxide (DMSO, Sigma) to a final concentration 
of 1 mM. TTR was added to the substrate in an equimolar ratio (5 µM), in a final volume of 
100 µL of reaction buffer (50 mM Tris pH 7). Hydrolysis of the fluorogenic substrate was 
monitored by measuring fluorescence at λem= 420 nm and λex= 320 nm in a fmax plate 
reader (Molecular Devices). Kinetics of the reaction was followed for 3 h at 37ºC. To 
convert arbitrary fluorescence units (RFU) in nmol of cleaved substrate, a calibration 
curve was obtained from the total cleavage of the fluorogenic peptide with chymotrypsin 
(which is also able to cleave Abz-ESFKVS-EDDnp) by incubating 1 nmol of Abz-ESFKVS-
EDDnp substrate with 1 Unit of chymotrypsin in a final volume of 200 µL of reaction buffer 
overnight at 37ºC; serial dilutions ranging from 0.005 to 1 nmol of cleaved peptide 
substrate were measured at λem = 420 nm and λex = 320 nm. Km was determined 
according to Michaelis-Menten using concentrations of substrate ranging from 0.5 to 100 
µM and 5 µM of TTR. The optimum pH for TTR activity was determined in 50 mM Tris pH 
ranging from 3 to 9. TTR complexed with RBP was obtained by incubation in a 1:4 (TTR: 
RBP) molar ratio for 1 h at 37ºC in the dark. Complex formation between TTR and T4 was 
performed according to Almeida et al . After ligand binding, TTR activity was tested as 
described above. As a control for the effect of TTR ligands, chymotrypsin activity was 
tested in the presence of RBP or T4 using the same conditions used for TTR. 
 
Cellular assays 
Cell lines were propagated in 12 well plates in monolayers and maintained at 37°C in a 
humidified atmosphere of 95% and 5% CO2. Cells were grown in Dulbecco´s Modified 
Eagle Media (DMEM, Life Technologies) supplemented with 10% fetal bovine serum 
(FBS, Sigma), 50 U/mL penicillin and 50 µg/mL streptomycin (Life Technologies) - 
complete medium. RN22 (rat schwannoma cell line), FAO (rat hepatoma) were from the 
American Type Cell Collection. SAHep (human hepatoma without TTR expression) and 
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Huh7 (human hepatoma with high levels of TTR expression) were kindly provided by Dr. 
João Monjardino (Imperial College, London, UK). RN22 cell lines were stably co-
transfected with human wt TTR cDNA, subcloned in p169ZT plasmid which contains the 
metallothionein inducible promoter (Sousa et al., 2002), and a plasmid conferring 
resistance to neomycin (pL2Neo, kindly provided by Dr. Paulo Vieira, Institut Pasteur, 
Paris, France), following the CaPO4-DNA precipitate method (Sambrook et al., 1989). 
RN22 cell lines stably transfected with human wt TTR cDNA were named RN22 wt. 
SAHep and FAO cell lines were co-transfected with a construct carrying human wt TTR 
cDNA under the control of the mouse endogenous TTR promoter (pGEM-2 pTTR exV3, a 
kind gift from Dr. Robert Costa, University of Illinois, Chicago) and the pL2Neo plasmid 
using Lipofectamin (Life Technologies Inc) according to the manufacturer’s 
recommendations. Briefly, 3 x 105 cells were plated in 100 mm tissue culture plates one 
day before transfection, and exposed to a mixture of lipofectamin and plasmid DNA for 5 h 
after which DMEM supplemented with 20% FBS was added. Resistant colonies were 
selected in medium supplemented with G418 (1 mg/mL, Sigma). SAHep and FAO cell 
lines stably transfected with human wt TTR cDNA were termed SAHep wt and FAO wt 
respectively. Huh7 and SAHep cells were grown until approximately 80% confluence after 
which the culture medium was removed and replaced by DMEM without FBS 
supplemented with 40 µg/mL DQ gelatin (Molecular Probes). DQ gelatin is an 
intramolecularly quenched substrate, heavily labeled with fluorescein, used as a substrate 
for several proteases. Proteolysis of DQ-gelatin yields fluorescent cleaved gelatin-
fluorescein peptides; the localization of fluorescence indicates therefore the sites of net 
proteolytic activity. For inhibition assays either 1 mg/mL pefabloc or 2 µg/mL aprotinin 
were added to the culture medium. Cells were observed 24 h later on a fluorescence 
microscope (Auxiovert 200 M, Zeiss). Images were acquired with a coupled digital camera 
(Zeiss), using either transmission or the FITC channel (λem = 515 nm and λex= 495 nm). In 
cellular assays using Abz-ESFKVS-EDDnp, approximately 80% confluent RN22, RN22 
wt, FAO, FAO wt, SAHep and SAHep wt cells, were incubated with 4 nmol of Abz-
ESFKVS-EDDnp at 37ºC for 24 h. To assess the effect of RBP, a molar excess of this 
TTR ligand was added to the culture medium for 1 h at 37ºC before addition of Abz-
ESFKVS-EDDnp. Fluorometric assessment of proteolysis was performed using 100 µL of 
each conditioned media and measuring fluorescence at λem = 420 nm and λex= 320 nm in 
a Molecular Devices fmax plate reader. After removing conditioned media, cells were 
treated with 0.1 M NaOH until complete lysis and total protein quantification was 
performed by the Bradford method (BioRad), using BSA ranging from 50 to 200 µg/mL as 
standard. TTR expression in each cell line was assessed by a TTR quantitative enzyme 
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linked immunoreactive assay (ELISA). 96 well plates (Maxisorp-Nunc) were coated 
overnight at 4ºC with polyclonal anti-rabbit TTR (DAKO, 1:500 in 0.1 M carbonate buffer) 
and blocked with 5% skim milk in PBS. 100 µL of each conditioned media were applied for 
1 h at room temperature. Development was performed using peroxidase conjugated anti-
human TTR (1:500 in PBS-0.05% Tween20) and 2,2´-azino-bis (3-ethylbenzthiazoline-6-
sulfonic acid) /H2O2. TTR concentration was calculated from a standard curve ranging 
from 5 to 200 ng/mL. Proteolytic activity was defined as nmol of cleaved substrate per µg 
of total cellular protein in each cell line. Three independent experiments were performed 
and results depict a representative experiment. 
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Results 
Identification of TTR proteolytic activity  
We have previously established that a fraction of plasma TTR circulates in high-density 
lipoproteins (HDL) through binding to apolipoprotein AI (apoA-I) (Sousa et al., 2000a). To 
further address the nature of the interaction between TTR and apoA-I we tried to obtain a 
complex of the two proteins by incubation at 37ºC and physiological pH. By SDS-PAGE 
analysis, we observed that apoA-I was cleaved in the presence of recombinant TTR 
(Figure 1A, lane 4). A major apoA-I fragment of approximately 26 kDa was seen, although 
upon higher incubation times, two extra apoA-I fragments could be observed (data not 
shown). This was the first evidence suggesting that TTR might be a cryptic protease able 
to use apoA-I as a substrate. To confirm this hypothesis, incubation of apoA-I with plasma 
TTR was performed and the same pattern of SDS-PAGE migration was obtained (Figure 
1A, lane 3). The fact that incubation of apoA-I with either recombinant or plasma TTR of 
different sources generated the same pattern of apoA-I degradation (Figure 1A), pointed 
to a TTR-intrinsic proteolytic activity and argued against the presence of a contaminant 
protease in the preparation. TTR preparations presented decreased proteolytic activity or 
completely lost activity with repeated freeze-thawing cycles. LCQ/ms/ms, a powerful tool 
in identifying protein contaminants in preparations, was performed in one of the 
recombinant TTR preparations and only TTR-related peaks were observed (data not 
shown), further suggesting that TTR itself is a novel cryptic protease. To further verify the 
ability of TTR to act as a protease we used casein zymography, as casein is well known to 
act as a universal protease substrate (Jobin and Grenier, 2003). When TTR was run on 
casein zymogram gels one major band of degraded casein was visualized (Figure 1B, 
arrow). To ascertain whether TTR was responsible for the appearance of the unstained 
casein degraded band, we performed anti-TTR western analysis of zymograms, which 
showed that the band with caseinolytic activity corresponded in fact to TTR (Figure 1B). 
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Figure 1 – Identification of TTR proteolytic activity. A. ApoA-I cleavage by TTR analysed by 
SDS-PAGE. Lane 1:  Molecular weight markers; lane 2: ApoA-I; lane 3: recombinant TTR; lane 4: 
apoA-I incubated with recombinant TTR ; lane 5: apoA-I incubated with plasmatic TTR. B. 
Identification of caseinolytic activity of TTR. Left: casein zymogram; right: anti-TTR western blot of 
zymogram gel. 
 
Serine protease inhibitors block apoA-I cleavage by TTR  
To characterize the nature of the proteolytic activity of TTR, we used a spectrum of 
protease inhibitors and tested their ability to block apoA-I cleavage by TTR. α2-
macroglobulin (α2M), an inhibitor of all classes of proteases, completely inhibited 
proteolysis of apoA-I (data not shown); pefabloc, PMSF and DFP, serine proteases 
inhibitors, abolished apoA-I processing by TTR, whereas inhibitors of other protease 
classes were without effect (Figure 2). Chymostatin and TPCK, inhibitors of chymotrypsin-
like serine proteases were also able to block TTR activity (Figure 2). These data 
suggested that TTR has a chymotrypsin-like serine protease activity.  
 
 
Figure 2 - SDS-PAGE analysis of inhibition of apoA-I cleavage by TTR using different 
classes of protease inhibitors. ∗ - protease inhibitors that inhibit apoA-I cleavage by TTR. 
 
________________________________________________________________________________________Chapter 1 
 
 75 
Identification of the cleavage site on apoA-I 
To establish the cleavage site in apoA-I, we started by performing N-terminal sequencing 
of apoA-I fragments generated upon incubation with TTR. As the identified N-terminus of 
the major proteolytic fragment of apoA-I was intact, we concluded that cleavage was 
occurring in the C-terminus of the protein and subsequently analyzed the major apoA-I 
proteolytic fragment by MALDI-MS. A C-terminally deleted apoA-I was identified, 
presenting MS peaks spanning from aminoacid residues 1 to 215 of the protein (Table1). 
As can be seen by comparison of MALDI-MS of tryptic peptides derived from full-length 
apoA-I and apoA-I digested by TTR (Table1), cleavage by TTR occurred between 
aminoacid residues 216-226 of apoA-I, as the 216-226 peptide peak, corresponding to the 
sequence QGLLPVLESFK, was missing in the tryptic MS analysis of apoA-I digested by 
TTR (Table 1). To determine the exact cleavage site, the highest MW fragment of apoA-I 
digested by TTR was subjected to C-terminal sequencing. This analysis identified the 
cleavage site in apoA-I as being after Phe 225. For subsequent proteolytic assays, a 
fluorogenic peptide corresponding to aminoacid residues 223 to 228 of apoA-I (Abz-
ESFKVS-EDDnp), encompassing the sequence that is being cleaved by TTR, was used. 
 
Table 1 - MS analysis of tryptic peptides derived from full-length apoA-I and from TTR-
digested apoA-I. + present; - absent 
Position Sequence Full-length 
apoA-I 
TTR-digested 
apoA-I 
1-10 DEPPQSPWDR + + 
1-12 DEPPQSPWDRVK + + 
13-23 DLATVYVDVLK + + 
13-40 DLATVYVDVLKDSGRDYVSQFEGSALGK + + 
24-40 DSGRDYVSQFEGSALGK + + 
28-40 DYVSQFEGSALGK + + 
46-59 LLDNWDSVTSTFSK + + 
60-77 LREQLGPVTQEFWDNLEK + + 
60-83 LREQLGPVTQEFWDNLEKETEGLR + + 
62-77 EQLGPVTQEFWDNLEK + + 
62-83 EQLGPVTQEFWDNLEKETEGLR + + 
97-106 VQPYLDDFQK + + 
97-107 VQPYLDDFQKK + + 
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107-116 KWQEEMELYRQK + + 
108-116 WQEEMELYRQK + + 
117-131 QKVEPLRAELQEGAR + + 
119-131 VEPLRAELQEGAR + + 
119-133 VEPLRAELQEGARQK + + 
132-140 QKLHELQEK + + 
141-149 LSPLGEEMR + + 
141-151 LSPLGEEMRDR + + 
154-160 ARAHVDAL + + 
154-173 ARAHVDALRTHLAPYSDELRQR + + 
161-171 THLAPYSDELR + + 
189-195 LAEYHAK + + 
207-215 AKPALEDLR + + 
216-226 QGLLPVLESFK + - 
216-239 QGLLPVLESFKVSFLSALEEYTKK + - 
227-238 VSFLSALEEYTK + - 
227-239 VSFLSALEEYTKK + - 
 
 
Hydrolysis of the Fluorogenic peptide Abz-ESFKVS-EDDnp by TTR 
Different TTR preparations available in our laboratory were used to test the proteolytic 
cleavage of the Abz-ESFKVS-EDDnp fluorogenic peptide. All the recombinant batches of 
protein, as well as TTR isolated from plasma, retained the ability to cleave the fluorogenic 
peptide. In an attempt to establish a possible correlation between proteolysis and 
pathological or physiological processes, preparations used included both wt or different 
TTR mutations either related to amyloidogenesis or to structural mutants with biological 
implications such as T4 binding. The following TTR mutants were used: Val30Met, the 
most frequent mutation related to ATTR; Leu55Pro, which is associated to the most 
aggressive form of ATTR; Thr119Met, a nonpathogenic variant shown to have a protective 
effect on the clinical evolution of the disease; Glu92Cys and Ser117Cys, mutants 
designed with the purpose of stabilizing the dimer/tetramer interactions. TTR activity was 
apparently independent from these constraints (data not shown) suggesting that the 
conformational changes occurring either on amyloidogenic variants of the protein or in 
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stabilized dimer/tetramer interactions do not compromise proteolytic activity. The optimum 
pH determined for TTR cleavage was approximately 7; the same optimum pH was 
determined for cleavage of apoA-I (data not shown). The cleavage reaction of the 
fluorogenic peptide yielded a Km of 29 µM, as determined by Michaelis-Menten kinetics 
(Figure 3A). The proteolytic activity of TTR preparations purified by HPLC was tested in 
each of the eluted fractions in activity assays using Abz-ESFKVS-EDDnp as substrate. 
The fractions corresponding to TTR elution clearly overlapped with fractions with 
proteolytic activity towards Abz-ESFKVS-EDDnp (Figure 3B), further demonstrating TTR-
specific cleavage of the fluorogenic peptide. The putative influence of the major TTR 
ligands (T4 and RBP) on its proteolytic activity was tested; we observed that whereas RBP 
completely inhibited TTR activity, T4 only produced an approximately 15% decrease of 
TTR mediated proteolysis (Figure 3C). As a control for the effect of TTR ligands in its 
proteolytic activity, the activity of chymotrypsin in the presence of either RBP or T4 was 
tested. Chymotrypsin´s activity was unaltered by the presence of RBP or T4 (Figure 3C), 
therefore showing that the inhibition produced by these ligands is TTR-specific. 
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Figure 3 - Hydrolysis of the fluorogenic peptide Abz-ESFKVS-EDDnp by TTR. A. Michaelis-
Menten kinetics of TTR cleavage using Abz-ESFKVS-EDDnp as substrate. B. Analysis of 
proteolytic activity of HPLC eluted fractions during the course of TTR purification. Inset: SDS-page 
analysis of the eluted fractions. C. Effect of TTR major ligands (T4 and RBP) on the hydrolysis of 
Abz-ESFKVS-EDDnp by TTR and chymotrypsin.  
 
Assessment of proteolysis using cellular assays  
To assess the ability of TTR to exert its proteolytic activity in cellular assays, we started by 
comparing the degradation of DQ gelatin by hepatomas without TTR expression (SAHep) 
and with high levels of TTR expression (Huh7). DQ gelatin is an intramolecularly 
quenched substrate of gelatinases and several other proteinases (including serine 
proteases) that allows a rapid and highly sensitive assessment of proteolytic activity. 
Whereas Huh7 presented high degradation of DQ gelatin (Figure 4A, Huh7, second 
vertical panels), SAHep displayed lower fluorescence (Figure 4A, SAHep, first vertical 
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panels), indicative of a decrease in the capacity to degrade this substrate. Furthermore, in 
the presence of pefabloc, a protease inhibitor of TTR activity, Huh7 lost their ability to 
degrade DQ gelatin, as observed by the lack of fluorescence (Figure 4A, Huh7, third 
vertical panels); in contrast, the addition of aprotinin, a protease inhibitor that we 
previously showed to be unable to block TTR-mediated proteolysis, did not affect the 
ability of Huh7 to degrade DQ-gelatin (Figure 4A, Huh7, fourth vertical panels). These 
results suggested that in cellular assays TTR was proteolytically active. We followed by 
performing additional experiments where gelatin was replaced by the specific TTR 
substrate; to quantify TTR-related proteolysis in cellular assays, hydrolysis of Abz-
ESFKVS-EDDnp in different cell lines expressing TTR was assessed and compared to the 
activity of control cell lines lacking TTR expression. Each of the cell lines expressing TTR 
presented an approximally two fold increased level of degradation of the fluorogenic 
peptide when compared to the same cell line lacking TTR expression (Figure 4B). We 
therefore show that TTR produced in cells of different sources is able to cleave a peptide 
corresponding to the C-terminus of apoA-I. In order to demonstrate that this increase in 
cleavage of Abz-ESFKVS-EDDnp is TTR-specific we tested the influence of RBP, a TTR 
ligand that inhibits its proteolytic activity, using the RN22 cell line. In the presence of RBP, 
RN22 expressing TTR lost the ability to degrade Abz-ESFKVS-EDDnp displaying 
degradation levels similar to the ones of RN22 cells without TTR expression (Figure 4B, 
left chart). This result further demonstrates that TTR is a novel cryptic protease with 
potential physiological relevance. 
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Figure 4 - Analysis of TTR proteolytic activity in cellular assays. A. Assessment of proteolysis 
in cellular assays using DQ-gelatin as substrate. First and second vertical panels: magnification 
20x; third and fourth vertical panels: magnification: 40x. Upper panels: transmission; lower panels: 
FITC channel. B. Hydrolysis of the fluorogenic peptide Abz-ESFKVS-EDDnp by cell lines either 
lacking (-) or expressing (+) TTR, in the presence (+) or absence (-) of RBP in the cell culture 
media. 
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Discussion 
In this report we describe TTR as a novel cryptic protease and identify apoA-I as one of its 
possible natural substrates. At this point we cannot exclude the hypothesis that under 
physiological conditions TTR might have other substrates; these putative new substrates 
should be the subject of future investigation in order to further elucidate the role of TTR 
activity. The presence of a non-identified proteinase contaminant in our preparations, 
which would be co-purified with TTR, is highly unlikely given the data reported here, 
namely the similar enzymatic properties of TTRs from different sources, the high degree 
of purity of our preparations as demonstrated by LCQ/MS/MS, the co-elution of the 
enzymatic activity with the TTR peak isolated by HPLC and the specific inhibition of 
activity by TTR ligands.  
Other cryptic plasma proteases have been reported, namely human plasma fibronectin, a 
multifunctional glycoprotein that has been shown to have in its structure a cryptic 
degrading serine proteinase activity, fibronectinase (Lambert Vidmar et al., 1991a). 
Recombinant and isolated human fibronectinase were subsequently used to define 
substrate specificity and roles in physiological and pathological processes (Schnepel and 
Tschesche, 2000). Based on the inhibition of TTR proteolytic activity by general serine 
protease inhibitors, as well as its cleavage preference for a Phe residue on P1 and an 
optimum pH of 7, we propose a serine-like protease activity for TTR. The specificity of 
TTR cleavage on full length apoA-I (Phe-Lys) has similarity with other well-characterized 
serine-like proteases, namely endopeptidase H2, a human urine chymotrypsin-like serine 
proteinase that hydrolyzes Phe-Lys bonds in neuropeptides (Casarini et al., 1992), and 
mammalian chymotrypsin-like enzymes, including rat mast cell proteases I and II and 
human skin chymases that have preference for a Phe residue on P1 and hydrophobic 
aminoacid residues in P2 and P3 (Powers et al., 1985).  
Analysis of the primary structure of TTR to identify a possible canonical catalytic triad (His 
Asp Ser) is difficult to accomplish; TTR has eleven Ser residues, four Asp residues and 
four His residues. Furthermore, TTR lacks canonical structural protease determinants. 
Moreover, TTR is a tetramer of 4 identical subunits and is possible that residues from 
different monomers can contribute to the catalytic triad. It is interesting to note that 
tryptase, a mast cell-specific proteinase that has been recently implicated as a mediator of 
inflammation, is a proteinase that is only active as a heparin-stabilized tetramer (Pereira et 
al., 1998). The identification of the catalytic amino acids in TTR will be discussed later in 
this thesis (chapter 2). 
Given the possibility that in vivo the proteolytic activity of TTR might be modulated by a 
third factor; we evaluated the effect of TTR main ligands in its activity. Our results suggest 
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that the binding site of T4 (a central hydrophobic channel in the TTR tetramer) does not 
correspond to the proteolytically active site of the protein as when TTR is complexed to T4 
its activity is well retained; however binding of RBP to TTR abolishes proteolysis. This fact 
can be explained either by steric hinderance caused by RBP (that would cause 
inaccessibility of the substrate) or by the fact that the aminoacid residues on TTR that bind 
RBP may play a role on catalysis.  
The C-terminal domain of apoA-I is important in both lipid binding and self-association 
(Gorshkova et al., 2000); furthermore, it has been previously reported that deletion of 
residues 221-243 (helix 10) abolishes cholesterol efflux in cultured cells (Panagotopulos 
et al., 2002). It is therefore possible that the regulation of the C-terminal truncation of 
apoA-I performed by TTR has impact in lipid metabolism. The susceptibility of the C-
terminus of apoA-I to proteolysis is well documented in the literature (Eberini et al., 2002) 
and agrees with the fact that the N-terminus of this protein is fully structured when 
compared to the unstructured C-terminus. It has been recently reported that mast cell 
human chymase, a chymotrypsin-like neutral protease, cleaves the C-terminus of apoA-I 
in discoidal pre-beta migrating reconstituted HDL particles at position Phe 225 (Lee et al., 
2003), the same position that is cleaved by TTR. In this study it was concluded that 
chymase reduces the ability of apoA-I in discoidal rHDL particles to induce cholesterol 
efflux therefore supporting the concept that extracellular proteolysis of apoA-I is one 
pathophysiologic mechanism leading to the generation and maintenance of foam cells in 
artherosclerotic lesions. The same reasoning is possible for TTR cleavage of apoA-I after 
Phe 225; therefore the ability of TTR to cleave apoA-I present in HDL or discoidal pre-beta 
migrating reconstituted HDL should be further addressed. 
 We have previously identified an amyloidogenic variant of apoA-I, where analysis of fibrils 
revealed co-deposition of N-terminal fragments of mutated apoA-I and wt TTR (de Sousa 
et al., 2000). As we here identified C-terminal cleavage of apoA-I by TTR, one can 
speculate that this event may trigger apoA-I fibril formation. Understanding the role of TTR 
proteolysis in amyloidoses and under physiological conditions, namely the relevance of 
apoA-I as a natural substrate of TTR, might have an impact not only in amyloidoses but 
also in disorders related to lipid metabolism. The impact of apoA-I cleavage by TTR is 
discussed in detail in chapter 3 of this thesis. 
The evidence that TTR contains a cryptic protease in its structure is new and together with 
recent findings describing similar activity in fibronectin (Schnepel and Tschesche, 2000) 
constitutes an important model to study the physiological relevance of cryptic proteases. 
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Abstract 
Transthyretin (TTR) has been recently described as a novel cryptic plasma protease 
having as substrate apolipoprotein A-I (apoA-I). Until today, neither the catalytic 
mechanism nor the physiological function of TTR proteolysis have been elucidated. 
Several indications, as an optimum pH of activity of approximately 7, cleavage after a Phe 
residue in apoA-I, and inhibition by serine protease inhibitors, allowed the assumption of 
TTR being a “Ser-like” protease. In this work we used site-directed mutagenesis and 
active site labeling to identify the catalytic residues of TTR active site. Each TTR 
monomer comprises 11 serine residues; only Ser46 is found in the vicinity of a His-Asp 
pair. However, a Ser46Ala TTR-mutant retained proteolytic activity. A number of enzymes 
with Ser-Lys catalytic dyads are currently known as is the case of Lon-protease and 
Signal-peptidase. Extended structural analysis of TTR revealed Ser77 and Ser85 as being 
located in proximity to a pair of lysines (Lys76, Lys80). Both serines are highly conserved 
among species and are located close to the binding site of retinol binding protein (RBP), a 
natural inhibitor of TTR proteolytic activity. Site-directed mutagenesis of Ser77 and Ser85 
revealed no significant reduction of Kcat/Km for the Ser77Ala and Ser85Ala mutants. 
Unexpectedly, Lys76Ala and Lys80Ala mutants were completely devoid of proteolytic 
activity. To ascertain whether inactivity was in fact due to the mutation and not to an 
additional protein modification, we compared the Maldi-MS spectra of inactive versus 
active preparations. We observed that the proteolytic inactive TTR preparations presented 
an extra mass peak corresponding to TTR modified with glutathione. By LC-ESI-MS we 
determined that TTR glutathionylation occurs at the residue Cys10. However, TTR 
Cys10Ala mutant retained proteolytic activity and was inhibited by glutathione, indicating 
the presence of additional binding sites for glutathione on the TTR molecule besides 
Cys10. Docking of TTR with glutathione suggested that after binding to Cys10 an extra 
binding site for glutathione was observed located near the regions encompassing the 
residues of the dimer-dimer interface and those in the RBP binding site. Interestinlgy, 
among those residues are included the putative candidates Ser77, Lys76 and Lys80. Our 
results show that the site-directed mutagenesis approach was affected by post-
translational modifications occurring in the process of expression of recombinant TTR; i.e. 
the Kcat/Km results vary not only according to the amino acid substitution but also 
according to random modifications introduced in TTR during protein production. As an 
alternative method to identify TTR catalytic amino acids, active site labeling was 
performed. Regarding this methodology, although we observed inhibition by peptidyl 
phosphonate compounds that specifically modify the nucleophile of the active site of 
serine proteases, we were not able to identify the modification sites by MALDI-MS, 
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probably due to the low percentage of active enzyme in the TTR preparations as 
determined by active site titration. Even so, the screening performed with the 
phosphonate library of suggested that apoA-I is probably not the prime substrate for TTR 
proteolytic. TTR was preferentially inhibited by compounds with a Lys residue in P1 
position, whereas in apoA-I TTR cleavage occurs after a Phe residue. In conclusion, the 
approaches used to identify the catalytic residues of TTR were directly affected by post-
translational modifications of the enzyme occurring during purification, as well as by the 
low percentage of active enzyme present in the final TTR preparation. Future studies 
should be performed not only aiming at obtaining unmodified TTR preparations with 
increased percentage of active enzyme, but also at obtaining crystals or TTR bound to a 
specific inhibitor 
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Introduction 
The homotetrameric plasma protein transthyretin (TTR) is a carrier of thyroxine (T4) and 
retinol, in the latter case through binding to retinol binding protein (RBP) (Raz and 
Goodman, 1969). In addition, a small fraction of TTR is bound to high-density lipoproteins, 
through interaction with apolipoprotein A-I (apoA-I) (Sousa et al., 2000a). We have 
previously shown that besides its transport activities, TTR is able to cleave off the C-
terminus of apoA-I, thereby acting as a novel type of protease (Liz et al., 2004). TTR has 
been described as a cryptic protease not only because it lacks canonical structural 
protease determinants, but also because its physiological function is apparently unrelated 
to proteolysis (Liz and Sousa, 2005). 
In a first attempt to identify the catalytic class of TTR, we used a spectrum of inhibitors of 
different classes of proteases. PMSF, Pefabloc, DFP, TPCK and chymostatin, serine 
protease inhibitors, abolished apoA-I processing by TTR. Inhibitors of other protease 
classes were used and no inhibition was observed. This data suggested that TTR has a 
serine protease activity. The preference for a Phe residue on P1, as determined in the 
cleavage of apoA-I, as well as an optimum pH for activity of approximately 7, supported 
the suggestion of TTR being a novel serine-like protease (Liz et al., 2004). 
Almost one third of the known proteases belong to the mechanistic class of serine 
proteases, named for the presence of a nucleophilic serine in the catalytic active site. In 
canonical serine proteases, three residues form the essential catalytic triad: Asp, His and 
Ser. The Asp-His-Ser triad can be found in four of the major clans of serine proteases, 
which are typified by chymotrypsin, subtilisin, carboxypeptidase Y, and Clp protease 
(Rawlings et al., 2006). The serine proteases are homologous, but locations of the three 
crucial residues differ somewhat, meaning that the order in sequence of the amino acids 
that constitute the triad is variable. For example, chymotrypsin has a catalytic triad of the 
type His-Asp-Ser while in subtilisin the catalytic residues are located in the order Asp-His-
Ser (Hedstrom, 2002). In more recently identified families of serine proteases, the 
members of the catalytic triad and the mechanism of action changed to some extent. 
Several proteases with novel catalytic triads and dyads have been found, which are 
termed non-canonical serine proteases (Polgar, 2005). In the sedolisin family, a family of 
carboxyl serine peptidases, the residues of the catalytic triad are Glu-Asp-Ser, with a Glu 
residue replacing the His of the canonical triad (Wlodawer et al., 2003). In the dipeptidase 
E family, constituted by exopeptidases that hydrolyse alpha-aspartyl bonds, the catalytic 
triad is constituted by the residues Ser-His-Glu (Rawlings et al., 2006). In this case the 
Glu residue replaces the Asp residue of the canonical triads. Besides variations in the 
constituents of the canonical catalytic triad, several Ser-Lys/His dyads have been 
Chapter 2________________________________________________________________________________________ 
 
 92 
described. In the LexA, Lon protease, and signal peptidase I families, the active site is a 
Ser-Lys dyad (Dalbey et al., 1997; Paetzel and Dalbey, 1997; Luo et al., 2001). These 
enzymes follow the canonical acyl-enzyme pathway of serine proteases. In the Rhomboid 
family, a family of membrane-bound serine proteases from Drosophila, a catalytic dyad 
also exists but formed by Ser-His (Wang et al., 2006). 
Analysis of the primary structure of TTR to identify a possible canonical catalytic triad 
(His-Asp-Ser) or even a catalytic dyad (Ser-Lys/His) is difficult to accomplish; not only 
TTR is an homotetrameric protein, but also each TTR monomer has eleven Ser residues, 
four Asp residues, four His residues and eight Lys residues. Moreover, it is possible that 
residues from different monomers can contribute to the catalytic triad. Nevertheless, the 
availability of the TTR three-dimensional structure constitutes a powerful tool for the 
analysis of putative TTR catalytic residues.  
Our previous work has shown that when TTR is complexed to T4 its proteolytic activity is 
not significantly affected, while binding of RBP to TTR abolishes proteolysis (Liz et al., 
2004). The TTR structure complexed with T4 and RBP is well characterized. The binding 
site for T4 is located in the central hydrophobic channel of the TTR tetramer (Blake et al., 
1978b); according to our results, the central channel does not allocate the catalytic site of 
TTR. Regarding RBP, its effect on TTR proteolytic activity can be explained either by 
steric hindrance, which would cause inaccessibility of the substrate to the active site, or by 
the fact that TTR amino acid residues that bind RBP may play a role in catalysis. The 
crystal structure of the TTR-RBP complex shows that each RBP monomer makes contact 
with three of the four TTR subunits (Monaco et al., 1995), what supports the hypothesis of 
steric hindrance to explain the inhibitory effect on TTR activity. TTR amino acids involved 
in RBP binding are: Val20, Arg21, Lys76, Lys80, Ala81, Leu82, Gly83, Ile84, Ser85, 
Pro86, Asp99, Ser100, Arg103, Tyr104 and Asn124 (Monaco et al., 1995); the Ser, Lys 
and Asp residues in the TTR-RBP contact region might have a role on TTR proteolytic 
activity, as they may be part of the catalytic site of TTR.  
TTR three-dimensional structure is highly conserved among vertebrates, with the most 
important regions such as the hydrophobic core and the areas involved in quaternary 
structure interactions or ligand binding being maintained. Considering the putative 
physiological relevance of TTR proteolytic activity, it is reasonable to consider that the 
residues involved on this novel TTR function might be conserved among different species. 
In this study we used site-directed mutagenesis and active site labeling to identify the 
catalytic residues of the TTR active site.  
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Methods 
Protein Production 
Recombinant wt TTR and TTR mutants were produced in BL-21 pLys Escherichia coli 
cells transformed with pET plasmids carrying TTR cDNA. After bacterial lysis, proteins 
were isolated and purified as previously described (Liz et al., 2004).  
 
Site-directed mutagenesis 
The wild-type TTR cDNA, cloned into the pET vector was used to produce mutant TTR 
molecules by site-directed mutagenesis (Quick Change site-directed mutagenesis kit; 
Stratagene). These mutants were constructed using two mismatched primers, introducing 
a 1±3 base substitution in the original sequence.  
Table 1 – List of primers used for TTR site-directed mutagenesis 
Mutation Sense and Antisense Primers  
C10A 5’-CACCGGTGAATCCAAGGCTCCTCTGATGGTCAAAG-3’ 
5’-CTTTGACCATCAGAGGAGCCTTGGATTCACCGGTG-3’ 
S46G 5’-GGGAGCCATTTGCCGGTGGGAAAACCAGTGAG-3’  
5’-CTCACTGGTTTTCCCACCGGCAAATGGCTCCC-3’ 
S50A 5’-GCCTCTGGGAAAACCGCTGAGTCTGGAGAGCTG-3’  5’-CAGCTCTCCAGACTCAGCGGTTTTCCCAGAGGC-3’ 
S52A 5’-GGGAAAACCAGTGAGGCTGGAGAGCTGCATGGG-3’ 5’-CCCATGCAGCTCTCCAGCCTCACTGGTTTTCCC-3’ 
K76A 5’-GAAATAGACACCGCATCTTACTGG-3’  5’-CCAGTAAGATGCGGTGTCTATTTC-3’  
S77A 5’-GGAAATAGACACCAAAGCTTACTGGAAGGCACTTG-3’ 5’-CAAGTGCCTTCCAGTAAGCTTTGGTGTCTATTTCC-3’  
K80A 5’-CCAAATCTTACTGGGCGGCACTTGGCATCT-3’ 5’-GAGTGCCAAGTGCCGCCCAGTAAGATTTGG-3’   
S85A 5’-GGAAGGCACTTGGCATCGCCCCATTCCATGAGCATGC-3’  5’-GCATGCTCATGGAATGGGGCGATGCCAAGTGCCTTCC-3’  
 
 
All PCR-amplified products were treated with DpnI (Stratagene) to digest non-mutated 
parental DNA template, and one tenth of the reaction volume, containing the circular, 
mutated dsDNA, was used to transform XL1-Blue supercompetent cells (Stratagene). 
Minipreps of plasmid DNA preparations were produced and tested by sequencing, as a 
service by SEQLAB, Germany. After protein production, as described above, protein 
mutations were confirmed by MALDI-MS analysis of the trypsin-digested TTR peptides. 
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Kinetic assays  
TTR proteolytic activity was tested with two distinct fluorogenic peptides, one 
encompassing the apoA-I sequence cleaved by TTR, Abz-ESFKVS-EDDnp (AI peptide; 
Global Peptide) (Liz et al, 2004), and the other derived from the sequence of the myelin 
basic peptide, Abz-YGGRASDQ-EDDnp (MBP peptide; as discusse in chapter 4 of this 
thesis). These substrates are internally quenched fluorescent peptides, where Abz (ortho-
aminobenzoic acid) is the fluorescent donor and EDDnp [N-(ethylenediamine)-2,4-
dinitrophenyl amide] is the fluorescent quencher. Hydrolysis of the fluorogenic substrates 
at 37ºC in 50 mM Tris pH 7 (reaction buffer) was followed by measuring the fluorescence 
at λem= 420 nm and λex= 320 nm in a fmax plate reader (Molecular Devices). Specificity 
rate constants (Kcat/Km) were determined under pseudo first-order conditions (Le Bonniec 
et al., 1996). TTR (5 µM total protein) was added to the substrates (8 µM) in a final volume 
of 100 µL of reaction buffer. Reactions were followed for 1 h, for the Abz-ESFKVS-
EDDnp, or 30 min, for the Abz-YGGRASDQ-EDDnp. Pseudo first order rate constants 
were obtained from the linear plots where the y axis corresponds to Ln ((Fmax-
Ftime)/Fmax), where Fmax is the fluorescence corresponding to total degradation of 8 µM 
substrate and Ftime is the fluorescence measured at each time point, and the x axis 
corresponds to the time of reaction. The slope of the linear plots, corresponding to the first 
order rate constants, was divided by the total enzyme concentration to provide Kcat/Km. 
 
Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) 
MALDI analysis was performed as a service by the Proteomics Unit at IPATIMUP, Porto. 
For determination of the full-length mass of TTR preparations (full-length MS), in-solution 
samples of the protein were desalted using ZipTip columns (Millipore). Protein elution was 
performed using 5-10 mg/mL MALDI matrix (α-ciano-4-hydroxy-cinnamic acid) dissolved 
in 50% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA). For tryptic-MS analysis, in-
gel samples were washed with the following solutions: 1) 5% ACN in 50 mM sodium 
bicarbonate, 2) 50% ACN solution in 50 mM sodium bicarbonate, and 3) 100% ACN. After 
destaining, gel bands were digested with trypsin; protein extraction from the gel was made 
with a 60% ACN and 0.1% TFA. After the digestion process, samples followed the same 
treatment as for full-length MS. All MALDI analyses were performed with an Applied 
Biosystems 4700 Proteomics Analyzer. Acquisitions were made in a reflective mode, for 
molecular weights lower than 4000 Da, or in linear mode for higher molecular weights. 
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Reverse-Phase chromatography  
TTR Ser46Gly preparations (100 µg) were separated by Reverse Phase (RF) 
Chromatography using a Knauer K-1001 HPLC system with a C18 250 x 4.6 mm column 
(Merck). Elution was carried out with a linear gradient (35-80%) ACN in 0.1 % v/v TFA for 
55 minutes at a flow rate of 1 mL/min. Absorbance was monitored at 220 nm using a DAD 
Knauer K-2800 diode array detector. The isolated peptides were collected, freeze-dried 
and submitted to MS analysis, as previously described. 
 
Liquid chromatography electrospray ionisation tandem mass spectrometry (LC-ESI-MS) 
In-gel TTR samples were digested with trypsin. Following this procedure, samples were 
desalted using C18 zip-tip, and analysed by LC-ESI-MS. Briefly, peptides were injected 
into the LC system (Ultimate 3000, LCPackings), and eluted into the mass spectrometer 
using a C18 column (75 µm I.D. 15 cm long) and multiple linear steps gradient from 5% 
mobile phase A (2% ACN, 0.1% fluoroacetic acid (FA)) to 100% mobile phase B (98% 
ACN, 0.1% FA), over 70 minutes at 0.2 µL/min. The mass spectrometer (4000 QTRAP, 
Applied Biosystems), operated with a nanoESI source in an Information Dependent 
Analysis (IDA), acquiring repeatedly a full scan (to select more intense ions), an enhanced 
resolution scan (to determine ions charge), and fragmentation of the 3 most intense ions. 
This 10 seconds cycle was repeated over the 70 min run. Acquired data were analysed 
using Mascot search algorithm, Protein Pilot (Applied Biosystems) and PEAKS – de novo 
sequencing software (Biosolutions). 
 
Effect of redox agents on TTR proteolytic activity 
We examined the effect of redox agents, namely 1,4-Dithiothreitol (DTT; Sigma) and 
oxidized glutathione (GSSG; Sigma), on TTR proteolytic activity. The enzyme (5 µM) was 
pre-incubated in the presence of each compound (concentrations used detailed in the 
results section) for 15 minutes at 37ºC before adding the substrate. Activity assays were 
performed as described above, using the MBP peptide. Relative fluorescence values were 
converted to percentages of residual activity relative to non-incubated controls.  
 
Protein Docking 
The structure of a glutathione molecule was created and optimized using CHEMOFFICE 
SUITE 8.0. Docking of the glutathione molecule to the structure of the TTR tetramer (PDB 
1TTA) was performed using in silico docking. The docking was done using the program 
HEX 4.5. Covalent bonds were created with CHEMOFFICE SUITE 8.0 and the structure 
was optimized. First CHEMDRAW was used to run 1000 cycles of molecular dynamics. 
The structure was then imported into DEEPVIEW. Using the GROMOS forcefeld available 
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in this program we ran an energy minimization of the structure. The final structure was 
assumed as being optimized. 
 
Chemical modification of TTR with protease inhibitors 
For chemical modification, TTR (5 µM) was incubated with each of the following protease 
inhibitors: Pefabloc SC (4 mM; Roche), DFP (100 µM; Calbiochem), and PMSF (1 mM; 
Sigma). After a 30 min incubation at 37ºC, reactions were run on a 15% SDS-PAGE gel 
and visualized by Coomassie Blue staining. MALDI-MS of the trypsin-digested gel band 
corresponding to modified TTR was performed as a service by the Protein Chemistry Core 
Facility at Columbia University, as previously described (Liz et al., 2004).  
 
TTR screening with a library of phosphonate inhibitors 
Library screening was carried out in a dose response manner with inhibitor concentrations 
ranging from 1 to 50 µM or 0.01 to 1 µM. TTR (5 µM) was incubated with the inhibitors for 
30 min at 37ºC, in 50 mM Tris pH 7. After enzyme-inhibitor incubation, 5 µM of the 
substrate Abz-ESFKVS-EDDnp was added and the kinetics of the reactions were followed 
at 37ºC for 1 h, as described above. Relative fluorescence values were converted to 
percentages of residual activity relative to uninhibited controls.  
 
Inhibition pattern of TTR cleavage of fluorogenic peptides 
For analysis of the inhibition pattern of TTR proteolytic activity using as substrate the MBP 
fluorogenic peptide, TTR (2.7 µM) was pre-incubated for 30 min at 37ºC in reaction buffer 
with the following inhibitors: 1 mM PMSF (Sigma); 1 mM Benzamidine (Sigma); 100 µM 
TPCK (Roche); 100 µM TLCK (Roche) and 1 mM 1,10-phenanthroline (Roche). After 
enzyme-inhibitor incubation, 10 µM of MBP substrate were added and activity was 
followed as described above. Relative fluorescence values were converted to percentages 
of residual activity relative to uninhibited controls. 
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Results 
Identification of the nucleophilic serine of TTR catalytic site 
Analysis of serines residues within TTR 
Several indications including an optimum pH for activity of approximately 7, inhibition by 
serine protease inhibitors and cleavage in apoA-I after a Phe residue, allowed the 
assumption of TTR being a Serine protease (Liz et al., 2004). In order to identify TTR 
serine residues that could constitute candidates to work as the nucleophile in the 
proteolytic reaction, we started by analysing the pattern of conservation of TTR serine 
residues among several vertebrate species (Figure 1A), and in parallel by checking the 
three-dimensional arrangement of each candidate residue. TTR has 11 serine residues 
(Figure 1B); starting from the N-terminus of the protein, the first serine residue is Ser8 that 
although being conserved among approximately 75% of the species analysed, is located 
in a non-structured region of the protein (Blake et al., 1978b). In the C-terminus direction, 
the following serines are Ser23, Ser46, Ser50 and Ser52; these residues are not highly 
conserved among the vertebrate species, what would exclude the possibility that one of 
these residues would be the catalytic amino acid. However, analysis of the three-
dimensional structure of TTR showed that Ser46 was the only TTR serine residue 
accommodating a structural arrangement, in combination with His31 and Asp74, 
compatible with a canonical serine protease triad. The analysis of Ser46 as the putative 
catalytic amino acid of TTR will be detailed later in this section. Besides not being 
conserved, residues Ser23, Ser50 and Ser52 do not contain a structural arrangement 
compatible with a serine protease active site, as determined by analysis of TTR three-
dimensional structure. The residues Ser77 and Ser85 also constituted two possible 
candidates as not only these residues are conserved in approximately 67% and 75% of 
the analysed vertebrate species, but also are located in the TTR-RBP binding site; this 
region seems essential for TTR protelytic activity as when complexed to RBP, TTR is 
proteolytically inactive (Liz et al., 2004). Moreover, Ser77 and Ser85 present a structural 
arrangement compatible with a non-canonical active site of a serine protease. In the C-
terminal part of the protein are located four additional serine residues: Ser100, conserved 
in 50% of the species analysed and involved in RBP binding to TTR, but not structurally 
favored to constitute the catalytic amino acid; and Ser112, Ser115 and Ser117, which 
although being highly conserved, are not structurally favored as they are positioned in the 
hydrophobic core of the protein, the binding site for T4. We have previously shown that the 
region for T4 binding is not essential for TTR proteolytic activity, as the complex TTR-T4 is 
proteolytically active (Liz et al., 2004). In conclusion, three serine residues, Ser46, Ser77 
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and Ser85 were considered putative candidates to act as the nucleophile of the catalytic 
site of TTR.  
 
 
 
 
Figure 1 – Analysis of TTR serine residues. A: Amino acid sequence alignment of vertebrate 
TTRs. Dots indicate residues that are identical to those of Homo sapiens TTR. The first amino acid 
of the mature human TTR subunit is indicated with an arrow, secondary structural elements of the 
human TTR subunit are presented above the alignment. Shaded amino acids correspond to the 
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ones that reside in the central channel and are thought to participate in hormone binding. Amino 
acid numbers denoted below the alignment are based on the mature H. sapiens TTR subunit. TTR 
serine residues are boxed in red. Adapted from (Manzon et al., 2007). B: Ribbon representation of 
the TTR tetramer. Serines highlighted. Kindly provided by Dr Ana M Damas, Molecular Structure 
Group, IBMC. 
 
Proteolytic activity of wt TTR  
In order to analyse the possibility of each of the putative candidates to act as the catalytic 
amino acid, we compared the proteolytic activity of mutants of the selected candidates 
with the activity of wt TTR. We started by defining the specificity rate values for wt TTR. 
We measured Kcat/Km for wt TTR using two distinct fluorogenic substrates; one 
encompassing the region cleaved by TTR in apoA-I (AI peptide), and the other derived 
from the sequence of the myelin basic protein (MBP peptide). We determined 
aproximately 20-fold higher values for the kinetic constants of wt TTR when using the 
MBP peptide relatively to the ones obtained for cleavage of the AI peptide (Table 2). As 
such, we decided to use the MBP peptide as substrate to perform the comparisons 
between the different TTR mutants and wt TTR. Although protein production was 
performed always under the same conditions, we observed some variability in the Kcat/Km 
among distinct preparations of wt TTR, as shown by the standard deviation values 
obtained (Table 2); concerning that fact, we compared the specificity rates obtained to the 
TTR mutants having as a reference the range of values obtained with the wt protein.  
Table 2 - Specificity rate constants (Kcat/Km) for wt TTR  
Substrate     Kcat/Km*10
4 min-1µM-1
average SD
AI peptide 10.5 5.1
MBP peptide 225.9 104.3  
  SD – standard deviation 
 
Ser46: a putative candidate to act as the nucleophile in a canonical catalytic triad 
A catalytic triad of the type His-Asp-Ser constitutes the typical active site of serine 
proteases. Analysis of the three-dimensional structure of TTR to identify residues that 
could accommodate a canonical triad, suggested that His31, Ser46 and Asp74 had an 
arrangement compatible with the typical triad of serine proteases (Figure 2). Ser46 would 
act as the nucleophile, His31 as the general base that would assist the nucleophilic attack 
of Ser46, and Aps74 would act as the stabilizer of the His residue.  
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Figure 2 - Ribbon representation of the putatice catalytic triad of TTR. Putative nucleophile 
Ser46, general base His31 and acid Asp74 highlighted. Kindly provided by Dr Ana M Damas, 
Molecular Structure Group, IBMC. 
 
To ascertain whether Ser46 could work as the nucleophile in the catalytic machinery of 
TTR, we mutated this residue to a Gly and determined the specificity rate constants 
(Kcat/Km) of the mutant comparing with the values obtained for wt TTR (Table 3). We 
produced several preparations of TTR Ser46Gly and observed some variability among the 
Kcat/Km values calculated. From the several protein productions, we had protein batches 
presenting complete loss of activity (TTRSer46Gly_i), but also batches with a Kcat/Km 
value within the range of values obtained for the wt protein (TTRSer46Gly_a). The 
mutation of the Ser residue to a Gly was confirmed in all preparations by MS analysis of 
the trypsin-digested proteins (data not shown). Considering the fact that one of the 
preparations of TTR Ser46Gly, where mutation was confirmed, showed regular proteolytic 
activity, we considered that this residue could not act as the catalytic amino acid of TTR. 
Table 3 - Specificity rate constants (Kcat/Km) for TTR Ser46Gly. TTRSer46Gly_i: TTR 
preparation proteolytically inactive; TTRSer46Gly_a: TTR proteolytically active. 
Protein Production K cat/Km*10
4 min-1µM-1
TTR Ser46Gly_i NA
TTR Ser46Gly_a 113.2  
     NA- no activity 
 
 
Ser77 or Ser85: two candidates to comprise the catalytic amino acid in a non-
canonical active site 
As the only possible catalytic triad in TTR was the one comprising Ser46, which by 
mutagenesis retained activity, we followed by searching possible catalytic amino acids of 
TTR, participating in a non-canonical serine protease active site. Several non-canonical 
serine proteases have been identified as the case of ATP-dependent Lon protease that 
employs a Ser-Lys catalytic dyad in which the Lys residue plays the role of a general base 
and activates the hydroxyl group of Ser for catalysis (Botos et al., 2004). Analysis of the 
three dimensional structure of TTR suggested that Ser77 and Ser85 presented the best 
arrangement compatible with a non-canonical Ser-Lys dyad, with one of the serine 
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residues acting as the nucleophile and Lys76 or Lys80 as the best candidates to act as 
the general base (Figure 3). 
 
 
Figure 3 - Ribbon representation of the putative non-canonical active site of TTR. Putative 
nucleophiles Ser77 or Ser85, and general bases Lys76 or Lys80 highlighted. Kindly provided by Dr 
Ana M Damas, Molecular Structure Group, IBMC. 
 
To analyse whether TTR proteolytic activity was dependent on a non-canonical catalytic 
dyad, TTR Ser77Ala, TTR Ser85Ala, Lys76Ala and Lys80Ala mutants were produced by 
site-directed mutagenesis and their proteolytic activity was assessed. Several batches of 
the mutants were produced and the respective mutation was confirmed by tryptic-MS 
(data not shown). Although presenting Kcat/Km values lower than the ones obtained for the 
wt protein, both Ser77Ala and Ser85Ala retained proteolytic activity  (Table 4). In the case 
of TTR Ser77Ala, we observed variability in the proteolytic activity, with Kcat/Km values 
changing with protein batches, as shown by the high standard deviation values. 
Regarding TTR Ser85Ala, although the Kcat/Km value obtained is approximately 4-fold 
reduced comparing with the average value obtained for the wt protein, the mutant is 
clearly proteolytic active. As for both Ser77Ala and Ser85Ala mutants, we had protein 
preparations where the mutation was confirmed and proteolytic activity was retained, we 
discarded the hypothesis that one of these residues would act as the nucleophile in TTR-
mediated catalysis.  
In respect to Lys76Ala and Lys80Ala TTR mutants, proteolytic activity was lost in all the 
preparations produced (Table 4). This result was unexpected as the hypothesis was that 
one these Lys residues could act as a general base of a catalytic dyad in which either 
Ser77 or Ser85 would be the nucleophile. As we determined that the putative nucleophile 
mutants were active, it was surprising to observe the loss of proteolytic activity with the 
mutation of the referred Lys residues. 
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Table 4 - Specificity rate constants (Kcat/Km) for TTR mutants Lys76Ala, Ser77Ala, Lys80Ala 
and Ser85Ala 
    Kcat/Km*10
4 min-1µM-1
average SD
TTR Ser77Ala 72.2 50.8
TTR Ser85Ala 50.3 9
TTR Lys76Ala NA -
TTR Lys80Ala NA -  
                            SD - standard deviation; NA- no activity 
 
 
Proteolytic inactive preparations of TTR are modified with glutathione 
As referred to above we detected in our assays some variability in the proteolytic activity 
of TTR preparations depending on the protein production. Moreover, the complete loss of 
activity in the Lys76Ala and Lys80Ala mutants was quite surprising, as the putative 
partners to constitute the TTR catalytic machinery, Ser77 or Ser85, were active. To clarify 
that question, we performed full-length MS analysis of the Lys76Ala and Lys80Ala inactive 
preparations to check for possible protein modifications. Both the Lys76Ala and the 
Lys80Ala preparations presented two mass peaks (Figures 4A and 4B); for both 
preparations, the peak with lower mass (peak “a”) displayed an increase in mass of 
approximately 40 Da relatively to the predicted TTR mass, while the higher-mass peak 
(peak “i”) presented an increase in mass of approximately 307 Da relatively to the 
predicted TTR mass. In parallel, we performed the full-length MS analysis of TTR 
preparations of different batches of the same mutant presenting opposite behaviors in 
terms of proteolytic activity. One of these was TTR Ser46Gly, for which some batches 
presented complete loss of proteolytic activity, whereas others retained proteolytic activity 
(as described above). We observed that the TTR Ser46Gly active preparation presented 
only one major mass peak (Figure 4C), while the inactive preparation presented two mass 
peaks (Figure 4D); peculiarly, as described for the Lys76Ala and Lys80Ala, the extra peak 
observed in the inactive preparation of TTRSer46Gly had a mass variation of 307 Da 
comparing with the predicted mass of the mutant. Moreover, in the inactive preparations, 
the peak with lower mass (peak “a”) was common to the single protein peak of the active 
preparations. As such, the presence of a second mass peak (peak “i”), displaying a mass 
of plus 307 Da relatively to the predicted TTR mass, in the inactive preparations is 
probably the cause of protein inactivation.  
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Figure 4 – Full-length Maldi-MS analysis of recombinant TTR preparations. A. TTR Lys76Ala 
(inactive mutant); B. TTR Lys80Ala (inactive mutant); C. TTR Ser46Gly proteolytically active; D. 
TTR Ser46Gly proteolytically inactive. “a” peaks correspond to non-modified TTR and “i” peaks 
correspond to modified TTR. 
 
To assure that the higher mass peak observed by MS in inactive TTR preparations 
corresponded in fact to modified TTR, we performed reverse phase chromatography of an 
active and of an inactive Ser46Gly preparation. In accordance with the MS analysis, we 
observed the presence of only one major eluted peak in the preparation of active protein, 
and two major eluted peaks in the inactive preparation. Tryptic-MS analysis of the 
collected fractions corresponding to each of the HPLC-eluted peaks, showed that all 
peaks corresponded to TTR (data not shown). This demonstrated that the additional peak 
observed in the full-length MS spectra of inactive TTR preparations corresponds to 
modified TTR. As such, the loss of proteolytic activity observed in the TTR mutants 
described, was independent from the mutation and resulted from protein modification. 
Regarding the single TTR peak present in active preparations (peak “a”) it is important to 
refer that its mass was found to be variable: in some MS analyses it corresponded to the 
calculated molecular weight of TTR (based on the amino acid sequence), while in others it 
presented an increase in mass ranging from 30 to 80 Da (data not shown). These 
modifications are probably due to oxidation of the protein, which can occur during sample 
handling (Biroccio et al., 2006). Nevertheless, these low mass modifications that were 
sometimes present in proteolytic active preparations of TTR, were not responsible for the 
inactivation of TTR proteolysis.  
Chapter 2________________________________________________________________________________________ 
 
 104 
Several post-translational modifications of TTR have been detected in the plasma, such 
as dihydroxylation (32 Da), phosphorylation (80 Da), cysteinylation (120 Da) and 
glutathionylation (306 Da) (Terazaki et al., 1998). Interestingly, the increase in mass 
caused by the protein modification observed in our preparations corresponded to one of 
the modifications previously detected in plasma TTR, a glutathionylation. Glutathione 
reacts with reactive protein sulphydryls; in plasmatic TTR, glutathionylation occurs in the 
unique Cys residue, which is located at position 10 (Terazaki et al., 1998). To verify if 
glutathione was the modifier present in our TTR preparations lacking proteolytic activity, 
we performed LC-ESI-MS analysis, under non-reducing conditions, of the peptides 
generated by trypsin digestion of active and inactive preparations of TTR Ser46Gly. The 
software analysis of the ESI-MS results, programmed to detect the known post-
translational modifications of proteins, showed that in the preparation of inactive TTR, 
glutathione was present in the trypsin-generated TTR peptide containing Cys10 (Table 5). 
In the preparation of active protein, no modification of Cys10 was observed (data not 
shown).  
Table 5 - De novo sequencing of trypsin-generated peptides of TTR Ser46Gly proteolytically 
inactive analysed by LC-ESI-MS 
Identified peptide sequences Protein region 
GPTGTGESKCPLMVK 1-15 
(GlutathionationC)PL(OxM)VK 10-15 
VLDAVR 16-21 
GSPAINVAVHVFR 22-34 
YTIAALLSPYSYSTTAVVTNPK 105-126 
 
 
To further confirm that glutathione modifies TTR by reacting with Cys10 residue we 
compared the full-length MS spectrum of either wt TTR or TTR Cys10Ala after incubation 
with 50 mM glutathione. In the case of wt TTR, we observed that addition of glutathione to 
the protein preparation generated a shift of 307 Da in the predicted protein mass of 
unmodified TTR; this mass shift was similar to the one observed in the preparations of 
proteolytic inactive TTR (Figure 5A). Regarding Cys10Ala, glutathione addition did not 
alter the mass spectrum of the protein, suggesting that glutathione is not able to modify 
the mutant due to the absence of the Cys residue (Figure 5B). All together, our results 
show that, on a random basis, some TTR preparations are modified with glutathione, 
which forms a disulfide bond with Cys10 residue, and that this modification completely 
inhibits TTR proteolytic activity.  
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Figure 5 – Full-length Maldi-MS analysis of TTR incubated with glutathione. A. Mass spectra 
of wt TTR non-incubated (left spectrum, wt TTR) or incubated with glutathione (right spectrum, wt 
TTR+GSSG). B. Mass spectra of TTR Cys10Ala non-incubated (left spectrum, TTR Cys10Ala) or 
incubated with glutathione (right spectrum, TTR Cys10Ala+GSSG). “a” peaks correspond to non-
modified TTR and “i” peaks correspond to glutathione-modified TTR.  
 
TTR Cys10Ala mutant is proteolytically active, and inhibited by glutathione 
As we determined that modification by glutathione of the Cys10 residue completely 
blocked TTR proteolytic activity, we hypothesized that Cys10 could play an essential role 
in the TTR catalytic machinery. However, we determined that the mutant TTR Cys10Ala 
has a catalytic efficiency similar to the wt protein, as shown by a Kcat/Km value of 115.4*10-
4 min-1µM-1, which is within the range of values determined for wt TTR. This result 
demonstrated that alteration of the Cys10 residue is not crucial for TTR proteolytic activity. 
Furthermore, in experiments where we added glutathione to active TTR preparations and 
subsequently tested their proteolytic activity, we observed that glutathionylation inhibits 
both wt TTR and TTR Cys10Ala activities (Figure 6). This result was not expected, as MS 
analysis of TTR Cys10Ala modified with glutathione did not show any modification of the 
protein (Figure 5B). 
 
Figure 6 – Effect of oxidized glutathione (GSSG) on TTR proteolytic activity. 
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Using docking methods we verified that, as expected, the most likely TTR binding site for 
the first molecule of glutathione is in the pocket where the Cys10 residue lies. This is in 
agreement with our experimental data that found glutathione covalently bound to Cys10. 
To pursue the analysis of glutathione binding to TTR, we created, in silico, a TTR tetramer 
that is fully glutathionylated in all its Cys10 residues. This final structure was then used to 
investigate where an additional molecule of glutathione would preferably dock; we 
observed that the TTR residues located within a distance of 6 Å from glutathione belong to 
the dimer-dimer interface region and to the RBP binding site. Among the TTR residues 
that were shown to interact with glutathione are included the putative candidates Ser77, 
Lys76 and Lys80 (Figure 7). However, our experimental data suggested that Ser77 is not 
the nucleophile of the TTR active site.  
 
Figure 7 – TTR docking with glutathione. A. Representation of glutathione (GSH; in green) 
docking to the TTR tetramer. B. Representation of all TTR residues located within 6 Å of 
glutathione. C. Representation of glutathione interaction with TTR residues Ser77, Lys76 and 
Lys80. 
 
DTT reduces TTR glutathionylation, but inhibits TTR proteolytic activity 
We have demonstrated that glutathione inactivates TTR proteolytic activity. To verify 
whether DTT could reduce the disulfide bond formed between glutathione and TTR, we 
analysed the MS spectrum of a preparation of inactive TTR (presenting two mass peaks) 
after incubation with 10 mM DTT; we observed that in the presence of DTT, the second 
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mass peak corresponding to the modification by glutathione was significantly reduced 
(Figure 8A). As DTT was able to remove glutathione modification, we hypothesized that 
the reducing agent could activate the TTR preparations devoid of proteolytic activity. 
However, DTT inhibits wt TTR proteolytic activity (Figure 8B). The same inhibitory effect 
was observed with TTR Cys10Ala (Figure 8B), meaning that DTT is not blocking 
proteolytic activity through interaction with the free sulphydryl group of Cys10. We also 
analysed the effect of DTT on an inactive preparation of TTR and observed that the 
proteolytic activity was not restored (data not shown). These results show that although 
DTT reduces TTR glutathionylation, it does not re-establish TTR proteolytic activity.  
 
Inactive TTR Inactive TTR+DTT
a
i
a
i
A
 
Figure 8 - DTT effect on TTR proteolytic activity. A. Full-length MS spectra of a proteolytically 
inactive TTR preparation non-incubated (left spectrum) or incubated with DTT (right spectrum). “a” 
peaks correspond to non-modified TTR and “i” peaks correspond to glutathione-modified TTR. B. 
Effect of DTT on the proteolytic activity of wt and Cys10Ala TTR. 
 
B 
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TTR chemical modification with serine protease inhibitors showed no labeling of the 
catalytic residues 
Chemical modification with protease inhibitors is commonly used to identify nucleophilic 
catalytic residues. For chemical modification of proteases, the enzymes are modified with 
irreversible inhibitors that covalently bind the active site residues; after chemical 
modification, enzymes are denaturated, digested with a standard protease such as trypsin 
to produce peptide fragments which can be analysed by MS (Rauber et al., 1988). We 
have previously shown that Pefabloc, PMSF, and DFP, three covalent modifiers of serine 
proteases, block TTR proteolytic activity (Liz et al., 2004). In order to identify the active 
site residues of TTR, we performed chemical modification of the enzyme with each of the 
three referred inhibitors. MS analysis after trypsin digestion of TTR incubated with 
pefabloc showed modification of several TTR peptides, suggesting that pefabloc inhibition 
of TTR proteolytic activity is non-specific. In the cases of PMSF and DFP, we were unable 
to observe any modification by MS analysis of the trypsin-generated TTR peptides (data 
not shown). 
 
TTR is preferentially inhibited by peptide phosphonate inhibitors with a Lys residue at P1 
position and a Pro residue at P2 
In order to identify the nucleophilic serine of TTR active site, we used a library of peptide 
phosphonate inhibitors. These compounds are irreversible inhibitors of serine proteases. 
The mechanism of inhibition of serine proteases by peptidyl phosphonates is shown in 
Figure 8. In a first step, the active site Ser hydroxyl group attacks the phosphorus atom, 
forming a pentacoordinate intermediate. In the next step, one of the phenoxy groups 
leaves and a stable tetravalent phosphonylated derivative is formed (Powers et al., 2002).  
 
H
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Figure 9 – Mechanism of inhibition of serine proteases by peptide phosphonates. Adapted 
from (Powers et al., 2002). 
 
In a first screening, performed in order to select the most effective inhibitors, we tested the 
phosphonate inhibitors at concentrations ranging from 1 to 50 µM (50 µM corresponds to 
a 10-fold molar excess in relation to the total enzyme concentration used). We divided the 
________________________________________________________________________________________Chapter 2 
 
 109 
compounds in three distinct groups, according to the inhibition potency; the most potent 
inhibitors were the ones that at 1 µM were able to block more that 75% of TTR activity 
(Figure 9). Analysis of the structures of the most potent compounds showed that TTR was 
preferentially inhibited by compounds with a basic residue as Lys in the P1 position and a 
Pro residue in P2.  
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Figure 10 – Screening of TTR proteolytic activity with a library of substrate-based 
phosphonate inhibitors. A. Chemical structure of the compounds yielding < 50% inhibition at 50 
µM. B. Chemical structure of the compounds yielding > 50% inhibition at 50 µM. C. Chemical 
structure of the compounds yielding > 75% inhibition at 1 µM. Inhibition rates are presented below 
each compound.  
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In a second screening we selected the compounds presenting more than 75% of inhibitory 
effect at 1 µM concentration, and performed the experiment using inhibitor concentrations 
ranging from 1 to 0.01 µM. This second screening was performed to assess whether the 
most potent inhibitors presented a dose-response effect, which we could not determine 
using inhibitor concentrations from 1 to 50 µM as at those concentrations almost complete 
inhibition was already observed (data not shown). We observed that all compounds 
presented a dose-response effect on TTR proteolytic activity (Figure 10). The 
irreversibility of the inhibitors was confirmed by dilution of the incubation reaction of TTR 
and inhibitor; TTR did not recover activity after dilution for 1 h (data not shown). The fact 
that these compounds were shown to be irreversible and presented a dose-response 
effect in a nanomolar range, allowed us to make use of the inhibition studies to perform 
the active site titration of TTR. We determined a concentration of active enzyme of 
approximately 0.3 µM using the compounds JCP42 and JCP65 (data not shown), 
suggesting that in active TTR preparations, less than 10% of the total protein used is 
actually active. 
In order to identify TTR covalent modification by the phosphonate inhibitors we performed 
MS analysis of the enzyme incubated with each of the most potent inhibitors. We were 
expecting to observe a shift in the TTR mass, corresponding to the added mass of the 
inhibitor when bound to the enzyme. However, we didn’t detect any modification in the 
TTR mass (data not shown). In parallel, we also analyzed the MS spectrum of the 
complex enzyme-inhibitor after trypsin digestion. Still, we were not able to detect any 
modification of the trypsin-generated TTR peaks (data not shown).  
 
 
Figure 11 – Analysis of the inhibition of TTR proteolytic activity by peptidyl phosphonate 
inhibitors. 
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In proteolytic assays using as substrate the MBP fluorogenic peptide, TTR pattern of 
inhibition is altered 
We have previously shown that TTR cleavage of apoA-I is inhibited by serine protease 
inhibitors (Liz et al., 2004). To assess whether the same inhibition profile was observed in 
activity assays using as a substrate a fluorogenic peptide, we analysed the effect of 
several protease inhibitors on TTR cleavage of the MBP peptide. Unexpectedly, the serine 
protease inhibitors used were not able to block TTR proteolytic activity, i.e., the pattern of 
inhibition observed in apoA-I cleavage by TTR was altered when the substrate used was a 
MBP peptide. Inhibitors of cysteine and aspartic proteases were not tested, as the 
possibility that TTR would belong to those mechanistic classes is not plausible. TTR has 
only one Cys residue and we have shown that the mutation of that amino acid does not 
affect TTR activity; as for aspartic proteases, these enzymes are inactive at a pH above 6. 
Although we have previously shown that EDTA and phosphoramidon, two 
metalloprotease inhibitors, did not block apoA-I cleavage by TTR, we analysed the effect 
of 1,10-phenanthroline on TTR cleavage of the MBP peptide. 1,10-phenanthroline is a 
metalloprotease inhibitor that acts by chelating the essential metal atom of the enzyme. 
Surprisingly, that inhibitor completely abolished TTR proteolytic activity.  
 
 
Figure 12 - Pattern of inhibition of TTR cleavage of the fluorogenic peptide MBP. 
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Discussion 
TTR has been described as a novel cryptic protease (Liz et al., 2004). The cryptic nature 
of TTR proteolytic activity comes from the facts that not only it lacks canonical structural 
protease determinants, but also that its physiological function is apparently unrelated to 
proteolysis. Several characteristics of TTR proteolytic activity, as an optimum pH for 
activity of approximately 7, cleavage after a Phe residue, and a pattern of inhibition typical 
of serine proteases, suggest that the protein belongs to the mechanistic class of serine 
proteases.  
In this work we attempted to identify the catalytic residues of TTR active site by site-
directed mutagenesis and active site labeling. We started by performing an alignment of 
TTRs from different vertebrate species, as well as analysis of the three-dimensional 
structure of TTR, to establish which serine residues could constitute possible candidates 
to act as the nucleophilic amino acid of TTR active site. Among the 11 TTR serine 
residues, only Ser46, Ser77 or Ser85 were selected as possible candidates. The 
remaining serine residues were excluded based on the patter of conservation among the 
species analysed and structural arrangement. Ser8 is a well-conserved residue but is 
located in the N-terminus of TTR, which is a non-structured region of the protein (Blake et 
al., 1978b), implicating that difficultly this residue could constitute the nucleophile. Ser23 is 
conserved in approximately 50% of the species analysed; moreover, this residue, is 
situated at the dimer-dimer interface of the TTR tetramer and does not contain a structural 
arrangement compatible with the active site of a serine protease. The pattern of 
conservation of Ser50 and Ser52 is of only 29% and 25%, respectively, what makes it 
difficult to envisage the hypothesis that one of these residues could act as the catalytic 
residue in TTR proteolysis. Moreover, these residues were not structurally favoured to 
constitute the catalytic active site of TTR.  Nervertheless, we analysed TTR proteolytic 
activity of the mutants Ser50Ala and Ser52Ala. Ser50Ala presented a 40-fold decrease in 
proteolytic activity when compared to the wt protein, while Ser52Ala presented a decrease 
in Kcat/Km of only 4-fold (data not shown). These results suggest that Ser50 could play a 
role in TTR proteolytic activity; however, we determined that the protein preparation was 
modified, as will be discussed below, and as such the activity of the protein could not be 
related with the mutation introduced. Regarding Ser52, as the protein preparation where 
mutation was confirmed showed activity, we considered that this residue was not part of 
the catalytic active site of TTR. The Ser100 residue is conserved in 50% of the species 
analysed and is involved in RBP binding to TTR. However, the location of this residue in 
the TTR structure is not compatible with a catalytic active site of a serine protease. 
Regarding Ser112, Ser115 and Ser117, although being highly-conserved among 
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vertebrate species, these residues are located in the hydrophobic central channel of the 
TTR molecule which constitutes the binding site for T4. According to our previous results 
(Liz et al., 2004), the central channel does not allocate the catalytic site of TTR, what 
excludes Ser112, Ser115 and Ser177 as the possible nucleophile in TTR-mediated 
catalysis. 
The TTR residue Ser46, together with His31 and Asp74, were the only residues 
presenting an arrangement compatible with a catalytic triad typical for a serine protease. 
However, the mutant Ser46Gly retained proteolytic activity. The same result was obtained 
with Ser77 and Ser85; although constituting good candidates to work as the nucleophile in 
a Ser-Lys dyad, the mutants Ser77Ala and Ser85Ala did not present a significant 
decrease in proteolytic activity. Nonetheless, the substitution of the catalytic amino acid of 
a serine protease does not necessarily mean complete loss of activity; water can 
substitute for a missing functional group thus providing an alternative catalytic mechanism 
and consequently leading to an underestimation of the effect of the mutation. It is 
important to recognize that the catalytic triad may not be the sole source of protease 
activity; even with the active site disabled, mutant proteases may hydrolyse substrates 
faster than the uncatalyzed rate (Hedstrom, 2002). Taking into account these facts, 
mutation of putative nucleophile candidate residues would not lead to complete loss of 
activity but to a significant decrease in the hydrolytic rate. In the case of TTR this type of 
analysis would be complex due to the inconsistency in the results obtained for the kinetic 
parameters, which vary according to the presence of glutathionylation of the protein 
occurring during production. We observed that in two parallel productions of the same 
TTR mutant, always performed under the same conditions, the resulting proteins had 
significant differences in the catalytic performance, with glutathione modification 
abolishing proteolytic activity. Our results have shown that the Kcat/Km values obtained for 
the TTR mutants are not only dependent on the amino acid substitution, but also to 
random protein modifications occurring during the protein production steps. The 
modifications occurring probably derive from the expression system of recombinant 
protein; our system involves several steps of purification, an ion exchange 
chromatography followed by a native preparative gel electrophoresis (Liz et al., 2004). As 
such, the protein remains in contact with the bacteria proteins and culture medium for a 
significant amount of time. Although this method has been successfully used for TTR 
production in our lab, it is probably not the most adequate to perform proteolysis studies. 
In conclusion, the application of site-directed mutagenesis associated with our protocol for 
protein production, does not constitute an accurate method for identification of the 
catalytic residues of TTR. Regarding TTR glutathionylation, we observed that although not 
all the protein present in the preparations is modified, as shown by the presence of an 
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unmodified TTR peak in the MS analysis of TTR proteolytic inactive preparations, 
glutathione completely inactivates TTR. One reasonable explanation to that fact is that 
almost certainly not all the TTR protein preparation is proteolytically active; probably 
glutathione is modifying the total percentage of active enzyme within the TTR preparation, 
leading to complete loss of proteolytic activity.  
We have previously shown that TTR proteolytic activity is completely abolished when the 
protein in complexed with the ligand RBP (Liz et al., 2004). In the plasma, approximately 
50% of TTR circulates complexed with RBP, suggesting that physiologically only 50% of 
total TTR might be proteolytically active. In this work we identified glutathione as an 
additional inhibitor of TTR proteolysis. Although the percentage of glutationylated TTR 
present in the plasma is not described, it is known that the majority of TTR (85%-95% of 
total TTR) in circulation is posttranslationally modified, with the unmodified form of the 
protein accounting for 5%-15% of the total TTR (Lim et al., 2003). These observations 
suggest that physiologically RBP and/or glutathione might modulate TTR proteolytic 
activity. 
Several modifications have been described for TTR in human plasma; the most prevalent 
modifications occur in Cys10 and are cysteinylation, oxidation, sulfonation, 
glutathionylation, cysteinylglycylation, and homocysteinylation (Gales et al., 2007). We 
have observed the glutathionylation of the Cys10 residue in our preparations of 
recombinant TTR. However, TTR Cys10Ala was proteolytically active what suggested that 
inactivation by glutathione was not due to blocking of the Cys residue, but probably to 
either some alteration of the TTR structure or blocking of essential residues for catalysis, 
induced by the glutathione modification. In addition, although we could not detect 
additional sites of glutathionylation in the MS analysis performed, the inhibitory effect of 
glutathione on TTR Cys10Ala activity revealed that the chemical compound is probably 
modifying other regions of the TTR molecule; this suggestion is controversial as 
glutathione reacts with sulphydryl groups, and the only free sulphydryl group in TTR is the 
one of Cys10. Docking of glutathione to TTR suggested that when glutathione is 
occupying the Cys10 residues of the 4 TTR monomers, an additional binding site for the 
modifier is observed and includes the putative candidates Ser77, Lys76 and Lys80. This 
observation is not in agreement with our experimental data that suggested that Ser77 
does not constitute the catalytic residue of TTR active site. The modification of TTR by 
glutathione was also observed in some TTR crystal structures determined by the 
Molecular Structure Group at IBMC, Porto. In those structures, the electron density maps 
clearly showed extra density, revealing the presence of a molecule covalently bound to 
the thiol group of Cys 10. Since the density was not well defined in the maps, probably 
due to a low occupancy of the site, further analysis by mass spectroscopy was done and 
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revealed the presence of glutathione (Damas AM, personal communication). In order to 
establish the binding sites for glutathione on the TTR molecule, crystallographic studies of 
wt TTR (a preparation that was shown by full-length MS analysis not to be modified with 
glutathione during protein production) pre-incubated with glutathione, are currently 
underway. Glutathione has shown to be a covalent inhibitor of TTR proteolytic activity; 
having the structure of TTR complexed with this modifier will hopefully give insights into 
the catalytic active site of the enzyme. Recently, the crystal structure of TTR pre-
incubated with sulfite was determined (Gales et al., 2007); sulfite covalently binds to 
Cys10 and the two sulfite oxygens are involved in stabilizing interactions with His56 and 
Gly57, and water mediated interactions with Leu12 and Thr59. These interactions were 
shown to stabilize the TTR tetramer. Based on that structure, the authors suggested that 
glutathione is probably not able to mediate the interactions described for sulfite, being 
responsible for an alteration of TTR stability.  
We tested the effect of the sulphydryl-reducing agent DTT on TTR catalytic inhibition 
caused by glutathionylation. Although DTT was able to reduce glutathione modification, 
TTR proteolytic activity was not restored. This result could suggest that TTR is being 
modified by glutathione at sites other than cysteine residues. However, DTT inhibited TTR 
proteolytic activity in a dose-dependent manner, what was unexpected, as TTR structure 
does not contain disulfide bonds. DTT seems to be modifying TTR probably by non-
covalent binding and/or blocking the access of the substrates to the enzyme. 
In a different approach to identify the TTR catalytic residues, we performed the labeling of 
the enzyme with three protease inhibitors that are known to modify covalently the active 
site of serine proteases. MS analysis of TTR modified with pefabloc has shown that this 
compound inhibits TTR activity in a non-specific manner; all trypsin-generated TTR 
fragments were shown to be modified by pefabloc. Regarding DFP and PMSF, we did not 
detect any modification of TTR peptides. Nevertheless, the inhibition by PMSF and DFP 
points to the existence of a reactive serine on TTR molecule, as these compounds are 
very electrophilic, and react irreversibly with the nucleophilic serine forming stable 
tetrahedral adducts (Hedstrom, 2002). 
Peptide phosphonate protease inhibitors developed on the basis of DFP, were shown to 
label the active site of serine proteases by covalent modification of the nucleophilic serine 
(Powers et al., 2002). In a second attempt to identify the TTR nucleophilic serine by active 
site labeling, we performed a screening of TTR inhibition pattern using a library of peptide 
phosphonates. We observed that TTR was inhibited by several phosphonate compounds, 
being the most potent inhibitors constituted by a Lys residue in the P1 position and a Pro 
in P2. This result suggested that probably apoA-I is not the prime substrate of TTR 
proteolysis, as in that protein TTR cleaves after a Phe residue. Among the most potent 
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phosphonate inhibitors only one presented a Phe in P1. Further investigation on TTR 
substrate specificity should be performed. Regarding the major goal of the use of the 
phosphonates library, we were not able to identify the serine residue modified by the 
inhibitors. Nonetheless, we were able to perform the active site titration of TTR using the 
phosphonate inhibitors; we determined that the concentration of active enzyme is 
approximately less than 10% of the total amount of protein. This result constitutes a 
plausible explanation to the non-identification of TTR modification sites using the covalent 
inhibitors described; as they only label the active enzyme the amount of modified protein 
may represent a minor portion of the total amount of protein, which is probably not 
detected in the MS analysis. This explanation is valid for TTR modification not only with 
the phosphonate compounds but also DFP, PMSF and glutathione. Moreover, the fact 
that more than 90% of protein in a TTR preparation was proteolytically inactive was 
unpredicted, but is probably related with the protein production method. Besides the 
protein modifications introduced by the bacteria during production, the purification steps, 
performed at room temperature and inducing freeze drying, might contribute for 
inactivation of the enzyme.  
Controversial results were obtained when analyzing the inhibition profile of TTR cleavage 
of small substrates as the case of the fluorogenic MBP peptide. Besides the fact that TTR 
proteolytic activity was not inhibited by the serine protease inhibitors used, we observed 
complete abolishment of activity using 1,10 - phenanthroline. Nonetheless, this result 
does not directly imply TTR is a metalloprotease, as some members of other classes may 
be activated or stabilized by metal ions. However, analysis of the three-dimensional 
structure of TTR does not reveal any metal binding site in the protein molecule. The 
alteration of the inhibition profile with the change of substrate, from a 28 kDa protein as 
apoA-I to a small peptide, could probably be explained by the more facilitated access of 
the small substrate to the enzyme active site. However, it raises questions about the 
mechanistic class of TTR. On the other hand, the inhibition by the phosphonate inhibitors 
implies the presence of a reactive serine in the TTR active site. 
In conclusion, the methods used in this work for the identification of the catalytic residues 
of TTR, did not provide conclusive results as a consequence of the method used for the 
enzyme purification, which not only leads to protein modifications but also results in small 
amounts of proteolytic active protein.  
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Abstract 
A fraction of plasma transthyretin (TTR) circulates in high-density lipoproteins (HDL), 
through binding to apolipoprotein A-I (apoA-I). Moreover, TTR is able to cleave the C-
terminus of lipid-free apoA-I. In this study we addressed the relevance of apoA-I cleavage 
by TTR in lipoprotein metabolism and in the formation of apoA-I amyloid fibrils. We 
determined that TTR may also cleave lipidated apoA-I, being cleavage more effective in 
the lipid-poor pre-β-HDL subpopulation. Upon TTR cleavage, discoidal HDL particles 
displayed a reduced capacity to promote cholesterol efflux from cholesterol-loaded THP-1 
macrophages. In similar assays, TTR-containing HDL from mice expressing human TTR 
in a TTR knockout background had a decreased ability to perform reverse cholesterol 
transport, when compared to similar particles from TTR knockout mice, reinforcing that 
cleavage by TTR reduces the ability of apoA-I to promote cholesterol efflux. As amyloid 
deposits composed by N-terminal apoA-I fragments are common in the atherosclerotic 
intima, we assessed the impact of TTR cleavage on apoA-I aggregation and fibrillar 
growth. We determined that TTR-cleaved apoA-I has a high propensity to form 
aggregated particles and that it formed fibrils faster than full-length apoA-I, as assessed 
by electron microscopy. Also, we observed the presence of deposited apoA-I in 
amyloidoses not related with apoA-I mutations; full-length apoA-I was deposited in the 
case of Alzheimer´s disease and immunoglobulin light chain amyloidosis (AL 
amyloidosis), while in ATTR amyloidosis apoA-I was co-deposited either in the intact or in 
the C-terminally deleted form. These results suggest a role for TTR proteolysis in apoA-I 
deposition in vivo. Our results show that apoA-I cleavage by TTR may impact on HDL 
biology and in the development of atherosclerosis, by reducing cholesterol efflux and 
increasing the apoA-I amyloidogenic potential. 
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Introduction 
Transthyretin (TTR), a homotetrameric protein (Blake et al., 1978b), is the plasma carrier 
for both thyroxine (T4) and retinol, in the latter case through binding to retinol-binding 
protein (RBP) (Monaco, 2000). We previously determined that TTR has several 
connections to apolipoprotein A-I (apoA-I) biology: i) under physiological conditions, a 
fraction of plasma TTR circulates in high-density lipoproteins (HDL) through binding to 
apoA-I (Sousa et al., 2000a), ii) similarly to chymase (Lee et al., 2003), TTR is able to 
cleave the C-terminus of apoA-I after Phe225 (Liz et al., 2004), and iii) under pathological 
conditions, an amyloidogenic apoA-I mutation was identified, where fibrils presented both 
mutant apoA-I N-terminal fragments and wt TTR (de Sousa et al., 2000), suggesting that 
TTR might influence the generation of apoA-I fragments and apoA-I deposition. 
The mature form of apoA-I, the major protein component of HDL, can bind lipids to form 
structures ranging from: i) small lipid-poor complexes, ii) flattened discoidal particles of 
various discrete sizes containing only polar lipids (pre-β-HDL), and iii) polymorphic 
spherical particles (α-HDL), ranging from small particles containing only one molecule of 
apoA-I and a few phospholipids, to large particles containing up to four molecules of 
apoA-I in addition to other lipoproteins and a core enriched with cholesterol esters (CE). 
The α-HDL account for approximately 90% of all plasma apoA-I. In addition to a structural 
function, apoA-I is responsible for the major functions of HDL: its central region has been 
implicated in the activation of lecithin cholesterol acyltransferase (LCAT) (Uboldi et al., 
1996), whereas its C-terminal domain, including the region cleaved by TTR, has been 
pointed as specially important for promoting cholesterol efflux from cholesterol-loaded 
macrophages (Lee et al., 2003). These functions are pivotal for reverse cholesterol 
transport in which peripheral cell cholesterol is returned to the liver for subsequent 
metabolism. In this process, nascent discoidal HDL, the pre-β particles, interact with 
peripheral cells, including macrophages, to promote the removal of excess free 
cholesterol.  
The pathways through which HDL contribute to cholesterol efflux may occur through two 
mechanisms: i) a relatively non-specific interaction of apoA-I present in α-HDL with cell 
membranes, facilitated by the scavenger receptor class-B type I (SR-BI), followed by 
passive diffusion of free cholesterol, and ii) a high affinity interaction of lipid-free and lipid 
poor apoA-I (pre-β-HDL) with the membrane transporter adenosine triphosphate-binding 
cassette protein A-1 (ABCA-1) (Lee-Rueckert and Kovanen, 2006). After cholesterol 
uptake, discoidal pre-β HDL are converted into CE enriched spherical α-HDL, as a result 
of the action of plasma cholesterol-esterifying enzyme LCAT (Lee et al., 2002). CE in 
mature α-HDL may then be removed by several different pathways, including selective 
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uptake by the liver, mediated by SR-BI, the high-affinity HDL receptor that recognizes 
apoA-I and other apolipoproteins and is expressed in the liver and steroidogenic tissues 
(Landschulz et al., 1996). The process of reverse cholesterol transport is specially critical 
for macrophages, which lack the ability to regulate the influx of cholesterol from modified 
low-density lipoproteins (LDL), and are therefore easily transformed into cholesterol-
loaded foam cells (Favari et al., 2004), typical of early atherosclerotic lesions (Lee et al., 
2002). 
In pre-β-HDL, the C-terminal portion of apoA-I has been shown to be remarkably sensitive 
to proteolysis (Kunitake et al., 1990), which is probably related to the lack of an organized 
secondary structure of this region. In fact, several proteases found in the arterial intima, 
such as elastase (Ji and Jonas, 1995), metalloproteases (Lindstedt et al., 1999), plasmin 
and plasma kallikrein (Lindstedt and Kovanen, 2000), and the mast cell proteases 
chymase and tryptase (Lee-Rueckert and Kovanen, 2006), degrade apoA-I in pre-β-HDL 
particles in vitro. A crucial prerequisite for the action of HDL particles as efficient 
acceptors of cellular cholesterol is their integrity; in line with this concept, apoA-I cleavage 
by the above proteases has been widely demonstrated to impair the high-affinity 
component of cellular cholesterol efflux. It is also noteworthy that beyond acting on the 
balance of CE uptake/efflux by macrophages, apoA-I is further related to atherosclerosis 
as N-terminal fragments of apoA-I are frequently found as amyloid deposits in the aortic 
intima (Westermark et al., 1995). In the majority of the cases of amyloidosis in the 
atherosclerotic plaques, the fibrils are constituted by wt apoA-I (Mucchiano et al., 2001), 
although there are some cases caused by apoA-I variants (Amarzguioui et al., 1998). 
Apart from the ability of apoA-I to generate amyloid fibrils within atherosclerotic plaques, 
mutated apoA-I can cause several forms of hereditary systemic amyloidosis. Several 
apoA-I amyloidogenic variants have been reported, being the amyloid fibrils predominantly 
constituted by truncated forms of apoA-I corresponding to its 90 to 100 N-terminal 
residues (Obici et al., 2006). Proteolysis seems to be important for the pathogenicity of 
apoA-I possibly by creating fragments that adopt more easily the typical β-sheet 
conformation of the amyloid fibrils, than the intact molecule. However, in vitro, both full-
length apoA-I and N-terminal apoA-I fragments can form amyloid fibrils (Wisniewski et al., 
1995). ApoA-I is further related to amyloidosis, not only by being the major fibril 
constituent in apoA-I related amyloidosis but also as a minor constituent in various kinds 
of amyloidosis not related with apoA-I mutations. It has been reported that apoA-I 
colocalizes with senile plaques in patients with Alzheimer’s disease (Wisniewski et al., 
1995). In addition, recently it was shown that apoA-I colocalizes with amyloid deposits in 
various kinds of human systemic amyloidosis as is the case of amyloid A (AA 
amyloidosis), β2-microglobulin amyloidosis (Aβ2M amyloidosis), immunoglobulin light 
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chain amyloidosis (AL amyloidosis) and transthyretin amyloidosis (ATTR amyloidosis) 
(Sakata et al., 2005). In these cases there is no evidence whether apoA-I is present in the 
full-length or in the cleaved form.  
In the present work we investigated the relevance of apoA-I cleavage by TTR in HDL 
biology and in the apoA-I amyloidogenic potential.  
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Methods 
Mice  
Mice were handled according to European Union and National rules and all the studies 
performed were approved by the Portuguese General Veterinarian Board. TTR knockout 
mice (TTR KO) (Episkopou et al., 1993) and human TTR transgenic mice in a TTR KO 
background (hTTRxTTR KO) (Monteiro et al., 2006) in the 129/Sv background, were 
maintained at 24 ± 1ºC under a 12 h light/dark cycle and fed regular chow and tap water 
ad libitum. All animals were accustomed to regular handling.  
 
Production of recombinant human TTR 
Recombinant human TTR was produced in Escherichia coli D1210 transformed with a 
pINTR plasmid carrying the wt TTR cDNA as already described (Liz et al., 2004). Briefly, 
after osmotic shock proteins were separated on a diethylaminoethyl cellulose ion 
exchange chromatography column (Whatman). Negatively-charged protein fractions were 
dialyzed, lyophilized and TTR was isolated by preparative electrophoresis in native 
Prosieve agarose gel (FMC), following the supplier’s instructions. After electrophoresis, 
the TTR band was excised from the gel and electroeluted in a Elutrap system (Schleider 
and Schuell, S&S) in 5 mM Tris, 38 mM glycine pH 8.3 at 150 V at 4ºC overnight. 
 
Lipoprotein preparation 
ApoA-I from human plasma was from BioChemika. Spherical HDL (sHDL), enriched in α-
HDL and a minor subpopulation of pre-β-HDL (d=1.063 to 1.210 g/mL), were prepared 
from freshly isolated normolipidemic human plasma by sequential ultracentrifugation using 
a KBr/NaCl gradient (Havel et al., 1955). Mouse sHDL (d=1.063 to 1.210 g/mL) were 
isolated by ultracentrifugation, as described for human plasma. Reconstituted discoidal 
pre-β-migrating HDL (rHDL) were prepared by the sodium cholate dialysis technique 
(Jonas et al., 1989) using palmitoyloleoylphosphatidylcholine (POPC, Avanti Polar Lipids), 
cholesterol (Sigma), apoA-I, and sodium cholate (Sigma) in molar ratios of 80:8:1:80, 
respectively. Lipoprotein concentrations are expressed in terms of their protein content, as 
determined by the Lowry method (Lowry et al., 1951). TTR concentration in HDL was 
determined by the Laurel method (Laurel, 1965). 
 
ApoA-I cleavage by TTR 
Lipid free apoA-I, rHDL or sHDL particles were incubated with TTR in an equimolar ratio, 
in 50 mM Tris pH 7 overnight at 37°C. Control incubations were performed in the absence 
of TTR. For lipid free apoA-I and rHDL particles, following incubation, reactions were 
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analyzed in 15% SDS-PAGE gels and visualized by Coomassie Blue staining to 
determine the extent of apoA-I cleavage by TTR. For sHDL particles, proteins were 
separated on a 15% SDS-PAGE gel and then transferred to a nitrocellulose membrane 
(Amersham) for immunoblot identification of apoA-I and assessment of cleavage by TTR. 
For Western analysis, membranes were blocked with blocking buffer (10% nonfat dried 
milk in phosphate buffer saline - PBS), incubated overnight at 4ºC with goat polyclonal 
anti-human apoA-I (Calbiochem; 1:1,000 in blocking buffer), and subsequently for 1 h at 
room temperature with anti-goat IgG horseradish peroxidase complex (The Binding Site; 
1:10,000 in blocking buffer). Immunoblots were developed using 3, 3’-diaminobenzidine 
(Sigma) as substrate. For analysis of sHDL subpopulations (α and pre-β-HDL) upon TTR 
treatment, reactions were prepared as described above, concentrated, ressuspended in 
10 µL of barbital buffer (0.06 M, pH 8.6), electrophoresed at 40 mA for 2 h in 1% agarose 
gels in barbital buffer, and subsequently stained with Coomassie Blue. Migration patterns 
were compared with the migration of albumin in 2 µL of a human serum sample. The 
extent of apoA-I degradation by TTR was determined by densitometry. In every case, at 
least three independent experiments were performed. Results are presented as 
average±SEM. 
 
TTR detection in sHDL 
TTR detection in sHDL subpopulations was performed by Western blot analysis. Briefly, 
10 µg of sHDL particles were separated on 1% agarose gels in barbital buffer as 
described above. Gel regions corresponding to the α and pre-β-HDL subpopulations were 
identified based on their migration properties when compared to similar Coomassie Blue 
stained samples loaded in parallel. Unstained gel regions corresponding to the α and pre-
β-HDL subpopulations were excised from the agarose gel, applied to a second dimension 
15% SDS-PAGE gel and then transferred to a nitrocellulose membrane. Western analysis 
was performed as described above using the following primary antibodies: rabbit 
polyclonal anti-TTR (DAKO, 1:1,000) and rabbit polyclonal anti-RBP (The Binding Site, 
1:500). Western analysis using goat polyclonal anti-apoA-I (Calbiochem, 1:1,000) was 
performed to normalize the amount of loaded α and pre-β -HDL. 
 
Cholesterol efflux assays 
For studies using THP-1 cells (European Cell Culture Collection), these were routinely 
grown in suspension in RPMI media (Invitrogen) containing 10% fetal bovine serum (FBS) 
(Invitrogen), 50 units/mL penicillin and 50 µg/mL streptomycin (THP-1 complete medium). 
For each experiment, THP-1 monocytes were differentiated into macrophages by plating 
400,000 cells/well in 12-well tissue culture plates (Corning) and by supplementing the 
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media with 50 ng/mL phorbol 12-myristate 13-acetate (Sigma). After the differentiation 
period (3 days), THP-1-derived macrophages were incubated for 24 h in complete media 
containing 0.5 µCi 3H-cholesterol (Amersham)/well. For studies of apoA-I binding to 
ABCA-1, human embryonic kidney 293 cells overexpressing ABCA-1 (HEK293-ABCA-1) 
and control untransfected cells (HEK293) (a kind gift from Dr. Michael R. Hayden, 
University of British Columbia, Vancouver) were used. For cholesterol efflux assays, cells 
were plated in 12-well tissue culture plates (40,000 cells/well) in DMEM (Invitrogen) 
supplemented with 10% FBS, 50 units/mL penicillin and 50 µg/mL streptomycin (HEK293 
complete medium). When cultures reached approximately 50% confluence, cells were 
incubated for 24 h in complete media containing 0.5 µCi 3H-cholesterol. For both THP-1 
and HEK293 cells,  3H-cholesterol-loaded cells were washed and subsequently incubated 
with 25 µg/mL of different cholesterol acceptors (as detailed in the results), either intact or 
cleaved by TTR, in medium containing 0.2% fatty acid free bovine serum albumin (FAF-
BSA, Sigma), 50 units/mL penicillin and 50 µg/mL streptomycin. 4 h later, media were 
collected and cells were lysed with 0.1 M NaOH; the radioactivity associated with the 
conditioned media and cells was measured in a Microbeta Counter (PerkinElmer). When 
applicable, the amount of total protein in the cell lysate was determined by the Lowry 
method. The percentage of cholesterol efflux was calculated as (cpm in the medium at 4h/ 
(cpm in the medium at 4h + cpm in the cells)) x 100. For each condition, the percentage of 
cholesterol efflux in the absence of cholesterol acceptor was subtracted. Data is 
presented as average±SD. 
For analysis of ABCA-1 expression, total RNA from HEK293-ABCA-1 and HEK293 cells 
was isolated using Trizol (Invitrogen) and cDNA was obtained using the Superscript II kit 
(Invitrogen), according to the manufacturer’s protocol. Subsequently, PCR was performed 
using specific primers designed with PRIMER3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and the human ABCA-1 and β-actin sequences from the 
National Centre for Biotechnology Information database. Sense and anti-sense primers 
were: for ABCA-1, 5’-CTGCTAAGGAGGGAGCCTTT-3’ and 5’-
AAAAGGGCCACAAACTGTTG-3’, and for β-actin, 5’-CTATCCCTGTACGCCTCTGGC-3’ 
and 5’-GGCGTACAGGTCTTTGCGGATG-3’, respectively. Ethidium bromide-stained gels 
were scanned using a Typhoon 8600 (Amersham). The b-actin message served as an 
internal control. 
 
In vivo studies 
8 weeks old hTTRxTTR KO and TTR KO mice were fed for 18 weeks either a high-
fat/high-cholesterol diet (regular chow supplemented with 0.2% cholesterol and 21% fat, 
Mucedola) or a control diet (regular chow, Mucedola). Following this period, sHDL 
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particles were isolated from plasma by precipitation (Randox) and HDL-cholesterol levels 
were determined using an enzymatic colorimetric assay (Randox), following the 
manufacturer’s instructions.  
 
LCAT activation assay 
The LCAT assay was carried out using as substrate rHDL particles (incubated overnight 
at 37ºC in the presence or absence of an equimolar amount of TTR) and 75 µL of 
lipoprotein deficient serum (LPDS, 1.8 µg/µL total protein, fraction with d>1.21 obtained 
after ultracentrifugation to isolate sHDL particles) as the enzyme source. Reaction mixes 
were further supplemented with 4% FAF-BSA and 4 mM β-mercaptoethanol and 
incubated for 1 h at 37ºC. Parallel reactions performed by omitting LPDS from the reaction 
mix served as negative controls. Lipids were subsequently extracted twice with a 1:2 
chloroform:methanol solution. The extracts were collected, dried under a nitrogen stream 
and dissolved in 10 µL of the 1:2 chloroform:methanol solution. Samples were applied to 
thin layer chromatography plates (Merck) using chloroform:methanol:ammonium 95:5:0.8 
(v/v/v) as running solvent. Free and esterified cholesterol were quantified by densitometry 
and LCAT activity was measured as the ratio between esterified cholesterol and total 
cholesterol (free+esterified).  
 
Binding assays to the hepatic receptor SR-BI  
sHDL were iodinated following the iodogen method (Sousa et al., 2000b). Briefly, 15 µg of 
sHDL were added to reaction tubes coated with 10 µg of iodogen (Sigma), and containing 
100 µL of 0.25 M phosphate buffer and 1 mCi of Na 125I (PerkinElmer). The reaction was 
allowed to proceed in an ice bath for 20 min. Labeled sHDL was separated from free 
iodide in a 5-mL Sephadex G50 column (GE Healthcare). Low-density lipoprotein receptor 
(LDLr)-deficient Chinese hamster ovary cells overexpressing SR-BI (IdlA7-mSRBI) and 
untransfected cells (IdlA7) were a kind gift from Dr. Monty Krieger (Massachusetts 
Institute of Technology, Cambridge, MA). Cells were grown to confluence in 24-well plates 
(Corning) in Ham’s F12 medium (Invitrogen) containing 5% FBS, 2 mM glutamine 
(Invitrogen), 50 units/mL penicillin, 50 µg/mL streptomycin, and 500 µg/mL G418 
(Calbiochem) – complete medium. For competition assays, cells were washed in PBS and 
reefed with 0.3 mL of Ham’s F12 medium containing 0.5% FAF-BSA and 125I-labeled 
sHDL (100,000 cpm/well), in the presence of unlabeled competitors. As unlabeled 
competitors, sHDL (either untreated or previously treated with recombinant TTR, as 
described above) were used in concentrations ranging from 0 to 100 µg/mL. After 4 h 
incubation at 4ºC, cells were washed twice with ice-cold PBS and lysed with 1M NaOH, 
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after which cell-associated radioactivity was measured. Results were analysed using the 
GraphPad Prism software (Prism). 
 
Circular dichroism spectroscopy 
A stock solution of intact apoA-I was prepared at 0.16 mg/mL in 5 mM Tris pH 7 for 
spectroscopy and biophysical analysis. TTR-cleaved apoA-I (apoA-IΔ226-243) was 
obtained by incubation of apoA-I with TTR at 37°C during 60 h. This extended incubation 
time was performed in order to obtain 100% of the cleaved apoA-I product. For TTR 
removal, the reaction mixtures were passed through a Hi-Trap column (Amersham) 
coupled to a polyclonal anti-human TTR antibody (DAKO). The absence of TTR was 
confirmed by running the preparation in SDS-PAGE gels. After TTR removal, the apoA-
IΔ226-243 sample was prepared at a concentration of 0.16 mg/mL in 5 mM Tris pH 7. 
Protein concentrations were determined by Bradford (Bio-Rad). CD spectra were recorded 
in a Jasco J-815 spectropolarimeter equipped with Peltier temperature control and cell 
stirring. Far UV-CD spectra were recorded using 1 mm pathlength polarimetrically certified 
cells (Hellma). Unless otherwise stated, spectra were the result of 10 averaged spectra 
measured at 20ºC, from 190 to 260 nm, at 0.2 nm data pitch, with a 2 nm band width at 
100 nm/min. The program CDNN (Gerald Böhm, Martin-Luther-Universität, Halle-
Witthenberg, Germany), a neural network circular dichroism deconvolution program, 
trained from a built-in database comprising 33 reference spectra, was used for analysis of 
secondary structure. 
 
Dynamic light scattering  
Measurements were carried out in a Malvern Zetasizer nano ZS instrument, equipped with 
a 4 MW He–Ne Laser (632nm). Intact apoA-I and apoA-IΔ226-243 (0.16 mg/mL in 5 mM 
Tris pH 7) were centrifuged prior to measurements and a 1x1 cm quartz cuvette (Hellma) 
was used. The operating procedure was typically set to 20 runs, each being averaged for 
20s. Data was analyzed using the DTS software (Malvern) in respect to the distribution of 
particle diameter by volume. 
 
Fluorescence spectroscopy  
Measurements were carried out in a Varian-Eclipse fluorimeter with peltier temperature 
control, at protein concentrations of 2.1 µM (intact apoA-I) and 2.3 µM (apoA-IΔ223-245). 
Excitation was set to 295 nm, and emission spectra were recorded between 300 and 500 
nm. Excitation and emission slits were set to 10 nm. 
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ApoA-I fibrillogenesis studies 
For apoA-I fibril formation analysis, 200 µg of apoA-I were incubated with or without an 
equimolar amount of TTR in 50 mM Tris pH 7, overnight at 37ºC. TTR removal from the 
cleavage reaction was performed as described for the CD studies. The flow-through 
fractions (containing only apoA-I) were dialyzed in H2O pH 7 using a dialysis tubing with a 
cutoff of 7 kDa (allowing removal of the low molecular weight apoA-I fragments), 
concentrated, ressuspended at 2 mg/mL in 100 µL of 100 mM Tris pH 7.4 containing 0.2% 
azide, and incubated for 10 days at room temperature. As a negative control TTR alone 
(the same amount as the one used to cleave apoA-I) was passed through the Hi-Trap 
column and the flow-through was used for further analysis. For electron microcopy, 5 µL 
aliquots of each reaction (apoA-I alone, apoA-I plus TTR or TTR alone) were applied onto 
glow-discharged carbon-coated collodion films supported on 200-mesh copper grids. For 
negative staining, the grids were washed with deionized water and stained with 1% uranyl 
acetate. The grids were visualized with a Zeiss 902A microscope operated at 50 kV and 
exhaustively examined.  
 
Immunohistochemistry 
Paraffin sections from human autopsies/biopsies of Alzheimer´s disease, AL and ATTR 
cases were available in the laboratory. For histochemical demonstration of amyloid, 
paraffin sections were stained with Cong Red and observed under a polarization 
microscope to detect the characteristic green birefringence of the amyloid deposits. For 
human apoA-I immunohistochemistry, sections were deparafinated in histoclear (National 
Diagnostics) and dehydrated in a descendent alcohol series (100%, 90%, 80% and 70%, 
10 min each). After blocking endogenous peroxidase activity with 0.3% hydrogen peroxide 
(H2O2) in 100% methanol, sections were blocked in blocking solution (4% FBS and 1% 
BSA). Goat anti-human apoA-I (Calbiochem) diluted 1:2,000 or monoclonal anti-human 
apoA-I (MAb AI-4.1, a kind gift from Dr Dmitri Sviridov, Baker Heart Research Institute, 
Australia) (Allan et al., 1993) diluted 1:5 in blocking solution were added overnight at 4ºC. 
Incubation with either anti-goat or anti-mouse, coupled to biotin (both from Sigma, diluted 
1:20) was performed 30 min at 37ºC. For biotin detection, incubation either with extravidin-
peroxidase (1:20, Sigma) or extravidin-alkaline phosphatase (1:20, Sigma) was performed 
poFast Red (Sigma), respectively, and the sections were counterstained with Gill´s 
hematoxylin. The specificity of the apoA-I polyclonal antibody was confirmed by 
preabsorption of the antibody with antigen. Purified human apoA-I (200 µg) was mixed 1 
µL of goat anti-human apoA-I antibody. The mixture was incubated overnight at 37ºC, 
centrifuged at 10,000x g for 20 min, and the supernatant was used as the primary 
antibody in immunochemistry experiments. On parallel control sections, incubation with 
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primary antibody (either the polyclonal or the monoclonal) was replaced by blocking 
solution alone. 
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Results 
TTR cleaves preferentially lipid- free and poorly lipidated apoA-I  
We have previously determined that TTR is able to cleave the C-terminus of lipid-free 
apoA-I, after Phe225 (Liz et al., 2004). In order to further analyse putative physiological 
consequences of this cleavage, we evaluated the ability of TTR to cleave apoA-I present 
in different HDL particles, namely in rHDL and in sHDL isolated from human plasma 
(mainly composed by α-HDL but also containing a minor subpopulation of pre-β-HDL 
particles). We observed that TTR cleaves not only lipid-free apoA-I, as previously 
determined, but also lipidated apoA-I; SDS-PAGE analysis showed the appearance of an 
approximately 26 kDa band after treatment of either lipid-free apoA-I or apoA-I present in 
rHDL particles (Figure 1, left and middle panels, respectively). The extent of lipid-free 
apoA-I cleavage by TTR was 37±4%, whereas the extent of rHDL apoA-I cleavage was of 
only 10±1%. In the case of sHDL, although the appearance of an apoA-I fragment was not 
observed upon TTR treatment, a reduction of approximately 7±1% in the intensity of intact 
apoA-I was seen (Figure 1, right panel). Regarding the extent of rHDL and sHDL cleavage 
by TTR, similar results were obtained by performing quantification on Coomassie stained 
SDS-PAGE gels or on western blots (data not shown). This data shows that apoA-I 
cleavage by TTR was more effective in lipid-free apoA-I and lipid-poor rHDL (that mimic 
nascent discoidal pre-β-HDL particles) than in the fully-lipidated sHDL particles.  
 
 
Figure 1 - TTR cleavage of lipid-free apoA-I, rHDL and sHDL. Left and middle panels: SDS-
PAGE analysis of lipid-free apoA-I and rHDL incubated with (+) or without (-) recombinant TTR. 
Right panel: Anti-apoA-I Western analysis of sHDL incubated with (+) or without recombinant TTR 
(-). 
 
To further substantiate this observation, we analysed by agarose electrophoresis the 
ability of TTR to cleave the α and pre-β subpopulations present in sHDL. After treatment 
with TTR, a preferential loss of the pre-β-HDL subpopulation was observed (Figure 2): a 
40±9% decrease of pre-β-HDL particles was detected whereas a decrease of only 13±3% 
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of α-HDL was seen (Figure 2), further supporting that apoA-I present in lipid-rich particles 
is more resistant to TTR-mediated proteolysis. 
 
 
Figure 2 - Agarose electrophoresis of human sHDL incubated either with (+) or without (-) 
TTR. 
 
In addition to the predominant lipid-free form of TTR found in the plasma, a small fraction 
(1-2%) of this protein was reported to be transported in HDL through binding to apoA-I 
(Sousa et al., 2000a). In this respect, we investigated by Western analysis in which sHDL 
subpopulation TTR was present. We determined that TTR was present in a similar 
percentage, relatively to the amount of apoA-I, in both sHDL subpopulations (Figure 3). As 
the proteolytic activity of TTR is inhibited when the protein is in a complex with its ligand 
RBP (Liz et al., 2004), we followed by analysing the presence of RBP in the two 
subpopulations of sHDL and observed that RBP is only present in the pre-β subpopulation 
(Figure 3). This suggests that the TTR fraction present in the pre-β subpopulation might 
have its proteolytic activity inhibited by RBP. 
 
 
Figure 3 - Western analysis for TTR, RBP and apoA-I present in α and pre-β-HDL 
subpopulations from human sHDL. 
 
Upon TTR cleavage, apoA-I has a decreased ability to promote cholesterol efflux 
The C-terminal domain of apoA-I, including the region cleaved by TTR, is important for 
promoting cholesterol efflux from macrophages, where ABCA-1 expression is increased 
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upon cholesterol loading (Lee-Rueckert and Kovanen, 2006). To assess whether apoA-I 
cleaved by TTR displays functional changes impacting in its ability to promote high-affinity 
cholesterol efflux, we compared cholesterol efflux from cholesterol-loaded THP-1 
macrophages elicited by intact rHDL or rHDL previously cleaved by TTR. rHDL were 
added to cholesterol-loaded THP-1 macrophages in the low range of acceptor protein 
concentration (25 µg/mL), in which the high affinity efflux of cholesterol, mediated by 
ABCA-1, has been previously shown to dominate (Favari et al., 2004). We observed that 
upon cleavage by TTR, rHDL displayed an approximately 50% decreased ability to 
promote cholesterol efflux (Figure 4), thus showing that apoA-I function in promoting 
cholesterol efflux is impaired after TTR-mediated proteolysis.  
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Figure 4 - Percentage of cholesterol efflux from cholesterol-loaded THP-1 macrophages 
using as acceptor either intact rHDL (-) or rHDL cleaved by TTR (+). 
 
To assess whether transgenic mice carrying human TTR in a TTR KO background 
(hTTRxTTR KO) could be used as tools to further investigate the impact of apoA-I 
cleavage by TTR in cholesterol efflux, we assessed the ability of human TTR to cleave 
mouse apoA-I. For that, sHDL from TTR KO mice were isolated and exposed to 
recombinant human TTR, as detailed for human sHDL. In fact, human TTR was able to 
cleave not only human but also mouse apoA-I, as determined by the decrease in the 
intensity of mouse full-length apoA-I, upon TTR incubation (Figure 5A). As such, the 
comparison of the biological properties of sHDL isolated from TTR KO and hTTRxTTR KO 
mice may be useful to further assess the biological consequences of apoA-I cleavage by 
TTR. Similarly to what has been previously reported for human HDL (Sousa et al., 2000a), 
human TTR was detected in sHDL isolated by ultracentrifugation from hTTRxTTR KO 
mice (8 ng TTR/ µg total protein). Moreover, as described above for human sHDL, sHDL 
from hTTRxTTR KO mice displayed TTR both in the α and pre-β-HDL subpopulations 
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(Figure 5B). As predicted, given the presence of human TTR, sHDL from hTTRxTTR KO 
mice displayed an approximately 50% decreased ability to induce cholesterol efflux, as 
compared to sHDL isolated from TTR KO mice (Figure 5C). This result led us to measure 
HDL-cholesterol in both strains when fed a high-fat/high-cholesterol diet. TTR KO mice 
fed a high-fat/high-cholesterol diet had a 2.1 fold increase in the amount of cholesterol 
transported in HDL when compared to the same mouse strain fed with regular chow, 
whereas in hTTRxTTR KO mice, this increase was of only 1.3 fold. This result further 
supports the hypothesis that TTR diminishes the ability of HDL to perform reverse 
cholesterol transport. 
 
 
Figure 5 - A. SDS-PAGE analysis of sHDL isolated from TTR KO mice incubated in the absence  
(-) or in the presence (+) of recombinant human TTR. B. TTR Western analysis of α and pre-β-HDL 
subpopulations from hTTRxTTR KO mice sHDL. C. Percentage of cholesterol efflux from 
cholesterol-loaded THP-1 macrophages using as cholesterol acceptors sHDL isolated from TTR 
KO mouse plasma or hTTRxTTR KO mouse plasma. 
 
ApoA-I cleaved by TTR has decreased ability to bind to ABCA-1  
The diminished capacity of apoA-I cleaved by TTR to induce cholesterol efflux from THP-1 
cells suggested that C-terminally deleted apoA-I has a decreased capacity to bind ABCA-
1, as previously described (Chroni et al., 2003). To further address this issue, we 
performed cholesterol efflux assays in human embryonic kidney 293 cells untransfected or 
transfected with ABCA-1 (Brunham et al., 2005) using as cholesterol acceptor apoA-I 
(either intact or cleaved by TTR). The expression of ABCA-1 in HEK293-ABCA-1 cells and 
its absence in HEK293 untransfected cells was confirmed by RT-PCR (Figure 6A). In 
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untransfected HEK293 cells, the values of cholesterol efflux were residual and unaffected 
by TTR (Figure 6B). As predicted given the expression of the receptor, HEK293-ABCA-1 
cells presented an increase in the rate of cholesterol efflux when compared to 
untransfected cells. Moreover in HEK293-ABCA-1 cells, cleavage of apoA-I by treatment 
with TTR led to an approximately 50% decrease in the rate of cholesterol efflux (Figure 
6B), suggesting that the apoA-I fragment generated by TTR proteolysis has reduced 
ability to bind to ABCA-1. 
 
 
Figure 6 - A. RT-PCR analysis of ABCA-1 expression in HEK293 cells either untransfected 
(HEK293) or transfected with ABCA-1 (HEK293-ABCA-1). B. Rate of cholesterol efflux from 
HEK293 cells untransfected or transfected with ABCA-1 using as cholesterol acceptors lipid-free 
apoA-I either untreated (untreated apoA-I) or treated with TTR (TTR-treated apoA-I). 
 
ApoA-I cleavage by TTR has no effect on LCAT activation  
To evaluate whether the proteolytic modification of apoA-I by TTR also alters its ability to 
activate LCAT, we compared the esterification of cholesterol induced by intact with that 
induced by TTR-cleaved rHDL. No changes in the rates of cholesterol esterification were 
observed after proteolysis of rHDL by TTR (data not shown), suggesting that apoA-I 
degradation by TTR does not decrease its capacity to activate LCAT.  
 
TTR cleavage of ApoA-I present in sHDL does not affect binding to SR-BI 
Besides cholesterol efflux, another crucial step in reverse cholesterol transport is the SR-
BI-mediated selective uptake of CE in the liver that occurs upon interaction of SR-BI with 
apoA-I present in α-HDL. In this respect, we investigated the impact of apoA-I cleavage by 
TTR in SR-BI binding of intact sHDL and sHDL cleaved by TTR. This study was 
performed through competition assays using a cell line overexpressing murine SR-BI 
(IDLA7-mSRBI). Both intact sHDL and sHDL cleaved by TTR competed similarly with 125I-
sHDL binding to the receptor (Figure 7). As a control, the assay was performed using TTR 
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as a competitor; in this case, no binding to SR-BI was observed (data not shown), as 
previously described (Sousa and Saraiva, 2001), showing that TTR itself does not 
interfere in the assay. Moreover, assays performed with untransfected IdlA7 cells showed 
no binding of sHDL (data not shown). In conclusion, under physiological conditions, TTR 
probably does not impact on sHDL recognition by SR-BI as a consequence of the minute 
cleavage of apoA-I by TTR, when apoA-I is present in fully lipidated particles. 
 
 
Figure 7 - Cell association of 125I-sHDL to IDLA-mSRBI cells. Competition by sHDL, at 
increasing concentrations ranging from 0 to 100 µg/mL, when either intact (sHDL) or previously 
treated with TTR (sHDL+TTR). 
 
In vitro, TTR increases apoA-I aggregation and fibril formation 
Amyloid deposits in the aortic intima are very common in association with atherosclerosis: 
N-terminal fragments of apoA-I deposited as amyloid fibrils are present in human 
atherosclerotic plaques (Westermark et al., 1995). Proteolysis has been thought to play an 
important role in most types of amyloidoses; in several cases, an amyloid peptide is 
generated by proteolytic cleavage of the corresponding protein precursor. We 
hypothesized that cleavage of the C-terminus of apoA-I by TTR might influence its 
deposition as amyloid. To evaluate this hypothesis, structural consequences of apoA-I 
cleavage by TTR, as well the amyloidogenicity of full-length apoA-I and of TTR-cleaved 
apoA-I, were compared using several biophysical methodologies. We started by analysing 
the structural consequences of apoA-I cleavage by TTR, by comparing the relative 
content in a-helices by far-UV CD of intact apoA-I and apoA-IΔ226-243 (Table 1). The 
percentage of a-helices (45%) of freshly prepared intact apoA-I (as prepared) compares 
very well with the value reported in the literature (44%) (Tanaka et al., 2006). On the other 
hand, intact apoA-I prepared under the conditions in which the proteolytic digestion was 
carried out (under proteolysis conditions) had a substantially lower a-helix content, which 
was identical to the one obtained for apoA-IΔ226-243 (Table 1). From the analysis of the 
secondary structure content, it seems that loss in a-helices resulted mostly in b-strand 
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formation and in an increase in random conformations for both intact apoA-I and apoA-
IΔ226-243. In conclusion, under the studied conditions, there was no significant difference 
in the a-helical content of apoA-I (under proteolysis conditions) and its cleaved form apoA-
IΔ226-243, which is in accordance to what has been previously reported (Saito et al., 
2004). 
 
Table 1 - Secondary structure content in ApoA-I forms determined by far-UV CD. 
 
 
 
 
 
 
 
 
Considering the relatively long incubation period required to achieve the highest yield 
possible of apoA-IΔ226-243, the possibility that apoA-I aggregates or oligomers were 
being formed was investigated by dynamic light scattering (DLS) (Figure 8). The data 
obtained demonstrated that, in the absence of TTR, apoA-I was not aggregating during 
the period of 60 h incubation at 37°C (particle size variation from 5.4 to 5.5 nm). On the 
other hand, large size particles corresponding to aggregates were observed for the apoA-
IΔ226-243 (from 38 to 154 nm particles). These results suggest that by cleaving the 226-
243 apoA-I C-terminal region, TTR increases the aggregation propensity of apoA-I.  
Moreover, DLS analysis of apoA-I after thermal unfolding showed that whereas the size of 
intact apoA-I particles changed very modestly (from 5.2 to 7.2 nm), in apoA-IΔ226-243 
even larger particles are observed than before thermal denaturation (~90nm and 300nm) 
suggesting that thermal perturbation further enhances aggregation propensity in this 
variant (data not shown).  
 Secondary structure content (%) 
Protein α-helix β-strands  Random coil  
ApoA-Ia 45 ± 2 29 27 
ApoA-Ib 14 ± 1 51 35 
ApoA-IΔ226-243 16 ± 1 48 34 
a As prepared b Under proteolysis conditions (60 h at 37°C) 
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Figure 8 - Particle size distribution by volume (nm/%) determined from DLS measurements on 
freshly prepared apoA-I (squares, 5.42 nm/99.8%), apoA-I incubated 60 h at 37°C (triangles, 5.47 
nm/99.8%) and apoA-IΔ226-243 (circles, 38.4nm/70.9% and154.5 nm/29.1%). 
 
In order to monitor differences in the tertiary structure contacts of intact apoA-I (freshly 
prepared and prepared under proteolysis conditions) and apoA-IΔ226-243 we assessed 
Tryptophan Fluorescence emission. The position of the emission maximum obtained upon 
selective excitation of the Trp moieties at 295nm provides an indication of the environment 
around this residue: increasing exposure to solvent water red-shifts the emission maxima 
up to 355 nm, which corresponds to a fully solvent exposed residue. ApoA-I contains 4 
Trp residues, none in the cleaved region. ApoA-I incubation at 37°C during 60 h, as 
compared to non-incubated intact apoA-I results in a decrease of Trp-emission intensity 
and a slight red shift to 346nm (Figure 9), suggesting a conformational change. This 
observation agrees well with the loss of secondary structure as seen by far-UV CD and 
with the slight particle size increase observed by DLS. ApoA-IΔ226-243 is clearly more 
conformationally altered considering the red shift of the emission maxima at 20°C and the 
lowest fluorescence intensity (Figure 9). We further analysed the thermal unfolding of 
intact apoA-I (freshly prepared and prepared under proteolysis conditions) and apoA-
IΔ226-243 by Tryptophan Fluorescence emission and verified that whereas the thermal 
unfolding of intact apoA-I is fully reversible that of apoA-IΔ226-243 was only partially 
reversible (Figure 9). This behavior agrees well with a less organized fold of the 
ApoA1Δ226-243 variant, compatible with the presence of aggregates and/or overall 
conformational destabilization resulting from the cleavage. 
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Figure 9 - Fluorescence Trp Emission spectra of intact apoA-I (left), intact apoA-I 60 h 
incubated at 37°C (middle) and apoA1Δ226-243 (right), recorded at 20°C (solid), at 95°C 
(dash) and after cooling back to 20°C (dot). 
 
To further verify the hypothesis that apoA-I cleaved by TTR might be aggregating and 
forming fibrils, analysis of fibrillar growth by transmission electron microcopy was 
performed. We observed that following 10 days of incubation under conditions promoting 
fibrillar growth (Wisniewski et al., 1995), cleaved apoA-I already presented fibrils in 
contrast with the full-length protein where fibril formation was still not observed (Figure 
10), thereby supporting that cleavage of apoA-I by TTR enhances apoA-I deposition in the 
form of amyloid fibrils. In the control preparation starting with TTR alone, no fibrils were 
observed in the grid (data not shown), thus clearly demonstrating that fibrils observed 
when apoA-I is cleaved by TTR are not the result of a putative TTR contamination in the 
preparation. 
 
 
Figure 10 - Electron microscopy of negatively stained apoA-I fibrils (scale bar = 100 nm), 
previously incubated in the absence (-) or presence (+) of TTR. 
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ApoA-I cleaved by TTR is deposited in ATTR cases 
ApoA-I is related with amyloidosis, not only as a major constituent of amyloid fibrils, but 
also as a minor fibril constituent in several cases of amyloidosis not related with apoA-I 
mutations (Sakata et al., 2005). In apoA-I amyloidosis, N-terminal fragments mainly 
constitute the amyloid fibrils. In the cases of amyloidoses not related with apoA-I 
mutations there is no evidence whether the protein is present in the intact or in the 
cleaved form. We determined that TTR proteolysis enhances the amyloidogenic potencial 
of apoA-I in vitro. To determine if TTR proteolytic activity impacts on apoA-I deposition in 
vivo, we investigated whether apoA-I deposits in the full-length or in the C-terminally 
cleaved form, in amyloidosis in which apoA-I is not the main precursor protein. For that, 
we performed immunohistochemical analysis of tissues from Alzheimer´s disease, AL and 
ATTR amyloidosis, using a monoclonal antibody specific for an epitope within residues 
223-233 in apoA-I (Allan et al., 1993), which corresponds to the region cleaved by TTR 
(TTR cleaves apoA-I after Phe225). This monoclonal antibody would allow us to assess 
whether apoA-I deposited in the cases of ATTR amyloidosis and/or in other amyloidoses 
contains the C-terminal region cleaved by TTR or whether it deposits preferentially in a C-
terminally deleted form. We started by performing Congo red staining to localize the 
amyloid deposits. Amyloid deposition was confirmed in the brain of an Alzheimer´s 
disease patient (Figure 11, panel A), in the tongue of an AL amyloidosis patient (Figure 
11, panel D) and in the colon of ATTR patients (Figure 11, panels G and I). In the three 
different amyloidoses, all the Congo-red positive areas were immunoreactive for a 
polyclonal antibody against apoA-I (Figure 11, panels B, E, H and K). The 
immunoreactivity of the polyclonal antibody in the amyloid deposits was completely 
blocked by preabsorption of the antibody with human apoA-I (data not shown). This 
polyclonal antibody recognizes both intact and cleaved forms of apoA-I. The presence of 
apoA-I deposition in different amyloidoses is in accordance with previous studies that 
have shown the colocalization of apoA-I with several amyloidogenic proteins. We followed 
by analyzing the same areas for immunoreactivity against MAb AI-4.1 which recognizes 
only full-length apoA-I and not apoA-I cleaved by TTR, as confirmed by Western blot 
analysis of both apoA-I forms (data not shown). In the case of the brain of an Alzheimer´s 
patient, we detected mainly vascular deposits that showed positive reaction for both the 
polyclonal and monoclonal antibodies against apoA-I (Figure 11, panels A-C). The same 
was observed in the tongue of an AL case (Figure 11, panels D-F). These results show 
that in the cases of Alzheimer’s disease and AL amyloidosis, intact apoA-I is present in 
the amyloid deposits. In the case of TTR amyloidosis, the immunoreactivity with the 
monoclonal antibody was variable: in the colon of an FAP patient some areas showed 
immunoreactivity with both antibodies (Figure 11, panels G-I), while others were only 
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positive for the polyclonal antibody (Figure 11, panels J-L). This suggests that in ATTR 
amyloidosis amyloid deposits contain both intact and C-terminally deleted apoA-I, 
suggesting that TTR proteolytic activity may have an effect in apoA-I co-deposition in 
ATTR amyloidosis. 
 
Figure 11 - Analysis of human apoA-I immunoreactivity in amyloidosis cases not related 
with apoA-I mutations. Brain section of an Alzheimer’s disease case (A-C). Tongue of an AL case 
(D-F). Colon of an ATTR case (G-L). Congo red staining (A,D,G,J – left panels). Anti-apoA-I 
immunohistochemistry using a polyclonal antibody (B,E,H,K – middle panels) and the monoclonal 
antibody MAb AI-4.1 (C,F,I,L – right panels) agains human apoA-I. 
A B C 
D E F 
G H I 
J K L 
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Discussion 
Previous in vitro studies demonstrated that several proteases, including matrix 
metalloproteases (Lindstedt et al., 1999), plasmin and kallikrein (Lindstedt and Kovanen, 
2000) and two mast cell proteases, chymase and tryptase (Lee-Rueckert and Kovanen, 
2006), can degrade apoA-I present in pre-β-HDL particles, thereby impairing cellular 
cholesterol efflux. In this report we show that TTR has a similar effect: not only TTR 
cleaves apoA-I in the C-terminus after the same residue as chymase (Phe225) (Liz et al., 
2004), but also TTR is more effective in cleaving apoA-I present in lipid-poor pre-β-HDL 
particles, resulting in an impairment in the ability of rHDL to promote cholesterol efflux 
from macrophages. The reason underlying the increased susceptibility for proteolysis of 
apoA-I in lipid-poor pre-β-HDL is probably related to an increased exposure of domains 
vulnerable to protease attack when compared to apoA-I in large spherical α-HDL 
(Kunitake et al., 1990). Despite a low extent of proteolysis, rHDL have approximately 50% 
decreased ability to promote cholesterol efflux. The same was observed with plasmin and 
kallikrein, two plasma proteases found in the arterial intima, that only produce a slight loss 
of apoA-I in HDL3 (ultracentrifugally separated particles with d= 1.125-1.21, containing 
pre-b-HDL), but lead to an approximately 50% decrease in HDL3-mediated cholesterol 
efflux (Lindstedt and Kovanen, 2000). Although, as documented above, a number of 
proteases cleave rHDL particles to a small extent, this cleavage results in a considerable 
decrease in the ability of the particle to perform cholesterol efflux; the reason underlying 
this apparent discrepancy is unclear.  
Under physiological conditions, it was previously determined that 1-2% of human plasma 
TTR circulates in HDL, through binding to apoA-I (Sousa et al., 2000a), but the relevance 
of this finding remained obscure. In that study, TTR was not detected in HDL from 
hTTRxTTR KO mice probably because gel filtration instead of ultracentrifugation was 
employed as the method for HDL isolation. We now show that similarly to humans, TTR is 
present in sHDL isolated from transgenic mice for human TTR. Moreover, these particles 
have a decreased ability to promote cholesterol efflux when compared to sHDL particles 
isolated from TTR KO mice, further suggesting that TTR, either present in HDL or 
circulating in the plasma, may impact in HDL biology. Also, we found that when fed a high-
fat/high-cholesterol diet, hTTRxTTR KO mice present a lower HDL-cholesterol increase as 
compared to TTR KO mice. This observation probably results from a decreased ability of 
HDL from hTTRxTTR KO mice to mediate cholesterol efflux, as a consequence of apoA-I 
cleavage by TTR. In our studies we were unable to observe apoA-I fragments in the sHDL 
particles isolated from either hTTRxTTR KO mice, or human plasma samples which would 
further confirm apoA-I proteolysis by TTR in vivo. This might be related to a low cleavage 
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of sHDL particles by TTR. In this respect, it is interesting to note that upon cleavage, N-
terminal apoA-I fragments have been shown to dissociate from lipids (Obici et al., 2006) 
precluding the isolation at d=1.063 to 1.210 g/mL of pre-b particles containing C-terminally 
deleted apoA-I. This most likely results from the fact that the C-terminal portion of apoA-I 
determines intimate contact with lipids. Moreover, the fact that truncated forms of apoA-I 
lacking the C-terminus cannot associate with HDL, might explain the fast catabolism of N-
terminal proteolytic apoA-I fragments. 
ApoA-I is responsible for the major functions of HDL: its central region has been 
implicated in the activation of LCAT (Uboldi et al., 1996), whereas its C-terminal domain is 
crucial for induction of cholesterol efflux (Lee et al., 2003). Concerning the mechanism of 
cholesterol efflux, it may occur through two distinct mechanisms: i) lipid-free or lipid-poor 
apolipoproteins promote the efflux of free cholesterol by interacting with ABCA-1 in the 
cell membrane and ii) mature HDL can acquire free cholesterol by aqueous diffusion 
mediated by SR-BI. In this work, by using THP-1 cells, we show that TTR proteolysis of 
rHDL decreases the ABCA-1-mediated component of cholesterol efflux, as our 
experiments were performed in the low range of acceptor protein concentration, where the 
cholesterol efflux mediated by this receptor dominates. This was further confirmed in 
cholesterol efflux assays using HEK293 cells either untransfected or transfected with 
ABCA-1; in this assay, cleavage of apoA-I by TTR decreased the rate of cholesterol efflux 
by HEK293-ABCA-1 cells, further supporting that the effect of TTR on apoA-I-mediated 
cholesterol efflux is ABCA-1 dependent. Moreover, this result suggests that apoA-I 
cleaved by TTR has reduced affinity for ABCA-1 as it has been previously shown that the 
ability of apoA-I to bind ABCA-1, as assessed by crosslinking, is correlated to the ability of 
the protein to induce cholesterol efflux (Chroni et al., 2004). In that report, C-terminal 
mutants of apoA-I lacking the 220-231 region presented a decreased ability to bind ABCA-
1 and to promote lipid efflux (Chroni et al., 2004). Our results are in agreement with that 
study as the apoA-I fragment generated by TTR proteolysis lacks part of the crucial region 
mediating the interaction with ABCA-1 and as such cholesterol efflux is affected. 
In relation to LCAT, rHDL cleavage by TTR did not alter its ability to activate this enzyme. 
This result is in accordance with the fact that the central region of apoA-I, and not the C-
terminus domain of the protein, is thought to be important for LCAT activation (Uboldi et 
al., 1996). Interestingly, similar limited proteolysis of apoA-I in rHDL by four different 
proteases (chymotrypsin, trypsin, elastase, and subtilisin) has been reported to produce a 
relatively stable N-terminal polypeptide of approximately 22 kDa, which retains LCAT 
activation (Ji and Jonas, 1995).  
Another important step in the mechanism of reverse cholesterol transport is the selective 
uptake of HDL CE mediated by SR-BI that occurs in the liver and steroidogenic tissues 
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(Landschulz et al., 1996). Efficient functioning of SR-BI depends on productive binding of 
apoA-I to the receptor. Although the precise apoA-I binding site for SR-BI has not been 
identified, previous reports showed that the C-terminal region of apoA-I is important for 
SR-BI recognition (Liadaki et al., 2000). However, we observed that apoA-I cleavage by 
TTR has no effect on sHDL binding to SR-BI, probably as a consequence of the minute 
cleavage of the spherical particles by TTR.  
Intimal amyloid associated with atherosclerotic plaques is derived from a major N-terminal 
fragment (1-69) of apoA-I (Westermark et al., 1995). Several amyloid fibril proteins are 
also composed by fragments of larger precursors indicating that a proteolytic step is 
important in the pathogenesis of the amyloid forms, possibly by uncovering a normally 
hidden fibrillogenic fragment in the precursor. In this respect, it is possible that upon TTR 
cleavage, apoA-I becomes more prone to fibril formation. Under the conditions used, upon 
incubation of lipid-free apoA-I with TTR, a single 26 kDa apoA-I fragment is formed. To 
address the stability of the apoA-I fragment generated by TTR proteolysis (apoA-IΔ226-
243) we performed circular dichroism experiments. Under extended incubation times, 
similar to those used to obtain 100% cleavage, intact apoA-I had an identical α-helix 
content to the one obtained for apoA-IΔ226-243. This is in accordance with previous 
experiments that have shown that in lipid-free conditions, there is little difference in the α-
helical content of apoA-I (44±3%) and apoA-IΔ223-243 (40±2%); apoA-I Δ223-243 is the 
reported C-terminal apoA-I deletion closest to the one performed by TTR (Saito et al., 
2004). That difference became significant only in the presence of lipids (69% for intact 
apoA-I versus 45% for the cleaved form of the protein). However, we observed that apoA-
IΔ226-243 presents an overall conformational destabilization and a higher propensity for 
aggregation when compared to intact apoA-I. Moreover, in conditions promoting fibril 
formation, apoA-IΔ226-243 formed fibrils whereas the intact protein did not. The 
hypothesis that TTR might intervene in apoA-I fibril formation had previously been raised. 
Under pathological conditions, amyloid fibrils from a patient carrying an apoA-I mutation 
presented both apoA-I N-terminal fragments and wt TTR (de Sousa et al., 2000), 
suggesting that TTR might influence the generation of apoA-I fragments and apoA-I 
deposition. In summary, we have now shown that apoA-I cleaved by TTR has a higher 
propensity to form aggregates than intact apoA-I and forms fibrils faster than the full-
length protein, suggesting that TTR increases apoA-I amyloidogenicity in vitro.  
Also, we analysed a putative in vivo effect of TTR proteolytic activity in apoA-I deposition 
as amyloid. In accordance with previous results (Sakata et al., 2005), we observed the 
presence of apoA-I in cases of amyloidoses not related with apoA-I mutations. Using a 
monoclonal antibody against the C-terminal region of apoA-I (residues 223-233), we 
determined that apoA-I is present in the intact form in the cases of Alzheimer´s disease 
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and AL amyloidosis, while in ATTR amyloidosis apoA-I is co-deposited either in the intact 
or the C-terminally deleted form. These results suggest that TTR proteolytic activity might 
have an effect in apoA-I deposition in the case of ATTR amyloidosis. However, more 
tissues from ATTR and from other amyloidosis not related with apoA-I mutations should 
be analysed. The reason for apoA-I deposition in amyloidosis not related with apoA-I 
mutations remains unclear. Studies concerning the relation between apoA-I and the 
precursor protein of each type of amyloidosis are needed. In the case of ATTR 
amyloidosis, TTR proteolytic activity against apoA-I, and also the fact that both proteins 
co-exist in HDL, might explain the co-localization of apoA-I in the TTR amyloid deposits, 
as in this type of amyloidosis we observed the presence of both intact and C-terminally 
cleaved apoA-I in the deposits. Plasma lipoproteins, such as chylomicron/VLDL, HDL and 
LDL have affinity for TTR (Sun et al., 2003). Recently, immunohistochemical studies 
revealed the presence of HDL in the amyloid fibrils of tissues from autopsied FAP patients 
(Sun et al., 2006). These observations raise the question of whether apoA-I is present in 
the lipid-free or lipidated form in ATTR amyloidosis. In our experiments we used a 
monoclonal antibody against the C-terminus of apoA-I that was previously shown to have 
little or no reactivity to lipidated apoA-I (Allan et al., 1993), suggesting that in the 
amyloidosis cases analysed in this work apoA-I is deposited in the lipid-free form. 
This work shows that the TTR-apoA-I interaction is important both under physiological and 
pathological conditions. TTR may intervene in HDL biology and in atherosclerosis, by 
reducing HDL-mediated cholesterol efflux and by increasing apoA-I amyloidogenicity. The 
question arising from our results is: is TTR present in a proteolytic active form in the 
microenvironment surrounding foam cells? Most of TTR circulates in the plasma in the 
lipid-free form but 1-2% of the protein circulates in HDL both in the pre-β and α 
subpopulations. There is no evidence for the presence of plasmatic TTR in the intima; 
however, the extracellular fluid of the intima is rich in lipid-poor HDL species, such as pre-
β-HDL that promote cholesterol efflux from macrophages. This issue raises a second 
question: is the TTR fraction present in pre-b-HDL active and by degrading apoA-I acts as 
a local modulator of cholesterol efflux from foam cells? Moreover, RBP (a TTR ligand 
which inhibits its proteolytic activity) could only be detected in the pre-β subpopulation. It 
is noteworthy that our previous studies (Sousa et al., 2000a) did not detect RBP in HDL 
isolated by gel filtration, probably as a consequence of the different isolation method of 
the particles. Although we now show that both TTR and RBP are present pre-b-HDL we 
cannot assure that in this subpopulation TTR is complexed with RBP, as it may be bound 
to other lipoprotein components. Even if in pre-β-HDL, TTR and RBP are present as a 
complex, circulating pre-β-HDL could still be degraded by lipid-free TTR, which is the 
major form of the protein present in the plasma. In any of these scenarios, TTR might 
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cleave the C-terminus of apoA-I reducing its capacity to promote HDL-mediated 
cholesterol efflux and increasing apoA-I amyloidogenicity. 
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Abstract 
In addition to transporting retinol and thyroxine in the plasma, a fraction of transthyretin 
(TTR) is carried in high-density lipoproteins through binding to apolipoprotein A-I (apoA-I). 
Following interaction with apoA-I, TTR is able to cleave its C-terminus after residue 
Phe225. As apoA-I might not constitute the prime TTR substrate, we further investigated 
TTR substrate specificity. Distinct methods were used to determine both the primary and 
secondary specificity of TTR: i) the profile of TTR degradation of oxidized insulin B chain 
demonstrated cleavage of Tyr-Leu, Tyr-Thr and Phe-Phe peptidic bonds, and ii) results 
from P-diverse libraries showed a P1 preference for Lys>Ala>Arg>Leu≥Met>Phe>Tyr, 
whereas P2, P3 and P4 preferences were broad; as such, we were unable to identify the 
optimal sequence for TTR cleavage. Nevertheless, the determined P1 preference points 
to the possible existence of other TTR substrates besides apoA-I, as TTR cleaves apoA-I 
after a Phe residue and not after the preferred Lys, Ala or Arg residues. Several studies 
using TTR knockout (KO) mice revealed new TTR functions specifically related to the 
nervous system: i) TTR regulates neuropeptide maturation: TTR KO mice present 
increased levels of neuropeptide Y as a consequence of peptidylglycine α-amidating 
monooxygenase (PAM) overexpression and ii) TTR enhances nerve regeneration after 
crush by promoting increased axonal outgrowth. We hypothesized that some of the new 
TTR functions might not be related to the lack of the protein itself but to the lack of its 
proteolytic activity. In this respect, we assessed whether the proteolytic activity of TTR 
was related to its ability to participate in neuropeptide processing and to enhance neurite 
outgrowth, by comparing the effects of wt TTR with a proteolytic inactive TTR preparation 
(TTRprot-). Both wt TTR and TTRprot- led to a similar decrease of PAM expression in PC12 
cells, excluding the involvement of TTR proteolytic activity in controlling neuropeptide 
maturation. However, we demonstrated that TTR is able to cleave NPY in vitro, which 
could contribute for increased NPY levels in TTR KO mice. Additional results are needed 
to confirm TTR proteolysis of NPY in vivo. To assess the putative involvement of TTR 
proteolytic activity in neurite outgrowth, we measured neurite outgrowth in PC12 cells 
cultivated in the presence of wt TTR or TTRprot-. Cells grown with TTRprot- displayed 
decreased neurite length as determined by measuring the length of the longest neurite. 
These results suggested that the proteolytic activity of TTR is relevant for the ability of 
TTR to promote neurite outgrowth. The search for TTR substrates involved in this process 
is under investigation. DIGE analysis of nerve extracts incubated with TTR showed that 
neurofilament light polypeptide is a putative TTR substrate. Additionally, assays with a 
library of fluorogenic peptides derived from the sequence of myelin basic protein (MBP) 
have shown that TTR was able to cleave one of the MBP peptides (YGGRASD) with 
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approximately 40-fold increased activity when compared to that determined using the 
apoA-I peptide as a substrate. Further experiments demonstrated that TTR is able to 
cleave MBP in vitro. MBP proteolysis by TTR may impact on TTR ability to promote nerve 
regeneration. By showing that TTR is able to cleave NPY, MBP and that its proteolytic 
activity is needed for its ability to increase axonal growth, this study further contributes to 
establish the relevance of TTR in the biology of the nervous system. 
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Introduction  
Transthyretin (TTR) is the plasma homotetrameric carrier of thyroxine (T4) and retinol (Raz 
and Goodman, 1969), in the latter case through binding to retinol binding protein (RBP). In 
the plasma, a small TTR fraction is carried in high-density lipoproteins (HDL), through 
binding to apolipoprotein A-I (apoA-I) (Sousa et al., 2000a). Besides being a transporter, 
TTR is able to cleave the C-terminus of apoA-I, being a novel cryptic protease. To date, 
the mechanism and physiological function of this proteolytic activity have not been fully 
elucidated. Several indications including an optimum pH for activity of approximately 7, 
inhibition by serine protease inhibitors and cleavage in apoA-I after a Phe residue, allowed 
the assumption of TTR being a Serine protease (Liz et al., 2004). However, TTR catalytic 
mechanism remains to be solved. The cryptic nature of TTR proteolytic activity comes not 
only from the fact that it lacks canonical structural protease determinants, but also 
because it’s physiological function is apparently unrelated to proteolysis (Liz and Sousa, 
2005). 
We addressed the relevance of apoA-I cleavage by TTR in lipoprotein metabolism and 
determined that TTR cleaves not only lipid-free but also lipidated apoA-I. Upon TTR 
cleavage, HDL display a reduced capacity to promote cholesterol efflux. Also, we 
determined that TTR increases apoA-I amyloidogenicity (Liz et al., 2007). However, we 
cannot exclude that apoA-I might not be the prime natural TTR substrate. We previously 
determined a Km of 26 µM for TTR cleavage of a fluorogenic peptide encompassing the 
region cleaved in apoA-I (ESFKVS), which reflects a low affinity for this substrate (Liz et 
al., 2004). Moreover, screening of TTR with a library of phosphonate inhibitors 
demonstrated that TTR is preferentially inhibited by compounds with a basic residue as 
Lysine in the P1 position (Liz et al., unpublished data). This result further suggests the 
existence of other natural TTR substrates as cleavage in apoA-I occurs after Phe, and not 
after the preferred Lys residue. 
To properly function, proteases must preferentially select their target substrates in the 
presence of other proteins. While many factors impact protease substrate selection, one 
of the key aspects is the complementarity of the enzyme active site with the residues 
surrounding the cleaved bond in the substrate. The cleavage specificity reflects the 
preferred amino acid residues for protease cleavage. In reference to peptide substrates, 
the nomenclature used refers to amino acids in the N-terminal side from the cleavage site 
as P1, P2, P3… counting in the N-terminal direction, and to amino acids in the C-terminal 
side of the cleavage site as P1’, P2’, P3’…counting towards the C-terminus (Schechter 
and Berger, 1967). In this work, we investigated TTR substrate specificity by using 
different strategies: (i) analysis of TTR degradation of oxidized insulin B chain, and ii) TTR 
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profile with combinatorial substrate libraries containing most combinations of natural 
amino acids at each subsite position in order to determine the P4-P1 substrate 
preference. The approaches described can identify sequences for optimal cleavage by 
TTR, which are useful to search for putative natural substrates with identical sequences. 
However, these studies do not identify in vivo substrates. One technique that can 
potentially identify and characterize natural protease substrates and their products is 
differential fluorescence gel electrophoresis (DIGE), in conjunction with mass 
spectrometry (MS). The two major sites of TTR synthesis are the liver and the choroid 
plexus of the brain that are respectively the sources of TTR in the plasma and 
cerebrospinal fluid (CSF). In this work, we investigated the presence of natural TTR 
substrates in the plasma by performing DIGE. 
Several TTR mutations are related to a neurodegenerative disease named familial 
amyloid polyneuropathy (FAP) (Saraiva, 2001) characterized by the deposition of TTR 
fibrils particularly in peripheral nervous system (PNS) (Andrade, 1952). The origin of TTR 
deposited in the PNS of FAP patients is unknown. Under physiological conditions, TTR 
has access to the nerve through the blood and the CSF. A function for TTR in nerve 
biology could explain its preferential deposition, when mutated, in the PNS. Several 
studies using TTR knockout (KO) mice (Episkopou et al., 1993) revealed new TTR 
functions specifically related to the nervous system:  
- TTR is involved in sensorimotor performance (Fleming et al., 2007): TTR KO mice 
present a sensorimotor impairment when assessed functionally. 
- The absence of TTR is associated with increased exploratory activity and reduced signs 
of depressive-like behavior, as was demonstrated in standardized tasks used to assess 
depression, exploratory activity and anxiety performed in TTR KO mice (Sousa et al., 
2004). 
- TTR regulates neuropeptide maturation: TTR KO mice present increased levels of 
neuropeptide Y as a consequence of peptidylglycine α-amidating monooxygenase (PAM) 
overexpression. PAM is the only enzyme that C-terminally amidates peptides and 50% of 
all known neuropeptides require amidation to be active. NPY acts on energy homeostasis 
by increasing white adipose tissue lipoprotein lipase (LPL) and decreasing thermogenesis; 
accordingly, TTR KO mice present increased LPL expression and activity in white adipose 
tissue, PNS, and central nervous system (Nunes et al., 2006). 
- TTR enhances nerve regeneration after crush by promoting increased axonal outgrowth: 
TTR KO mice present a decreased regenerative capacity after sciatic nerve crush 
(Fleming et al., 2007).  
The fact that apoA-I is possibly not the major substrate of TTR together with the 
preferential deposition of TTR in the nerve, and the phenotype of TTR KO mice, makes 
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important the analysis of the physiological relevance of TTR proteolytic activity in the 
nerve. If some of the phenotypes described for TTR KO mice are related to the lack of 
TTR proteolytic, a TTR substrate should exist in the nervous system. In this respect, we 
assessed the effect of TTR proteolytic activity in two of its described functions related with 
the nervous system, namely neuropeptide processing and nerve regeneration.  
The determination of TTR novel substrates will allow us to gain insights in the 
characterization of the physiological relevance of TTR proteolytic activity, which can have 
an impact to further establish TTR as a protein involved in nerve biology. 
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Methods 
Proteins 
Recombinant wt TTR and TTR Ser85Ala (TTR mutant proteolytically inactive, displaying 
two mass peaks as determined by Mass Spectometry (MS) analysis and discussed in 
chapter 2) were produced in BL-21 pLys Escherichia coli cells transformed with pET 
plasmids carrying TTR cDNA. After bacterial lysis, proteins were isolated and purified as 
previously described (Liz et al, 2004). 
 
Digestion of oxidized insulin B chain 
Digestion of oxidized insulin B chain (50 µg, Sigma) by TTR (50 µg) was carried out for 6 
hr at 37ºC in 50 mM Tris pH 7. Reaction was stopped with 0.6 % (v/v) trifluoroacetic acid 
(TFA) (final concentration). After centrifugation (12,000 g, 2 min), the fragments were 
separated by RP-HPLC in a C18 column, using a Merck Hitachi system with a Hi-Pore 
RP-318 250 x 4.6 mm column (BioRad). Elution was carried out with a linear gradient (0-
80%) of acetonitrile in 0.1 % v/v trifluoroacetic acid for 30 minutes at a flow rate of 1 
mL/min. Absorbance was monitored at 220 nm. The isolated peptides were collected, 
freeze-dried and submitted to automated amino acid sequencing. 
 
Combinatorial Peptide Libraries 
To profile TTR preferences at substrate positions P4-P1, we used combinatorial 
fluorogenic peptide libraries. To determine the P1 preference of TTR, we used a P1-
diverse library of soluble positional protease substrates with 160,000 members each 
containing the fluorogenic leaving group 7-amino-4-carbamoylmethylcoumarin (Raymond 
et al., 2003). The P1-diverse library consists of 20 wells, in each of which only the P1 
residue remains constant, with each of the remaining sites containing equimolar mixtures 
of 20 amino acids for a total of 8,000 sequences per well. Similarly, the extended P4–P2 
specificity of TTR was explored by fixing the residue at the desired position in a given well. 
Assays were performed at 37 °C in 50 mM Tris pH 7.0. Final concentration for each 
substrate compound was 10 nM. Substrate hydrolysis was initiated by addition of enzyme 
(5 µM) and monitored fluorometrically with excitation at 380 nm and emission at 450 nm 
for 3 hr.  
 
Differential fluorescence gel electrophoresis proteome profiling 
Differential fluorescence gel electrophoresis (DIGE) was performed as a service by the 
W.M. Keck Facility, Yale University, New Haven, USA, according to the EttanTM DIGE 
manual (Amersham) available at http://keck.med.yale.edu/pdfs/Ettan%20DIGE% 
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20User%20Manual.pdf. Briefly, to compare the proteomic profile between two distinct 
samples, one sample was labelled with Cy-3 and the other with Cy-5, two N-
hydroxysuccinimidyl ester dyes (GE Healthcare). The protein concentration from each 
sample was quantitated by amino acid analysis to ± 0.1 µg accuracy. An equal amount of 
each sample was labeled and run in the DIGE experiment. 24 cm, pH 3-10 Immobiline 
(IPG) Drystrips (GE Healthcare) were rehydrated overnight with the two samples and 
isoelectric focussing was carried out. 12.5% SDS polyacrylamide gel electrophoresis 
dimension was run, and immediately after SDS PAGE, gels were scanned at 2 
wavelengths simultaneously on a GE Healthcare Typhoon 9410 Imager: 580 nm for Cy3, 
and 670 nm for Cy5. Gels were then fixed and stained with Sypro Ruby. GE Healthcare 
DeCyder software was used to quantify (this software includes an automatic background 
correction, spot volume normalization and volume ratio calculation), and to identify the 
differentially expressed protein spots with a fold change higher than 1.5. These spots 
were excised, high mass accuracy automated matrix-assisted laser desorption ionization 
(MALDI)-MS/MS spectra were acquired on each target (using the Keck Laboratory’s 
Applied Biosystems 4800 Tof/Tof instrument), and the resulting peptide masses were 
subjected to database searching using Mascot algorithms. 
In order to identify plasma substrates for TTR, we performed two distinct DIGE 
experiments. In the first experiment, 50 µL of plasma from TTR Knockout (KO) mice were 
incubated with 75 µg of either wt TTR or proteolytically inactive TTR (TTRprot-) in 50 mM 
Tris pH 7, overnight at 37ºC. For the DIGE experiment we had two samples corresponding 
to the TTR KO plasma incubation with wt TTR (KO+wtTTR sample) or TTRprot- 
(KO+TTRprot- sample), one labeled with Cy3 and the other with Cy5, respectively; 50 µg of 
each sample were loaded in the 2D gel. In a second experiment, 50 µL of plasma from 
TTR KO mice were incubated with or without 75 µg of wt TTR in 50 mM Tris pH 7, 
overnight at 37ºC. For the DIGE experiment we had two samples corresponding to the 
plasma incubation with wt TTR (KO+TTR sample) or without (KO sample), one labeled 
with Cy5 and the other with Cy3, respectively; 50 µg of each sample were loaded in the 
2D gel. 
To identify putative TTR substrates in the nerve, sciatic nerve segments from TTR KO 
mice were homogenized in 50 mM Tris pH 7. 100  µL of the nerve homogenates 
corresponding to approximately 400 µg of total protein were incubated with or without 60 
 µg of TTR in 50 mM Tris pH 7 overnight at 37ºC. For the DIGE experiment we prepared 
two samples corresponding to the nerve homogenate incubation with wt TTR (KO+TTR 
sample) or without (KO sample), one labeled with Cy5 and the other with Cy3, 
respectively; 90 µg of each sample were loaded in the 2D gel. 
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Influence of TTR proteolytic activity in neuropeptide maturation  
Neuropeptide processing was assessed by quantification of PAM and LPL expression and 
NPY content (Nunes et al., 2006) in PC12 cells (European Collection of Cell Cultures), a 
rat adrenal cell line with a neuronal-like phenotype. Cells were grown in 6-well plates in 
William’s medium E (Invitrogen) supplemented with 2mM L-glutamine (Sigma) and 10% 
fetal bovine serum (FBS) (Invitrogen). When cells reached 50% confluence, FBS was 
withdrawn and William’s medium E medium was supplemented with 100 ng/mL 2.5S 
nerve growth factor (NGF, Sigma) and 10% of TTR KO mouse serum, or 10% TTR KO 
mouse serum containing 300 µg/mL of recombinant TTR (either wt or TTRprot-). 72 h later, 
total RNA was isolated with Trizol (Invitrogen) and subjected to RT-PCR with the 
Superscript II kit (Invitrogen). PCR was performed for the appropriate number of cycles for 
each cDNA (20–40 cycles) at 95°C for 1 min, 56°C for 2 min, and 72°C for 3 min. Primers 
were designed using PRIMER3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) 
and the sequence from the National Centre for Biotechnology Information database. 
Sense and antisense primers were: i) Rat PAM: 5’-AAAAATGGAGCATCGGTCAG-3’ and 
5’-TTCCCTTTCCTCGGAATCTT-3’; ii) Mouse LPL: 5’-GCGTAGCAGGAAGTCTGACC-3’ 
and 5’-AGCCCTTTCTCAAAGGCTTC-3’; and iii) rat β-actin: 5’- 
TGTCACCAACTGGGACGATA-3’ and 5’-TCTCAGCTGTGGTGGTGAAG-3’. Ethidium 
bromide-stained gels were scanned using a Typhoon 8600 (Amersham) and amplified 
bands were quantified using the ImageQuant software (Amersham). Fluorescence density 
of each PCR-amplified band was normalized with the corresponding value of β-actin. NPY 
quantification in the cell conditioned media was performed by radioimmunoassay (RIA) 
with Bachem kits, as previously described (Nunes et al, 2005). 
 
TTR proteolysis of NPY 
Amidated NPY (Bachem, 2  µg) was incubated either with 5 µg of wt TTR or TTRprot-. Mass 
analysis of the reaction samples was performed by MALDI-MS (detailed in chapter 2), as 
a service performed at the IPATIMUP Proteomics Unit, Porto, Portugal. Assessment of 
NPY cleavage by TTR was analysed by comparing the molecular weight of NPY 
incubated with active wt TTR with the one incubated with TTRprot-. As a control, the 
molecular weight of NPY non-incubated with TTR was also determined by MALDI-TOF 
MS. 
 
Influence of TTR proteolytic activity in nerve regeneration 
The effect of TTR proteolytic activity in nerve regeneration was assessed performing 
neurite outgrowth assays (Fleming et al., 2007). PC12 cells were grown in 6-well plates in 
D-MEM medium (Invitrogen) supplemented with 10% FBS. When cells reached 50% 
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confluence, FBS was withdrawn and D-MEM medium was supplemented with 10% of 
either wt or TTR KO mouse serum, or 10% TTR KO mouse serum containing 300 µg/mL 
of recombinant TTR (either wt or TTRprot-). 40 h later, PC12 cells were fixed in 2% neutral 
buffered formalin for 30 min, washed with PBS and kept at 4°C until further analysis. 
Neurite size was determined from 50x magnified fields. At least 120 cells were analysed 
for each condition.  
 
Enzyme assays with FRET peptide libraries 
The FRET peptides were assayed in a Shimadzu RF-1501 spectrofluorometer at 37ºC. 
The assays were performed in 50 mM Tris pH 7. The enzyme (2.7 µM) was pre-incubated 
in the assay buffer before the addition of 10 µM substrate. Fluorescence changes were 
monitored continuously at λex=320 nm and λem=420 nm. The slope of the generated 
fluorescence signal was converted into micromoles of substrate degraded per min based 
on a calibration curve obtained from the complete hydrolysis of each peptide. The peptide 
cleaved bonds were identified by analysis of the hydrolysis reactions on a LC/MS – 2010 
from Shimadzu with the ESI probe. The HPLC column eluates were monitored by their 
absorbance at 220 – 365nm and by fluorescence emission at 420nm, upon excitation at 
320nm. 
 
Cleavage of myelin basic protein by TTR 
Homogenates of cerebellum from TTR KO mice were prepared by homogenising the 
tissue in 50 mM Tris pH 7. Total protein was quantified by the Bradford method. For 
assessment of cleavage of myelin basic protein (MBP) by TTR, 20 µg of cerebellum 
homogenate were incubated in the absence or in the presence of increasing amounts of 
TTR, ranging from 5 to 50 µg. Reactions were separated on a 15% SDS-PAGE gel and 
then transferred to a nitrocellulose membrane (Amersham). For Western analysis, 
membranes were blocked with blocking buffer (10% nonfat dried milk in phosphate buffer 
saline - PBS), and incubated 1 h at room temperature with primary antibodies diluted in 
blocking buffer, namely, goat polyclonal anti-MBP (Santa Cruz Biotechnology, 1:1,000), 
and mouse monoclonal anti-β-actin (Sigma, 1:5,000). Subsequently, incubation with 
horseradish peroxidase (HRP)-labeled secondary antibodies diluted in blocking buffer, 
namely anti-goat IgG-HRP (The Binding Site, 1:10,000) and anti-mouse IgG-HRP (The 
Binding Site, 1:5,000), was performed for 1 hour at room temperature. Blots were 
developed using the ECL PlusTM Western blotting reagents (Amersham Biosciences) and 
exposed to Hyperfilm ECL (Amersham Biosciences). Quantitative analysis of Western 
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blots was performed using the ImageQuant software (Amersham). Results are shown as 
the ratio between MBP and β-actin signals. 
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Results 
Proteolysis of oxidized insulin B chain confirms TTR preference for aromatic residues at 
P1 
The examination of the cleavage pattern of the proteolytic activity on a standard substrate 
such as the oxidized insulin B chain constitutes a common method for screening the 
specificity of a newly discovered protease. The oxidized insulin B chain sequence 
contains a useful variety of peptidic bonds available for cleavage, and also has an 
unfolded structure so that all peptide bonds are freely accessible (Beynon and Bond, 
1989). TTR digestion of oxidized insulin B chain generated two major insulin peptides as 
determined by the HPLC analysis of the incubation of the two proteins (data not shown). 
Control oxidized insulin B chain (in the absence of TTR) did not present fragmentation 
(data not shown). N-terminal sequencing of the insulin peptides generated by TTR 
proteolysis identified three cleavage sites: Tyr16-Leu17, Phe24-Phe25 and Tyr26-Thr27 
(Figure 1). These results suggested a TTR preference for an aromatic residue in the P1 
position, which is in accordance with the TTR cleavage site in apoA-I.  
 
 
Figure 1 – TTR degradation pattern of oxidized insulin B-chain. Amino acids are represented 
using the one-letter code. Arrows indicate TTR cleavage sites. 
 
Combinatorial Substrate libraries reveal changes in P1 specificity for TTR proteolysis 
In order to determine P1-P4 specificity for TTR cleavage, we used combinatorial peptide 
libraries. The P1 specificity was first defined using a library in which each of the P1 amino 
acids in a tetrapeptide was held constant while the other three positions contained an 
equimolar mixture of 20 amino acids. The P1 site preference for TTR cleavage was 
determined as being Lys>Ala>Arg>Leu≥Met>Phe>Tyr (Figure 2). To define the extended 
substrate specificities of TTR, we performed a screening for P2-P4 positions with libraries 
in which the P1 was fixed to a Lys residue (Figure 2).  The P2, P3 and P4 cleavage 
preferences were broad, what is common for some serine proteases, and as a 
consequence we were unable to determine a specific sequence for TTR cleavage. 
Regarding the results for the P1 preference, it is noteworthy that TTR cleaves apoA-I after 
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a Phe residue and not after the preferred residues Lys, Ala or Arg, what points to the 
possible existence of other TTR substrates. 
 
 
Figure 2 – Subsite preferences of TTR as determined by combinatorial P-diverse libraries. 
The y axis represents the substrate cleavage rates in picomolar concentrations of fluorophore 
released per second. The x axis indicates the amino acid held constant at each position, 
designated by the one-letter code; n= norleucine. 
 
ApoA-I is the sole plasma TTR substrate as confirmed by DIGE 
In order to identify other natural substrates for TTR in the plasma, we performed DIGE 
analysis of plasma from TTR KO mice subjected to proteolysis by TTR. In a first 
experiment we had two samples corresponding to plasma from TTR KO mice incubated 
with wt TTR (KO+wtTTR) or TTRprot- (KO+TTRprot-); the wt TTR-treated sample was 
labeled with Cy3 and the TTRprot- - treated sample with Cy5, and both were run in the 
same 2D gel. In a second experiment, samples corresponded to plasma from TTR KO 
mice either untreated (KO) or previously treated with wt TTR (KO+TTR). In this case, the 
untreated sample was labeled with Cy3 and the wt TTR-treated sample with Cy5, and 
both were run in the same 2D gel. To determine the differences in proteome profiling 
derived from proteolytic cleavage of a possible TTR plasmatic substrate, we selected only 
the common spots between the gels corresponding to each experiment. The majority of 
common spots between the 2 gels corresponded to the presence of TTR (black circle, 
Figure 3). In both experiments, there was one spot increased in the KO+wtTTR sample, 
which corresponded to a putative fragment originated by TTR cleavage of a plasma 
protein. This spot was analysed by MS and was identified as corresponding to C-
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terminally cleaved mouse apoA-I. We had previously shown that human TTR is able to 
cleave mouse apoA-I (Liz et al., 2007). Despite the fact that this result shows that DIGE 
enables the identification of TTR substrates, we were unable to identify new putative TTR 
substrates in the plasma. 
 
 
Figure 3 – Identification of putative plasmatic TTR substrates by DIGE analysis. Dige analysis 
of TTR KO plasma incubated in the presence or absence of wt TTR; spots highlighted in blue 
correspond to proteins increased in KO+TTR sample and spots highlighted in red correspond to 
proteins increased in KO sample. TTR and the apoA-I fragment are indicated. Note that only spots 
highlighted in blue were present in both DIGE experiments. 
 
TTR proteolytic activity is not relevant for TTR ability to regulate neuropeptide maturation 
The effect of TTR in modulating PAM expression observed using TTR KO mice was 
reproduced in in vitro assays where PC12 cells grown in the absence of TTR were shown 
to have increased PAM expression, NPY levels and LPL expression relatively to cells 
grown in the presence of TTR (either by growing cells with wt serum or with TTR KO 
serum supplemented with TTR; (Nunes et al., 2006)). To analyse the effect of TTR 
proteolytic activity in neuropeptide maturation, we performed similar experiments to the 
ones described; we analysed the expression levels of PAM and LPL, and NPY content in 
PC12 cells grown in the presence of TTR KO serum or TTR KO serum supplemented with 
either wt TTR or TTRprot-. If proteolytic activity was necessary for TTR participation in 
neuropeptide processing, it was expected that similarly to cells grown in the absence of 
TTR, in the presence of TTRprot-, PAM and LPL expression would be increased relatively 
to cells grown with wt TTR. Both wt TTR and TTRprot- lead to a similar decrease of PAM 
expression in PC12 cultures (Figure 4A). Regarding NPY content, conditioned media of 
PC12 cells grown in the presence of either wt TTR or TTRprot- displayed a similar decrease 
in NPY levels when compared with cells grown in the absence of TTR (Figure 4B). These 
results show that TTR proteolytic activity does not influence PAM expression, neither 
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affects PAM activity in NPY amidation; i.e., TTR proteolysis does not affect NPY 
maturation. Surprisingly, given their similar PAM expression levels and amidated NPY 
content, cells grown in the presence of TTRprot- had increased LPL expression levels when 
compared to cells grown with wt TTR (Figure 4C). Although these results suggest that 
proteolytic activity might have an effect in LPL expression, that effect could not, at this 
point, be explained by an alteration in NPY content. 
 
 
 
 
 
 
Figure 4 – PAM and LPL expression and NPY levels in PC12 cells. A. PAM semiquantitative 
RT-PCR analysis in PC12 cells grown in the presence of TTR KO mouse serum (KO), or TTR KO 
mouse serum containing either wt TTR (KO+TTR WT) or TTRprot- (KO+ TTRprot-). B. NPY levels in 
the conditioned media of PC12 cells grown in the presence of TTR KO mouse serum (KO), or TTR 
KO mouse serum containing either wt TTR (KO+TTR WT) or TTRprot- (KO+ TTRprot-). C. LPL 
semiquantitative RT-PCR analysis in PC12 cells grown in the presence of TTR KO mouse serum 
(KO), or TTR KO mouse serum containing either wt TTR (KO+TTR WT) or TTRprot- (KO+ TTRprot-). 
Results are presented as average ± SD; * P<0.05. 
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In vitro, TTR is able to cleave NPY 
As described above, PC12 cells grown in the presence of proteolytically inactive TTR 
display increased levels of LPL expression, a similar effect as observed in cells grown in 
the absence of TTR, which points to an effect of TTR proteolytic activity in LPL 
expression. In the case of cells grown in the absence of TTR, increased levels of NPY 
explain the increased levels of LPL expression. However, cells grown in the presence of 
TTRprot- displayed levels of NPY which were not statiscally different from the ones of cells 
grown with proteolytically active wt TTR, suggesting that the increase in LPL expression is 
not related with an increase in NPY content. To explain this effect, we hypothesized that 
NPY might be cleaved by TTR, and that the similar levels of NPY in cells grown either with 
wt TTR or TTRprot- were due to the fact that the antibody used in the RIA assay to quantify 
NPY, might not distinguish between intact and cleaved NPY, as it recognizes the amide 
group located in the C-terminus of this neuropeptide that might unaffected by TTR 
cleavage.  
To test our hypothesis, we assessed TTR ability to cleave amidated NPY in vitro. We 
analysed the MS spectra of full-length NPY or NPY incubated either with wt TTR or 
TTRprot-. We observed that both the sample of full-length (Figure 5A) or TTRprot- -incubated 
NPY (Figure 5B) presented only one mass peak, which corresponds to the molecular 
weight of intact NPY (4271 Da). In the case of NPY incubated with wt TTR, we observed 
the fragmentation of the neuropeptide as shown by the appearance of two mass peaks, 
one with 3826 Da and a second with 4111 Da, besides the peak corresponding to intact 
NPY with 4273 Da (Figure 5C). This result is in agreement with the observed increase in 
LPL expression in PC12 cells grown in the presence of TTRprot-; in this condition, higher 
levels of active amidated NPY would be present when compared to cells grown with wt 
TTR where amidated NPY was cleaved rendering it inactive and unable to increase LPL 
expression, as observed. The hypothesis that the anti-amidated NPY used in the RIA 
assay is unable to distinguish full-length NPY from TTR-cleaved NPY needs however 
further validation.  
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Figure 5 – MS analysis of TTR degradation of NPY. A. MS spectra of full-length NPY; B. MS 
spectra of NPY incubated with TTRprot-; C: MS spectra of NPY incubated with wt TTR. FL- full-
length NPY; Fr- NPY fragments. 
 
TTR proteolytic activity is necessary for TTR ability to promote neurite outgrowth 
Another function determined for TTR in the nervous system is its participation in nerve 
regeneration (Fleming et al., 2007). TTR KO mice present a decreased regenerative 
capacity after sciatic nerve crush when compared with wt mice. In vitro, neurite outgrowth 
of PC12 cells was decreased in the absence of TTR, which probably underlies the 
decreased regenerative capacity of TTR KO mice (Fleming et al., 2007). To assess the 
putative involvement of TTR proteolytic activity in neurite outgrowth, we assessed the 
neurite length, determined by measuring the length of the longest neurite in PC12 cells 
cultivated in the presence of either wt or TTR KO mouse serum, or TTR KO mouse serum 
containing either wt TTR or TTRprot-. PC12 cells exposed to TTR KO serum displayed a 
decrease in the size of the longest neurite when compared to cells grown with wt serum, 
as previously reported (Fleming et al., 2007). Addition of wt TTR to TTR KO serum was 
able to partially rescue the decrease in neurite length observed in PC12 cells grown with 
TTR KO serum (Figure 6). Cells grown with TTRprot- displayed a similar decreased neurite 
length as cells grown in the absence of TTR (Figure 6). These results suggest that the 
lack of TTR proteolytic activity, and not the absence of TTR itself, is the factor responsible 
for the decreased neurite length in PC12 cells, thus demonstrating that the proteolytic 
activity of TTR is relevant in TTR ability to promote neurite outgrowth.  
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Figure 6 – Neurite outgrowth in PC12 cells. Average size of the longest neurite of PC12 cells 
after exposure to WT serum (WT), TTR KO serum (KO), and TTR KO serum supplemented with wt 
TTR (KO+TTR WT) or TTRprot- (KO+TTRprot). Results are presented as average ± SD; * P<0.05 
 
Considering that the involvement of TTR in nerve regeneration is related with proteolytic 
activity, a TTR substrate should exist in the nerve. In order to identify such a substrate, we 
performed DIGE analysis of nerve extracts from TTR KO mice with (KO+TTR sample) or 
without (KO sample) incubation with wt TTR. In Figure 7, spots present in higher 
abundance in the KO+TTR sample are highlighted in blue and indicate putative cleavage 
products, and spots present in higher abundance in the KO sample are highlighted in red 
and correspond to possible substrates. 
 
 
Figure 7 – Identification of putative TTR substrates in the nerve by DIGE analysis. DIGE 
analysis of nerve extracts from TTR KO mice with and without incubation with wt TTR; spots 
highlighted in blue correspond to proteins increased in the KO+TTR sample and spots highlighted 
in red correspond to proteins increased in the KO sample. Numbers indicate spots analysed by 
MS; 1- serum albumin; 2- serotransferrin; 3- neurofilament-L; 4- unidentified proteins. 
 
Protein spots presenting differences between the two samples were analysed by MS for 
protein identification (Figure 7; Table 1). Among the identified spots, one protein with 
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particular interest to our study was neurofilament light polypeptide (NF-L), a marker of 
axonal degeneration (Zetterberg et al., 2007). Validation of NF-L as a substrate for TTR 
proteolytic activity should be further assessed. 
 
Table 1 – Differentially regulated proteins determined from DIGE analysis of nerve extracts 
incubated with TTR. Proteins with a positive value for Cy5/Cy3 ratio are increased in the nerves 
incubated with TTR, while proteins with a negative value for Cy5/Cy3 ratio are decreased in the 
nerves incubated with TTR. 
Protein Name Cy5/Cy3 ratio Accession number 
Serum albumin precursor -32.41 P07724 
Neurofilament light polypeptide -19.97 P08551 
Serotransferrin precursor -7.18 Q921I1 
 
In vitro, TTR is able to cleave MBP 
Myelin basic protein (MBP) is a myelin-associated protein that was shown to be degraded 
by several proteases in demyelinating diseases (Medveczky et al., 2006). Considering the 
role of TTR in nerve regeneration (Fleming et al., 2007), we decided to use an available 
library of FRET peptides derived from human MBP in our analysis of TTR substrate 
specificity. This library was designed to study the substrate specificity of human Kallikrein 
6, a protease abundantly expressed in the CNS and implicated in demyelinating diseases 
(Angelo et al., 2006). We tested 5 peptides from the MBP library and two of the peptides 
were hydrolysed by TTR (Table 4). The sequence cleaved with highest efficiency was 
YGGRASD with cleavage occurring in a Gly-Arg bond. TTR was able to cleave that 
peptide and presented approximately 40-fold increased activity when compared to that 
determined using the apoA-I peptide (ESFKVS) (Liz et al., 2004; chapter 1). In the second 
cleaved sequence (GKGRGLS), TTR hydrolysed the Ser-Gln bond. However, the Ser-Gln 
bond does not exist naturally in the MBP sequence as the Gln residue was introduced in 
the synthesis process of the FRET peptides. Nevertheless, TTR cleavage after either a 
Gly or a Ser residue was not observed by the methods used previously, as described in 
this chapter. 
 
Table 2 - Specific activity for TTR hydrolysis of the FRET peptide series derived from the 
human myelin basic protein (MBP) sequence. 
Sequence Specific Activity 
(nmol/ min . nmol E) 
Abz-YG↓GRASDQ-EDDnp 0.057 
Abz-GKGRGLS↓Q-EDDnp 0.026 
Abz-SHGRTQDQ-EDDnp No hydrolysis 
Abz-VTPRTPPQ-EDDnp No hydrolysis 
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Abz-GGDRGAPQ-EDDnp No hydrolysis 
↓-indicates the cleaved peptide bond 
 
Based on these results we analysed the ability of TTR to cleave MBP in vitro. For that, we 
incubated cerebellum homogenates from TTR KO mice without or with increasing 
amounts of TTR and performed a Western analysis to assess MBP proteolysis by TTR 
(Figure 8A). Our results shown that MBP was susceptible to the catalytic amounts of TTR, 
as demonstrated by the quantification of the 21.5 kDa isoform of MBP (Figure 8B). 
Moreover, we tested TTR ability to cleave purified bovine MBP; the same pattern of 
degradation observed in the cerebellum extracts was obtained for TTR proteolysis of 
isolated MBP (Figure 8C). These results confirm that in vitro, TTR is able to cleave MBP. 
Further studies should be performed to confirm MBP proteolysis by TTR in vivo. 
 
 
Figure 8 - TTR proteolysis of myelin basic protein (MBP). Anti-MBP and anti-β-actin Western 
blot of cerebellum extracts incubated with increasing amounts of TTR (A) and corresponding 
quantification of signal intensity (B). SDS-PAGE analyis of bovine MBP incubated with increasing 
amounts of TTR (C). 
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Discussion 
TTR is a protease able to cleave the C-terminus of apoA-I after the residue Phe 225 (Liz 
et al., 2004). By cleaving apoA-I, TTR impacts on HDL biology and in the development of 
atherosclerosis as it reduces the ability of apoA-I to promote cholesterol efflux and 
increases apoA-I amyloidogenicity (Liz et al., 2007). Previous results point to the fact that 
apoA-I might not be the prime TTR substrate: i) the Km value for TTR cleavage of a 
fluorogenic peptide encompassing the apoA-I sequence cleaved by TTR reflects a low 
affinity to that substrate (Liz et al., 2004), and ii) a screening performed with a library of 
peptide-based phosphonate inhibitors demonstrated that TTR is preferentially inhibited by 
compounds with a Lys residue in the P1 position and a Proline in the P2 position 
(unpublished data). In this work we investigated the existence of other putative natural 
TTR substrates rather than apoA-I. We started by analysing of the pattern of TTR 
degradation of oxidized insulin B chain; TTR cleaved three distinct peptidic bonds: Tyr-
Leu, Tyr-Thr and Phe-Phe. These results show a preference for an aromatic residue in P1 
position, which is in accordance with the cleavage site in apoA-I. In apoA-I TTR cleaves a 
Phe-Lys bond suggesting a P’ preference for a Lys, i.e, a basic hydrophilic amino acid. In 
oxidized insulin B chain P’ sites determined for TTR specificity were: Leu, Thr and Phe. 
While Thr is a hydrophilic amino acid, Leu and Phe are hydrophobic residues. This type of 
substrate specificity observed for TTR cleavage both in apoA-I and oxidized insulin B 
chain is similar to that of chymotrypsin, which prefers an aromatic residues in P1 and is 
non-specific for P’ site (Beynon and Bond, 1989). The degradation pattern of a standard 
protein such as the oxidized insulin B chain is useful for the determination of primary 
specificity (P1 and P1’ sites) of a protease. Nevertheless, in some cases, the secondary 
specificity, given by the P2 to Pn and P2’ to Pn’ sites, is also important as those positions 
provide enhanced binding to the active site pocket of the protease (Beynon and Bond, 
1989). As such, we assessed P1 to P4 preference for TTR cleavage using P-diverse 
libraries, and observed the following P1 preference for TTR: 
Lys>Ala>Arg>Leu≥Met>Phe>Tyr. This result did not provide a conclusive outcome in 
terms of TTR specificity for the P1 site; TTR prefers hydrophilic amino acids at P1 as Lys 
and Arg (a specificity similar to the one of trypsin) but is also able to cleave after 
hydrophobic/aromatic amino acids (as chymotrypsin). Furthermore, the results for P2 to 
P4 preference were broad (which is common for several serine proteases) and we were 
unable to determine a specific sequence for TTR cleavage. Nevertheless, the studies 
performed with the P-diverse libraries supported the hypothesis of the existence of other 
natural TTR substrates besides apoA-I. Future work regarding TTR substrate specificity 
includes the determination of the P’ preference through the use of peptide libraries 
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coupled to beads. These libraries are constituted by fluorescence quenched peptides, in 
which each peptide, composed of 7 randomly mixed amino acids, is coupled to resin 
beads. The residues in each of the 7 positions of each peptide are randomly 
encompassing the 20 amino acids of the genetic code. After incubation with the enzyme, 
the fluorescent beads are isolated and the amino acid sequences determined by Edman 
degradation, which enables the determination of the cleavage site and the Pn` residues, 
and consequently an optimal sequence for cleavage by TTR (St Hilaire et al., 2000). 
New TTR functions related to nerve biology have been recently identified. In this work we 
assessed the involvement of TTR proteolytic activity in two of the described functions, 
namely TTR participation in neuropeptide processing (Nunes et al., 2006) and TTR ability 
to promote nerve regeneration (Fleming et al., 2007). The effect of TTR in modulating 
neuropeptide processing was tested in in vitro assays where cells with a neuronal-like 
phenotype (PC12 cells) were grown either in the absence of TTR or in the presence of wt 
TTR or proteolytically inactive TTR (TTRprot-). We determined that both wt TTR and 
TTRprot- led to a similar decrease of PAM expression and NPY levels in cell cultures. This 
result excluded the involvement of TTR proteolytic activity in controlling neuropeptide 
maturation. However, similarly to cells grown in the absence of TTR, in the presence of 
TTRprot-, LPL expression was increased relatively to cells grown with wt TTR. This 
observation was not in agreement with the decreased levels of NPY observed in the cells 
grown with TTRprot-, as LPL expression is activated by NPY (Nunes et al., 2006). 
Nevertheless, we determined that in vitro TTR is able to cleave NPY. The determination of 
the NPY cleavage site generated by TTR hydrolysis will be performed, to gain further 
insights in TTR specificity. TTR proteolysis of NPY could be the explanation for the higher 
levels of LPL expression in cells grown with inactive TTR when compared to cells grown 
with active wt TTR; however, this hypothesis is contradicted by the fact that cells grown 
with either wt TTR or TTRprot- present similar NPY content. Studies are currently underway 
to ascertain whether the method of NPY quantification can distinguish the full-length NPY 
form from its TTR-cleaved form. If NPY cleavage by TTR is confirmed in cellular assays, it 
would be possible that, in addition to the decreased levels of PAM expression, cleavage of 
NPY by TTR contributed to the lower NPY levels observed in wt mice when compared to 
TTR KO mice (Nunes et al., 2006).  
To ascertain whether the proteolytic activity of TTR is related to its ability in enhancing 
nerve regeneration we measured neurite outgrowth in PC12 cells cultivated in the 
presence of wt TTR or TTRprot-. Cells grown with proteolytically inactive TTR displayed 
decreased neurite length as determined by size length of the longest neurite. This 
observation suggested that the proteolytic activity of TTR is relevant for TTR ability to 
promote neurite outgrowth. We followed by searching TTR substrates in the nerve that 
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could be involved in this process by DIGE. Neurofilament light polypeptide (NF-L) was 
decreased in TTR-incubated nerves, constituting a putative TTR substrate. 
Neurofilaments are expressed in neuronal cells and are one of the classes of intermediate 
filaments, which constitute the cytoskeleton of eukaryotic cells. NF-L expression was 
shown to be up-regulated in response to nerve injury; northern blot analysis of severed rat 
sciatic nerves detected NF-L mRNA, suggesting that NF-L may be involved in nerve 
regeneration (Sotelo-Silveira et al., 2000). NF-L received particular attention among the 
proteins identified in the DIGE analysis, as TTR enhances nerve regeneration after nerve 
crush (Fleming et al., 2007), a process in which NF-L is involved. However, validation of 
NF-L as a TTR substrate needs further investigation. Two other proteins, also decreased 
in TTR-incubated nerves, were identified in the DIGE analysis, but were excluded as 
putative TTR substrates. One of the proteins identified was albumin, which probably 
reflects a contamination of the nerve sample with serum. The second identified protein 
was transferrin. Transferrin is a monomeric serum glycoprotein, which binds iron atoms for 
delivery to cells through receptor-mediated endocytosis being retrogradely transported in 
the nerve (Dautry-Varsat, 1986). However, in previous experiments we assessed 
cleavage of transferrin by TTR, and the protein was not validated as a TTR substrate (Liz 
et al., unpublished data). The DIGE analysis did not provide further insights into TTR 
proteolysis of NPY; NPY analysis by denaturing electrophoresis is difficult to accomplish 
due the low molecular weight of the neuropeptide. Concerning the observation that TTR 
proteolytic activity is related with TTR ability to promote neurite outgrowth, which 
physiologically occurs after nerve injury, we plan to repeat the DIGE experiments following 
nerve crush. 
Studies performed with a library of fluorogenic peptides further reinforced that apoA-I is 
probably not the prime natural TTR substrate. TTR was able to cleave the sequence 
YGGRASD, derived from the sequence of the myelin basic protein (MBP). In the MBP 
peptide, TTR was able to cleave a Gly-Gly peptidic bond. Glycine is the smallest of the 
amino acids, suggesting a TTR preference for cleavage after small residues. However this 
observation is not in conformity with the results obtained with the P-diverse libraries. As 
the results obtained in the investigation of TTR substrate specificity did not allow the 
determination of an optimal sequence for TTR cleavage, studies based on the preferred 
sequence cleaved by TTR (YGGRASD), identified so far, are currently underway. 
Systematic variations to this sequence will be made in each of the amino acid positions; 
each of the positions in the peptide will be replaced by each of the 20 amino acids of the 
genetic code, to determine TTR specificity in the Pn and Pn’ sites.  
We further determined that TTR was able to cleave both purified MBP as well as MBP 
present in a cerebellum protein homogenate. However, we were not able to identify MBP 
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cleavage by DIGE analysis of nerve extracts incubated with TTR. In the CNS, MBP is one 
of the most abundant myelin proteins and degradation of myelin proteins has been the 
subject of study in several demyelinating diseases such as multiple sclerosis (MS) 
(Richter-Landsberg, 2000). Several brain proteases that degrade myelin protein in vivo or 
in vitro, like matrix metalloprotease-9 (MMP-9) (Leppert et al., 1998), calpain (Shields et 
al., 1999), myelencephalon-specific protease (MSP) (Scarisbrick et al., 2001), 
plasminogen activators (Gveric et al., 2001) and human trypsin 4 (Medveczky et al., 2006) 
have been implicated in myelinolysis. Extensive MBP degradation was demonstrated after 
traumatic brain injury (TBI); it was hypothesized that TBI-mediated axonal injury causes 
structural damages to the adjacent myelin membrane, instigating MBP degradation, which 
could initiate myelin sheath instability and demyelination (Liu et al., 2006). In the PNS, 
following injury, Schwann cells and macrophages rapidly remove myelin debris (Schafer 
et al., 1996). This reaction constitutes an important factor for PNS ability to regenerate 
(George and Griffin, 1994). MBP constitutes only 10–20% of PNS myelin (Jacobs, 2005), 
but is critical to maintain the integrity and compactness of peripheral nerve in development 
(Martini and Schachner, 1997) and after injury (LeBlanc and Poduslo, 1990). In the PNS, 
it was shown that MMP-9 controls myelin protein content after nerve injury 
(Chattopadhyay et al., 2007). As myelinolysis constitutes an important step in the 
regeneration of the PNS, it is possible that TTR proteolysis of MBP could be related with 
its ability to enhance nerve regeneration. To investigate our hypothesis future work will 
assess MBP cleavage by TTR in vivo; for that we will compare the MBP content of wt and 
TTR KO mouse brains and nerves. If this cleavage will be confirmed in vivo, subsequent 
studies, including in vitro myelination assays in the presence of either wt TTR or TTR 
without proteolytic activity will be performed. Regarding the cleavage site for TTR in MBP, 
which was determined as being after a Gly residue in the sequence YGGRASD, it is 
noteworthy that human kallikrein 6, a protease abundantly expressed in the central 
nervous system and implicated in demyelinating disease, is able to cleave the same 
peptidic substrate but after the Arg residue (Angelo et al., 2006). Moreover, human trypsin 
4, a serine protease involved in myelinolysis, cleaves the MBP protein after Arg residues 
(Medveczky et al., 2006). On the subject of these observations, we will confirm the TTR 
cleavage site using as substrate full-length MBP protein.  
Under physiological conditions TTR has access to the nerve through the blood and the 
CSF; the possibility of the existence of putative TTR substrates in the nerve was 
investigated in this work. In summary, our results suggested that TTR proteolytic activity is 
related with the recently described TTR functions in the nerve, and identified NPY and 
MBP as putative TTR substrates. Nevertheless, the existence of at least two putative TTR 
substrates in the nerve was unexpected regarding in vivo enzyme specificity and 
Chapter 4________________________________________________________________________________________ 
 178 
physiological relevance for TTR proteolysis. The confirmation of in vivo proteolysis of the 
identified substrates is crucial to clarify this subject.  
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Conclusions and future perspectives 
In this project we revealed a new function for the well-studied protein transthyretin (TTR); 
besides being the plasma carrier for thyroxine and retinol, TTR is a cryptic protease. We 
classify the proteolytic activity of TTR as being cryptic, as its physiological function is 
apparently unrelated to proteolysis and also as TTR lacks canonical structural protease 
determinants. The studies performed in order to characterize TTR proteolytic activity 
suggest that TTR is a serine-like protease. However, we were not able to identify the 
catalytic active site of TTR, mainly due to post-translational modifications occurring during 
the process used to produce the recombinant protein, which affect its catalytic activity and 
yield a low percentage of enzymatic activity. In this respect, future work should include the 
study of a suitable protein production protocol, aiming at obtaining unmodified TTR 
preparations with increased percentage of active enzyme. After achieving that goal, the 
approaches of site-directed mutagenesis, as well as active site labeling, might be used 
successfully to identify the catalytic machinery throught which TTR operates. In the 
process of characterization of the active site of TTR, we determined that glutathionylation 
completely abolishes TTR proteolytic activity. Regarding this observation, the 
crystallization of TTR complexed with glutathione is currently underway, as it might give 
insights into the catalytic active site of TTR. Glutathionylation is one of the several 
posttranslational modifications described for plasmatic TTR. In the plasma, the majority of 
TTR (85%-95% of total TTR) in circulation is posttranslationally modified, with the 
unmodified form of the protein accounting for 5%-15% of the total TTR. In the future, 
these observations should be taken in consideration when analyzing the physiological 
relevance of TTR proteolysis, as we determined that posttranslational modifications 
influence the catalytic properties of this protein. 
ApoA-I was identified as the unique plasmatic substrate for TTR. As such, we analysed 
the relevance of apoA-I cleavage by TTR and determined that it has both physiological 
and pathological effects; TTR impacts on HDL biology and in the development of 
atherosclerosis by reducing the ability of apoA-I to promote cholesterol efflux and 
increasing apoA-I amyloidogenecity. To further dissect the in vivo impact of TTR 
proteolysis in atherosclerosis, future work should assess the development of 
atherosclerosis in mice devoid of TTR and mice carrying TTR, both in an apo-E KO 
background, as this background favours the formation of atherosclerotic plaques. 
Considering the results obtained in this project, and if the ability of TTR to cleave apoA-I in 
vivo actually impacts on the development of atherosclerotic plaques, we expect that TTR 
KOxapo-E KO animals will probably be less prone to develop atherosclerotic lesions. 
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Recent studies using TTR KO mice revealed new TTR functions specifically related to the 
nervous system, by implicating this protein in i) sensorimotor performance, ii) behavior, iii) 
neuropeptide maturation and iv) nerve regeneration. In this respect, we analysed the 
relevance of TTR proteolytic activity in these processes, namely in neuropeptide 
processing and nerve regeneration. We determined that in vitro TTR is able to cleave 
neuropeptide Y (NPY) and myelin basic protein (MBP). We also demonstrated that TTR 
proteolytic activity is related with TTR ability to enhance neurite outgrowth. Future work 
should disclose whether the described effects occur in vivo to ascertain the relevance of 
the identified substrates. 
In summary, the present study established TTR as a novel cryptic protease. Furthermore, 
we show that TTR proteolytic activity might impact in both physiological and pathological 
conditions, namely in atherosclerosis and in the biology of the nervous system. 
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List of abbreviations 
 
AApoA-I ApolipoproteinA-I amyloidosis 
Aβ Amyloid beta protein  
ABCA-1 ATP-binding cassette transporter A1 
Abz ortho-amynobenzoic acid 
AD Alzheimer’s disease 
AL Immunoglobulin light chain amyloidosis  
ApoA-I Apolipoprotein A-I  
APP Amyloid precursor protein 
ATTR Transthyretin amyloidosis 
CE Cholesteryl ester  
CNS Central nervous system 
CSF Cerebrospinal fluid 
DFP Diisopropylfluorophosphate 
EDDnp N-(ethylenediamine)-2,4-dinitrophenyl amide 
FAC Familial amyloid cardyomyopathy 
FAP Familial amyloid polyneuropathy 
FC Free Cholesterol  
GSSG Oxidized glutathione 
HDL High density lipoprotein 
KO Knockout 
LCAT Lecitin cholesterol acyl transferase 
LDL Low density lipoprotein  
LDLr Low density lipoprotein receptor 
LPL Lipoprotein lipase 
MBP Myelin basic protein 
NF-L Neurofilament light polypeptide 
NPY Neuropeptide Y 
PAM Peptidylglycine alpha-amidating monooxygenase 
PMSF Phenylmethanesulfonyl fluoride 
PNS Peripheral nervous system 
RBP Retinol-binding protein 
RCT Reverse cholesterol transport 
rHDL Reconstituted high density lipoprotein 
SR-BI Scavenger receptor class B type 1  
SSA Systemic senile amyloidosis 
T3 Triiodothyronine 
T4 Thyroxine 
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TBG Thyroxine-binding globulin 
TH Thyroid hormone 
THDP Thyroid hormone distributor protein 
TTR Transthyretin 
WT Wild type 
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